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ABSTRACT 
Chikungunya virus (CHIKV) is a mosquito-transmitted arthritogenic alphavirus 
that is a global public health burden. In 2013, CHIKV spread from the Eastern 
Hemisphere to the Americas where it has since spread to 45 countries and territories in 
the region and caused nearly two million cases. CHIKV disease in humans is 
debilitating, and characterized by a sudden onset of high fever, severe joint pain and 
inflammation. More severe outcomes, including death, occur in neonates, the elderly, 
and in those with underlying medical co-morbidities. In many patients, disease signs and 
symptoms, including joint pain, inflammation, swelling, and stiffness, as well as 
tenosynovitis, can last for months to years. Despite the global spread of CHIKV, the 
pathogenesis of chronic CHIKV disease is not well understood. A limited body of 
evidence suggests that CHIKV, and related arthritogenic alphaviruses, establish long-
term persistent infections in musculoskeletal tissues. Therefore, critically unanswered 
questions are whether chronic CHIKV disease is due to chronic infection, and if so, how 
does CHIKV evade seemingly robust innate and adaptive antiviral immune responses.   
To investigate persistent CHIKV infection, I used a mouse model that 
recapitulates many aspects of acute CHIKV disease and demonstrated that CHIKV 
infection persisted specifically in joint-associated tissue for at least 16 weeks, and that 
viral persistence was associated with chronic synovitis. By performing parallel infection 
studies in WT and immunodeficient mice, I showed that adaptive immune responses 
play a critical role in controlling rather than contributing to chronic disease pathogenesis. 
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In additional studies, I identified two strains of CHIKV, that differ at only five 
amino acid positions, with distinct outcomes in immunocompetent mice; namely long 
term persistence versus acute clearance. In detailed mapping studies, I found that a 
highly conserved glycine residue at amino acid position 82 in the CHIKV E2 glycoprotein 
promotes viral persistence and diminishes the potency of viral neutralization by human 
and murine antibodies that specifically target the E2 B domain. In contrast, an arginine at 
this position promotes viral clearance in joints of WT but not B cell-deficient mice and 
enhances viral neutralization. Finally, to investigate if persistence of CHIKV is associated 
with the acquisition of adaptive mutations, I isolated and characterized a strain of CHIKV 
from the serum of persistently infected Rag1-/- mice, which have an intact innate immune 
response but lack mature T and B cells. I found that polymorphisms in the E2 
glycoprotein and γ′ untranslated region of this strain enhanced early viral dissemination 
and viral virulence in naïve WT mice, suggesting that these mutations promote evasion 
of innate immune responses of mice. The research presented in this thesis expands our 
understanding of chronic CHIKV disease pathogenesis, describes new mechanisms by 
which pathogenic strains of CHIKV evade antiviral antibody responses to establish a 
persistent infection in joint-associated tissues, and identifies viral determinants selected 
during long-term persistence in mice. Collectively, this work provides new insights into 
the biological basis of chronic arthritis associated with CHIKV infection, mechanisms of 
chronic CHIKV infection, and will aid in the development of vaccines and antibody-based 
therapeutics against CHIKV. 
 
 The form and content of this abstract are approved. I recommend its publication. 
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Chikungunya Virus Genome Organization and Replication   
Chikungunya virus (CHIKV) is an enveloped positive sense RNA virus in the 
genus Alphavirus in the Togaviridae family. The Alphavirus genus is classified broadly 
based on phylogenetic analysis and antigenic cross-reactivity that correlates well with 
geographic distribution and disease signs (1). CHIKV is in the Semliki Forest antigenic 
complex and at the time of its discovery in the 1950s (2) was restricted to circulation in 
Africa and Asia. CHIKV shares this complex with the closely related o’nyong-nyong 
(ONNV), Mayaro (MAYV), Ross River (RRV) and SF viruses (SFV) (1). Viruses in this 
complex typically cause a musculoskeletal type disease in humans. CHIKV also shares 
a relationship to other human disease causing alphaviruses including western equine, 
Venezuelan equine, and eastern equine encephalitis viruses (WEEV, VEEV, EEEV 
respectively). These viruses circulate in the Americas and can cause a severe 
encephalitic type disease in humans with case fatalities approaching 30% (3). The 
prototypic alphavirus, Sindbis virus (SINV), is the causative agent of Pogosta disease in 
Scandanavia, and although phylogenetically more closely related to the encephalitic 
alphaviruses, SINV infections in humans often present with musculoskeletal symptoms 
(4).  
Like all alphaviruses, CHIKV has a positive sense single-stranded RNA genome 
of 11.5 to 12 kilobases (kb) with a 5′ N-7-methylguanosine cap and γ′ poly-A tail (5, 6) 
that can serve as an mRNA in the host cell (Fig 1-1A). Alphavirus genomes are 
organized into two open reading frames (ORFs). The 5′ two-thirds of the genome 
contains an ORF encoding the four non-structural proteins (nsP1-4) while the remaining 
one-third encodes a subgenomic ORF containing the structural proteins capsid, E2 and 
2 
 
E1 along with accessory proteins E3 and 6K. Recently, an additional protein produced 
by a ribosomal frameshift during translation of the subgenomic mRNA, termed 
transframe (TF), has been discovered in SINV- and CHIKV-infected cells that is 
important for viral pathogenesis in mice (7, 8).  
At the 5′ and γ′ ends of the genome and a junction region between the two ORFs 
are untranslated regions (UTRs) that have important functions in the viral life cycle. The 
5′ and γ′ UTRs of alphaviruses are diverse in size and sequence (9, 10) while the 
junction UTR is more conserved (11). Sequence and structural elements in the 5′ and γ′ 
UTRs interact with the viral replicase machinery to promote efficient replication of the 
positive and negative sense RNAs (12, 13). The junction UTR between the two ORFs 
encodes a promoter in the negative sense that is recognized by the viral replicase 
machinery to drive transcription of the 26S subgenomic mRNA from negative sense 
RNA templates (11). The 5′ genomic and subgenomic UTRs are also important in driving 
translation of their respective ORFs by recruiting host translation machinery (14, 15). In 
addition, there are important structural elements within the coding regions of the 
subgenomic RNA important for regulating translation of the subgenomic mRNA into the 
viral structural proteins despite host translational shutoff (16, 17). A stem-loop structure 
present in the 5′ UTR also has important functions in antagonizing innate immune 
restriction mediated by the interferon induced protein with tetratricopeptide repeats 1 
(IFIT1) (18) and the subgenomic 5′ UTR may be involved in host translational shutoff 
(19). The γ′ UTR of alphaviruses are diverse in both length and sequence except for a 
highly conserved 19nt element immediately preceding the poly-A tail that is essential for 
viral replication (10, 20). The γ′ UTR of most alphaviruses contains numerous repeat 
elements (10) that are likely important for recruiting host factors to stabilize the viral 
genome (21) such as the human antigen R protein (HuR) (22).  
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The alphavirus virion is an enveloped, spherical-shaped particle composed of a 
nucleocapsid containing the viral RNA genome surrounded by a host-derived lipid 
bilayer that is studded with 80 trimeric spikes. The E2 and E1 glycoproteins form a 
heterodimer (Fig 1-1B) and three heterodimers form a single spike (Fig 1-1C-D). E2 has 
several important ectodomains, domain A through C (Fig 1-1B) along with domains that 
span the viral envelope and interact with the nucleocapsid (not shown) (23). Domain A 
and B are predicted to be the location of host cell receptor binding (24), and while 
glycosaminoglycans may play a role in attachment (25), there likely exist additional 
undefined receptors necessary for viral entry. At a neutral pH, E2 domain B shields the 
E1 protein, particularly the fusion loop domain of E1 (Fig 1-1B) to prevent premature 
fusion (26, 27). Upon interaction of E2 with a host cell receptor, CHIKV undergoes 
clathrin-dependent (28, 29) or clathrin-independent epidermal growth factor 15 (Eps15)-
dependent endocytosis (30). Upon endosomal acidification, E2 and E1 undergo 
irreversible and dramatic structural rearrangements that expose the E1 fusion loop, alter 
the conformation of the spike and fuse the viral membrane with the endosomal 
membrane (26, 31, 32), releasing the encapsidated viral RNA into the host cell 
cytoplasm. The pH threshold of this rearrangement is dictated by interactions between 
residues of E2 and E1 (33, 34). This structural rearrangement of E2 and E1 is necessary 
for viral infectivity and lysosomotropic agents that interfere with endosomal acidification 
or antibodies that prevent E2/E1 rearrangement can block infection of the target cell (25, 
35, 36). Capsid association with host ribosomes is then hypothesized to trigger 
dissociation of the capsid and viral RNA (37) releasing the viral RNA into the cytoplasm. 
The viral RNA is then a template for the translation machinery of the host cell.  
Upon delivery of the viral RNA into the cytoplasm, host translation machinery 
translates the non-structural open reading frame to produce a polyprotein consisting of 
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nsP123 or nsP1234 depending on read-through of an Opal stop codon near the end of 
the nsP3 coding sequence (5, 38). This polyprotein consists of proteins necessary for 
replication of the viral genome. NsP4 contains the RNA-dependent RNA-polymerase 
(39, 40) and interactions between nsP4 and other non-structural proteins (41-46) form 
the viral replicase. NsP2 contains a protease domain necessary for processing of the 
polyprotein (47, 48). Processing of the early nsP123+4 replicase into nsP1+2+3+4 
replicase by nsP2-mediated cleavage at nsP1/2 and nsP2/3 sites switches replicase 
activity from production of negative-sense RNA intermediates to production of full length 
positive sense genomes (5, 49-51). In addition to full length positive-sense genomes, the 
replicase produces positive sense transcripts from an internal promoter in the junction 
between the 5′ and γ′ open reading frame (Fig 1-1A) that encode the structural 
polyprotein (5, 11).  
In addition to forming the replicase, the individual non-structural proteins have 
other important functions that facilitate viral replication. NsP1 contains methyltransferase 
and guanylyltransferase domains important for producing capped viral genomes (52, 
53). NsP2 is a multifunctional protein and in addition to the C-terminal protease domain 
encodes for NTPase, 5′-triphosphatase and helicase functions (54-56). NsP2 is also the 
principal viral protein responsible for interfering with host antiviral signaling, discussed in 
more detail later in this chapter. NsP3 contains a conserved N-terminal domain that can 
bind ADP-ribose (57) while the C-terminal half of the protein exhibits significant variation 
(58) and likely functions to interact with host factors (59, 60).  
In the later stages of replication, the subgenomic mRNA is translated at the 
endoplasmic reticulum (ER) membrane to produce a structural polyprotein. Capsid 
cleaves itself from the polyprotein in cis and is released into the host cytoplasm to 
associate with newly synthesized viral genomes via packaging signals located in the 
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nsP1 or nsP2 region of the genome (61, 62). The accessory protein E3 is associated 
with E2 in the pE2 polyprotein and chaperones the glycoproteins as they traffic through 
the ER and Golgi to prevent premature conformational changes (63). Host proteases 
further process the polyprotein as the proteins traffic through the ER and Golgi to 
produce the mature E2 and E1 glycoproteins (64). Cleavage of the pE2 protein into 
mature E2 is essential as viruses retaining bound E3 are non-infectious (65). The 
accessory protein 6K and likely TF function to promote proper processing and formation 
of E2/E1 dimers (8, 66, 67). The cytoplasmic tail of E2 associates with encapsidated 
viral genomes at the cell membrane and progeny virions are then released by budding 
(68).  
Chikungunya Virus Epidemiology     
 CHIKV was first described in the 1950s in Africa during an outbreak of viral fever 
(2). In the decades that followed, CHIKV caused sporadic outbreaks in Africa and Asia 
(69). CHIKV is maintained in nature by an obligate mosquito to vertebrate to mosquito 
life cycle and is principally spread by Aedes species mosquitoes. Most major epidemics 
are sustained by an urban, or mosquito to human to mosquito life cycle (70). However, 
epidemics of CHIKV have occurred in spillover from the sylvatic cycle in which the 
vertebrate host is forest dwelling non-human primates (71, 72). Phylogenetic analysis 
has identified three distinct genotypes of CHIKV: related East Central South African 
(ECSA) and Asian genotypes and a more divergent West African (WA) genotype (70). 
The most recent common ancestor for all CHIKV genotypes is estimated to have existed 
within the last 500 years (73). Divergence of the Asian genotype from the ECSA 
genotype is predicted to have occurred within the last 150 years, possibly even as late 
as the 1950s (73, 74).  
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 Although CHIKV was known to India and Southeast Asia, CHIKV of an ECSA 
genotype “re-emerged” into the Indian Ocean and Southeast Asian region beginning in 
2004. In 2004 to 2005, CHIKV spread from mainland Africa following an outbreak in 
Lamu Kenya, in which 75% of the population were infected (75), to islands in the Indian 
Ocean (38, 76) and to mainland India and causing several million estimated cases (77). 
The outbreak on La Reunion Island, a French territory, was particularly severe with one-
third of the island (>240,000 cases) becoming infected and atypical manifestations such 
as neurological complications and death reported (78). Viremic travelers returning from 
CHIKV epidemic regions initiated localized CHIKV epidemics in Italy (79, 80) and France 
(81, 82). CHIKV continued to spread from the Indian Ocean region reaching Southeast 
Asia with outbreaks in Sri Lanka (83), Thailand (84), Singapore (85), Malaysia (86) and 
Papua New Guinea (87). The rapid re-emergence of CHIKV out of Africa into the Indian 
Ocean region and beyond surprised public health experts and further studies indicated 
that this re-emergence was associated with adaptation to a new mosquito vector, Aedes 
albopictus, that likely facilitated rapid spread (88). Asian genotype CHIKV continued to 
circulate in these regions (89) and likely spread from Indonesia into the Pacific Ocean 
with outbreaks in New Caledonia and Yap Island (87, 90, 91). 
 Aggressive vector control was shown to be effective in limiting CHIKV epidemics 
in France, Italy and New Caledonia (79, 81, 91) and the Centers for Disease Control and 
Prevention (CDC) and Pan American Health Organization (PAHO) released a guide in 
2011 in preparation for the introduction of CHIKV in the Americas that stressed vector 
control as an important measure to contain any outbreaks (92). As anticipated, CHIKV 
emerged in the Americas in late 2013 and has since caused nearly two million cases 
throughout the Caribbean and North and South America (93, 94). The epidemic in the 
Americas started with an outbreak on the Caribbean Island of St. Martin (95), likely from 
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a traveler from Indonesia, China or the Philippines based on phylogenetic analysis of 
early viral isolates (96), demonstrating the speed at which international travel can 
disseminate CHIKV. Demonstrating a failure of public health authorities to contain the 
isolated emergence, CHIKV then spread from St. Martin to other islands in the 
Caribbean and rapidly reached mainland South America (97). Documented 
autochthonous transmission of CHIKV is now reported in 45 countries including limited 
outbreaks in the states of Florida and Texas (94, 98). The speed at which CHIKV spread 
in the Americas portended the introduction and spread of Zika virus (99) a flavivirus 
which is spread by similar Aedes mosquito vectors. The continued circulation and 
outbreaks of dengue virus in the Americas (100), another similarly vectored flavivirus, 
suggests CHIKV will continue to be a public health burden for years to come.  
Interestingly, the circulating genotype in the Americas is Asian in contrast to the 
ECSA genotype observed in the previous large scale epidemics of CHIKV in the Indian 
Ocean region (95, 96, 101) demonstrating that both CHIKV lineages can cause 
explosive epidemics. It is also unknown whether a “re-emergence” of CHIKV into the 
Americas and subsequent public health burden will be possible in the years to come, 
similar to what was observed in the Indian Ocean region when ECSA genotype CHIKV 
replaced Asian genotype CHIKV as the circulating strain. Indeed, ECSA genotype 
CHIKV has been observed in the Americas already (101) and due to unique genetic 
flexibility, ECSA viruses seem uniquely poised to exploit the Aedes albopictus vector 
(88, 102-104) which has a wider geographic distribution than Aedes aegypti, especially 




Chikungunya Virus Disease in Humans 
 Chikungunya derives from the Makonde language of Africa and translates to 
“become contorted” or “that which bends up” (106), reflecting the severe musculoskeletal 
disease exhibited by humans. Patients often describe the pain inflicted by CHIKV as 
excruciating and the worst pain they have ever experienced (107) and the first 
description of chikungunya by Marion Robinson in the 1950s described the pain as 
“frightening in its severity” (2). Following a bite from an infected mosquito, CHIKV 
disease in humans is characterized as an abrupt onset of fever and debilitating pain in 
the joints that typically lasts for one to two weeks but can last much longer (79, 107-
110). The majority of infected patients will become symptomatic (108, 111). These 
classical CHIKV symptoms have been consistent among geographically diverse 
outbreaks caused by CHIKV strains of all phylogenetic lineages (112-114). Joint pain 
typically afflicts the smaller peripheral joints (75, 115, 116) and inflammatory bone 
lesions can be observed by imaging of the joints in some patients (117, 118). In addition 
to these signs and symptoms, patients commonly report rash, headache, muscle pain, 
diarrhea and eye complications (78, 79, 85, 119). CHIKV may also be associated with 
increased neurological complications such as Guillain-Barré syndrome (120). 
Cumulatively, these symptoms are debilitating and usually interfere with daily activities 
(75, 121) and impose significant public health costs (122, 123). Related alphaviruses, 
RRV, ONNV and MAYV cause similar disease signs and symptoms in humans (124-
128).  
 Atypical outcomes of CHIKV infection such as heart failure, encephalitis, 
hepatitis, kidney failure and death were reported in recent CHIKV outbreaks (78, 129-
131) though these were typically seen in children or adults with co-morbidities. CHIKV 
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infection in neonates is particularly severe with frequent complications including 
encephalitis with prolonged neurologic sequela and even death (78, 132-135).  
 It is becoming increasingly appreciated that these initial inflammatory 
musculoskeletal disease signs and symptoms following acute infection with CHIKV, or 
related alphaviruses can take weeks to resolve (116, 124, 126, 136-139) and can 
develop into a protracted musculoskeletal disease that lasts for months to years. This 
chronic phase of CHIKV disease is discussed in more detail later in this chapter.  
Therapies and Vaccines Against Chikungunya Virus 
 Treatment of acute CHIKV disease typically consists of pain management 
through the use of pain killers and non-steroidal anti-inflammatory drugs. Management 
of chronic CHIKV musculoskeletal pain is based on the specific symptoms reported by 
the patient but can involve pain management along with corticosteroids or methotrexate 
(117). There are no established CHIKV-specific antivirals and although ribavirin showed 
efficacy in a small study of 10 patients (140) further studies are needed. 
Currently there are no approved vaccines for CHIKV. However, several vaccine 
candidates have shown efficacy and have reached various stages of pre-clinical and 
clinical trials. A formalin-inactivated CHIKV preparation was tested in the 1970s and 
showed efficacy in volunteers with an absence of side effects (141) although it was 
apparently not developed further. A live-attenuated CHIKV vaccine candidate was 
developed by serial tissue culture passaging of a virulent CHIKV isolate (142) and was 
found to be protective in volunteers (143). However, development of this vaccine was 
abandoned when it was found that a subset of these volunteers developed transient 
arthralgia suggesting insufficient attenuation. Indeed, it was found in subsequent studies 
that attenuation was due to only two amino acid changes in the vaccine virus (144). 
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Further studies with other vaccine platforms have shown promise. Virus like particles 
(VLP) induce protective immunity in mice and non-human primates (NHPs) (145, 146) 
and a small clinical trial suggested efficacy in humans with no adverse events (147). 
DNA-based vaccines induce strong humoral and cell-mediated immune responses (148) 
but have yet to reach human clinical trials. A live-attenuated CHIKV vaccine candidate, 
in which the promoter for the second open reading frame encoding the structural 
proteins was replaced with an internal ribosome entry site (IRES), showed significant 
attenuation and induced protective responses in mice (149-151). A measles virus-based 
CHIKV vaccine candidate reached phase I human clinical trials but showed severe 
adverse events in 17% of patients (152). Nevertheless, phase II trials of this vaccine 
candidate have been scheduled. Consequently, treatment of CHIKV is limited to 
palliative care and outbreaks can only be contained via vector control.  
Animal Models of Chikungunya Virus Pathogenesis 
 Animal models provide an invaluable tool for understanding CHIKV 
pathogenesis. NHPs can be successfully infected with CHIKV. Infection of rhesus and 
cynomolgous macaques with CHIKV results in viremia, fever, rash and joint pathology 
(153-155) and administration of high doses can result in a fatal encephalitic disease 
(153). In NHPs, joint-associated tissue, lymphoid tissue and the liver are major targets of 
infection (153, 155). In addition to NHPs, mice have been extensively used to study 
CHIKV pathogenesis. WT mice from commonly used inbred lines, such as C57BL/6 and 
129, exhibit an age-dependent outcome following CHIKV infection. Neonatal WT mice 
under 6 days of age uniformly succumb to infection while in 9 day old mice about one-
third of mice succumb (156). In WT mice older than 12 to 14 days, CHIKV causes no 
mortality (156-159). This age-dependent lethality of CHIKV infection reflects the severe 
disease often seen in CHIKV-infected infants. There are likely also host genetic 
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determinants of CHIKV infection outcomes as neonatal outbred CD1 or ICR mice exhibit 
much less mortality following CHIKV infection than the inbred C57BL/6 mice used for 
most CHIKV studies (160). In addition to an age-dependent lethal infection, mice are 
also able to recapitulate the musculoskeletal disease reported in humans. Two to four 
week old mice infected with CHIKV develop a disseminated infection with significant 
viremia and viral burdens in lymphoid tissue and joint associated tissue at early time 
points (157, 158). Adult mice also develop a musculoskeletal disease with similar 
viremia and viral tropism as seen in the younger mice (159). Mouse models are also 
useful for studying the pathogenesis of related alphaviruses such as RRV (161) and 
ONNV (162).  
Host Immune Response to Chikungunya Virus 
 CHIKV infection is highly cytopathic in vitro (163) and humans and animal 
models mount a robust innate and adaptive immune responses to control infection. The 
primary early defense against CHIKV and related alphaviruses is the type I interferon 
(IFN) response. CHIKV induces high levels of type I IFNs during the acute phase of 
infection in humans (164-167) and animal models (153, 159, 168, 169). Levels of type I 
IFNs correlate well with viral loads and decline as viremia is controlled (153, 159, 165), 
however, patients with chronic symptoms can have persistent IFN production months 
after infection (170). Defects in type I IFN signaling or IFN-induced effector functions 
greatly exacerbate CHIKV disease in mice (167, 171), and a complete absence of type I 
IFN signaling through deletion of the receptor for type I IFN leads to a rapidly fatal 
infection (165, 172). CHIKV exhibits a strong tropism for fibroblast type cells both in vivo 
(165) and in vitro (163) and it is likely these non-hematopoetic cells are the major 
sources of type I IFNs in vivo following CHIKV infection (165). Infected macrophages 
may also contribute to the type I IFN response in vivo (153, 173). 
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Sensing of the double stranded RNA replication intermediates produced by 
positive-sense RNA viruses is a central mechanism in the induction of the type I IFN 
response. In vivo mitochondrial antiviral signaling protein (MAVS), the adaptor protein 
downstream of the RIG-I-like RNA helicases (RLRs), is critical in inducing type I IFN in 
response to CHIKV infection (174) suggesting an important role for the RLRs in sensing 
CHIKV. Mice deficient in tir-domain-containing adapter-inducing interferon  (TRIF), the 
adaptor protein for toll like receptor 3 (TLR3), or myeloid differentiation primary response 
gene 88 (MyD88), the adaptor protein for toll like receptor 7 (TLR7) and others, had 
diminished type I IFN responses (174) suggesting important roles for the TLRs in 
sensing CHIKV in vivo as well. However, multiple innate sensors and pathways likely 
converge to recognize CHIKV infection and induce a protective IFN response as mice 
singly deficient in an RLR, TLR3 or adaptor proteins TRIF, MAVS and MyD88, had a 
mild phenotype compared to complete type I IFN deficient mice (165, 174). The 
interferon regulatory factors (IRF) 3 and 7 are central coordinators of TLR and RLR 
signaling (175) and CHIKV-infected Irf3/7-/- mice fail to induce an IFN response and 
rapidly succumb to the infection (174). IFN signaling induces hundreds of interferon 
stimulated genes (ISGs) (176) and IFN-induced viperin, tetherin, ISG15, spermidine-
spermine acetyltransferase (SAT1) and β’5′-Oligoadenylate synthetase (OAS) have 
been implicated as potential IFN-induced effectors that restrict CHIKV replication (167, 
171, 177, 178). 
Highlighting the importance of type I IFN in controlling the infection, CHIKV and 
related alphaviruses antagonize this process through a variety of mechanisms. 
Principally, the CHIKV nsP2 protein blocks IFN signaling by interfering with JAK/STAT 
signaling (179) and inducing host transcriptional shutoff (180, 181) by degradation of the 
catalytic subunit of the host DNA-dependent RNA polymerase (182). NsP2 can also 
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induce host translational shutoff via protein kinase R (PKR)-dependent and -independent 
mechanisms (183-185) but viral proteins are still efficiently expressed (16, 17). The 
cumulative effect of these processes prevents the host cell from translating paracrine or 
autocrine IFN signaling into an antiviral state while still allowing the virus to efficiently 
replicate. Determinants of sensitivity to type I IFN are also present in nsP1 perhaps by 
influencing capping of the viral genome (186). Despite these viral countermeasures, type 
I IFN remains essential in controlling early alphavirus infection.  
 In addition to inducing a robust type I IFN response, CHIKV and related 
alphaviruses induce a strong pro-inflammatory cytokine response. Pro-inflammatory 
cytokines and chemokines such as IL-6, TNFα, CCLβ (Monocyte chemotactic protein 1, 
MCP1) and CxCL10 have been found to be upregulated in humans, NHPs and mice 
infected with CHIKV or related alphaviruses (153, 159, 166, 167, 169, 187-190). In 
response to these pro-inflammatory signals CHIKV- and RRV- infected tissues are 
heavily infiltrated with inflammatory monocytes, macrophages and activated NK cells 
within days after infection (153, 161, 169, 170, 191, 192). These cellular infiltrates 
contribute to the severe tissue damage and joint pathology. Infiltration of these tissues 
temporally correlates with RRV-induced musculoskeletal tissue destruction (161, 193), 
mice depleted of macrophages or NK cells show reduced disease (169, 193, 194), and 
blockade of monocyte infiltration ameliorated virally-induced disease in mice (195). 
Infiltration of these tissues by macrophages and infection of osteoblasts can also disrupt 
bone homeostasis and trigger pathogenic bone loss (138, 195, 196). The severe tissue 
damage inflicted by these cellular infiltrates likely also requires complement activation 
via the mannose binding lectin pathway as mice deficient in this pathway have reduced 
tissue pathology despite similar cellular infiltrates (197, 198). However, disruption of 
monocyte and macrophage infiltration of these tissues by Ccr2 ablation leads to 
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exacerbated arthritic disease due to enhanced infiltration of the tissue by neutrophils 
(191). Furthermore, blockade of TNF signaling also exacerbated RRV-induced disease 
(199). In response to the severe tissue damage induced by these responses, 
macrophages engage a wound healing type response that suppresses antiviral T cell 
responses and delays viral clearance (159, 200). Together these results demonstrate 
that CHIKV infection induces a robust inflammatory immune response that is important 
both in resolving the infection while also promoting severe tissue destruction and 
delaying viral clearance.    
 A rapid and robust adaptive immune response is engaged to control CHIKV 
infection and this adaptive response acts to control the primary infection and likely 
prevents re-infection. In contrast to mice deficient in the type I IFN response, mice 
deficient in adaptive immune responses do not succumb to CHIKV infection (157, 168, 
201). However, mice or aged NHPs with defects in adaptive immunity exhibit protracted 
viremia and elevated viral burdens in various tissues following infection with CHIKV or 
RRV (154, 157, 168, 200) demonstrating the requirement of adaptive immune responses 
in controlling the primary CHIKV infection. My work presented in Chapter III and IV 
demonstrates that mice deficient in mature B and T cells exhibit elevated viral loads in 
musculoskeletal tissue in addition to persistent viremia for weeks post infection (157, 
202). 
Arthritogenic alphavirus infection induces a robust cell-mediated immune 
response. Musculoskeletal tissues are infiltrated by CD4 and CD8 T cells soon after 
infection with RRV or CHIKV (161, 169, 203), and CHIKV infection robustly activates 
circulating T cells in humans (164, 170). Activation of the T cell response contributes to 
control of CHIKV viremia (168) and RRV infection in muscle tissue (203). Suppression of 
this response by the highly inflammatory microenvironment of the infected tissue 
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contributes to delayed viral clearance (200) demonstrating a critical interplay between 
the innate and adaptive immune response to the infection. However, T cells are unable 
to control viral loads in joint tissue (203) and may even promote joint pathology (157, 
168, 204). CHIKV-infected patients maintain virus specific T cells at 12 months post-
infection (205) suggesting that the virus specific T cell response is sustained long term 
following CHIKV infection. However, the role of the T cell response in protecting against 
re-infection is unclear as adoptive transfer of vaccine-induced immune T cells did not 
confer protection in a lethal challenge model (206). 
CHIKV infection induces a robust humoral immune response and the antibody 
response to CHIKV and related alphaviruses has been extensively characterized, likely 
due to the ease of sample collection and analysis. CHIKV infection rapidly induces an 
IgM response with significant titers being detectable 4-5 days post infection in mice (201, 
202). Interestingly, CHIKV-specific and RRV-specific IgM can persist for months in 
humans following acute infection (89, 110, 207-210). Likewise, CHIKV-infected NHPs 
had detectable CHIKV-specific IgM at 180 dpi (211) and mice had CHIKV-specific IgM at 
402 dpi (201). In contrast, in my own studies I did not observe a protracted IgM 
response. Following inoculation of three week old WT mice with CHIKV I found that 
CHIKV-specific IgM titers declined below the limit of detection by 28 dpi (202) although 
the differing results may reflect differences in assay sensitivities. IgG responses are also 
rapidly induced with significant CHIKV specific IgG titers detectable within 6-10 days 
post infection in both mice and humans (201, 202, 212, 213) and by 16 dpi in NHPs 
(211). Induction of an optimal IgG response is T-dependent as mice deficient in CD4 T 
cells or MHC class II have diminished IgG responses (168, 201). The majority of 
antibody induced in humans, NHPs and mice targets the viral glycoprotein E2 (201, 211, 
212, 214, 215), likely due to its highly exposed nature on the virion (Fig 1-1B and C). 
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Additional antibody epitopes are found on the other CHIKV structural proteins capsid, E3 
and E1 in addition to epitopes in the non-structural protiens nsP1, nsP3 and nsP4 (201, 
211, 214) though their role in control of CHIKV is unclear. Antibody responses to 
infection by a particular virus in the SF antigenic clade confer some protection to 
infection by another virus in the clade, at least in animal models. Previous RRV infection 
or RRV specific anti-sera ameliorated CHIKV infection (159) and antibody induced by a 
CHIKV-based vaccine can protect against ONNV challenge (151). In contrast, pre-
existing alphavirus immunity may interfere with development of a robust humoral 
response to a heterologous alphavirus (216).  
Humoral immune responses are critical for controlling the primary infection and 
resolution of symptoms as B cell deficient mice sustain prolonged viremia for months 
post infection (157, 168, 201, 202) and early appearance of neutralizing antibody 
correlated with more rapid resolution of symptoms in CHIKV-infected humans (213). 
Diminished neutralizing antibody responses due to defects in TLR3 or TLR7 signaling 
are also associated with exacerbated musculoskeletal disease in CHIKV- or RRV-
infected mice (217, 218) and my work presented in Chapter IV demonstrates that poorly 
neutralizing antibody responses promote viral persistence (202). Administration of 
neutralizing CHIKV antibodies prior to or after infection can protect from development of 
musculoskeletal disease (36, 219), clear CHIKV from the circulation (157, 168) and even 
protect against lethal CHIKV infection in type I IFN deficient mice (206, 220, 221). In 
addition to neutralization of infectious virus, engagement of Fc receptors by antibody has 
been shown to be important for antibody mediated protection from disease (220).  
Chronic Chikungunya Virus Disease 
Since the first clinical description of CHIKV and in the decades that followed, a 
protracted course of musculoskeletal disease has been reported in patients following 
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CHIKV infection (2, 112, 222). In addition, protracted disease signs and symptoms have 
been reported to occur following RRV, MAYV and SINV infections (124, 126, 136, 189, 
223-225) suggesting this is a common clinical feature of arthritogenic alphavirus 
infection. However, our understanding of this phase of disease was limited due to limited 
outbreaks and small study cohorts. The unprecedented scale of the re-emergence of 
CHIKV in the mid-2000s brought public health awareness to chronic CHIKV disease and 
the large number of afflicted patients provided an opportunity to study the signs, 
symptoms, incidence and risk factors for developing chronic disease.  
Chronic CHIKV disease is typically characterized by persistent joint pain, 
redness, and swelling lasting for months to years that can occur in a continuous or 
intermittent pattern and is often of sufficient severity to interfere with daily activities (110, 
117, 226-228). Radiographical examination of joints of patients reporting chronic 
symptoms revealed pathologies such as joint effusion, bone erosion, synovial thickening, 
tendinitis, tenosynovitis, articular destruction, and cartilage destruction  (117, 118, 138). 
However, patients also reported joint pain in the absence of radiographical evidence of 
joint pathology (117, 170). Patients reporting chronic symptoms typically have elevated 
levels of pro-inflammatory cytokines such as IL-6, MCP-1 and granulocyte-macrophage 
colony stimulating factor (170, 229, 230) suggesting an ongoing inflammatory response. 
Although symptoms reported by patients exhibiting persistent pain following CHIKV 
infection may be similar, chronic CHIKV disease may be a collection of distinct 
pathologies affecting distinct regions within musculoskeletal tissues (117). In addition to 
protracted joint pain, patients also report ongoing fatigue and neurological complications 
following CHIKV infection (231).  
Although the incidence rate of chronic CHIKV disease varies between study 
cohorts and the time point of analysis, all studies undertaken to date have found a 
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significant portion of patients reporting chronic symptoms following acute infection (110, 
226, 227, 231-234). In an early study of patients returning from the Reunion Island 
outbreak, 88%, 86% and 48% of patients reported symptoms at 1, 3 and 6 months post 
disease onset, respectively (226). Similarly, 63.8% of patients on Reunion Island had 
persistent symptoms at 18-months post disease onset (110). Early reports of chronic 
CHIKV disease in the ongoing outbreak of CHIKV in the Americas suggest a similar 
pattern with the majority of patients reporting protracted symptoms for months post 
disease onset (235-237). Furthermore, these symptoms can persist for years. In a report 
of patients 36 months post CHIKV infection, 60% of patients continued to report ongoing 
arthralgia (208) and a recent retrospective study suggests the pain can last for 6 years 
or longer (117). The high prevalence of patients exhibiting symptoms months to years 
post infection challenge the notion that CHIKV infection is a self-limiting acute disease 
and rather suggests that CHIKV infection often develops into a protracted, chronic 
morbidity with significant disability imposed on patients. In areas where CHIKV circulates 
along with other viral causes of febrile illnesses, e.g., dengue, differential diagnoses of 
acute disease can be difficult (238). However, CHIKV, in contrast to dengue, seems to 
uniquely cause persistent, chronic musculoskeletal disease signs and symptoms which 
can be used to distinguish the infections (83, 239). Therapy is limited principally to 
analgesics although corticosteroids and the chemotherapeutic agent methotrexate have 
shown efficacy in reducing chronic symptoms (117, 121). 
 Several risk factors for development of protracted CHIKV disease have been 
identified. Most consistently, increasing age is positively correlated with the incidence of 
chronic CHIKV disease (170, 208, 227, 232-234, 239). Other risk factors include co-
morbidities such as pre-existing joint pain (110, 227) and female gender (85, 234). 
Contrastingly, initial disease severity has been found to both negatively (213, 240) and 
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positively correlate with development of chronic disease (110, 115, 227, 232). 
Importantly, in regards to work in this thesis, delayed development of a neutralizing 
antibody response also predicted development of chronic disease (213).  
 Despite the large number of patients exhibiting persistent CHIKV disease, the 
underlying causes of the disease signs and symptoms remains unknown. One potential 
explanation is that CHIKV induces a rheumatoid arthritis (RA)-like immunopathology 
(241). Virally induced autoimmunity can occur through a variety of mechanisms (242-
244) including molecular mimicry or continual activation of RNA sensing pathways. 
Molecular mimicry between an SFV derived peptide and host myelin results in a fatal 
autoimmune disease in SFV-infected mice (245) demonstrating that a related alphavirus 
can induce an autoimmune disease via this mechanism. 
However, evidence for a CHIKV induced autoimmune disease is lacking. Acute 
CHIKV infection induces a pro-inflammatory cytokine response similar to what is induced 
during the early development of RA (166, 187, 241, 246). Patients exhibiting chronic 
CHIKV disease have elevated levels of pro-inflammatory cytokines similar as to what 
has been observed in RA (170, 229, 230, 247-249) and inflammatory infiltrates of 
chronically-inflamed joints are similar between CHIKV- or RRV-infected patients (170, 
250) and RA (251). Despite these many similarities with RA, chronic CHIKV disease has 
important distinctions from RA principally the reporting of chronic CHIKV disease 
symptoms in the absence of rheumatoid factor (RF) and anti-citrullinated peptide 
antibodies (112, 170, 209, 252-255), hallmarks of classical RA (256). Finally, my work 
presented in chapter III demonstrates that mice deficient in adaptive immune responses 
exhibit persistent joint pathology for weeks post infection (157) suggesting that chronic 
joint pathology can occur in the absence of adaptive immunity. Cumulatively, these data 
suggest that the protracted musculoskeletal disease induced following infection with 
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CHIKV or related alphaviruses is due to a sustained inflammatory response and, while 
sharing similarity to RA, is a distinct rheumatic manifestation unlikely to be due to virally-
induced autoimmunity. However, why patients sustain a pro-inflammatory response for 
weeks to months after CHIKV infection is unclear. 
 A building body of evidence suggests that CHIKV and related alphaviruses 
establish long term chronic infection of joint-associated tissue. In humans, CHIKV RNA 
and antigen were found in synovial macrophages of inflamed joints 18 months post 
disease onset (170). CHIKV antigen was detected in muscle satellite cells from a muscle 
biopsy collected from a patient reporting persistent symptoms 3 months post disease 
onset (257). Similarly, RRV RNA was also detected in synovial biopsies of patients 
reporting persistent symptoms weeks post disease onset (250). Although limited, these 
data suggest that CHIKV and related alphaviruses can establish persistent infections in 
humans. Further supporting this hypothesis are studies from animal models of CHIKV 
infection. Infection of NHPs with CHIKV leads to detectable viral antigen and infectious 
virus in lymphoid and joint associated tissue for at least 6 weeks post infection (153-
155). Localization of CHIKV antigen within these tissues suggests that macrophages 
may serve as the cellular reservoir of persistent CHIKV infection in NHPs (153). 
Furthermore, several studies have established that CHIKV infection persists in tissues of 
experimentally-infected mice. Mice infected with a recombinant CHIKV expressing 
luciferase had detectable luciferase activity in joint tissue for at least 60 dpi (204). 
Infection of WT C57BL/6 mice with CHIKV resulted in detection of both positive and 
negative sense viral RNA, indicative of active viral replication, in joint associated tissue 
for at least 180 days post infection (168). My work presented here in chapter III and IV 
further supports the hypothesis that CHIKV infection can result in viral persistence and 
associated joint pathology (157, 202). Infection of three to four week old WT mice with 
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CHIKV results in detection of CHIKV in a variety of tissues such as the serum, joint-
associated tissue, muscle, brain, liver and spleen. In contrast to early time points, at later 
time points I found that CHIKV was efficiently cleared from the majority of tissues with 
the exception of joint-associated tissue where CHIKV RNA persisted for at least 16 wpi. 
Persistence of viral RNA in joint-associated tissue was correlated with evidence of 
ongoing synovitis in these tissues. Similar observations have been made following 
MAYV infection of mice (Michael Diamond, personal communication).  
Cumulatively these data suggest that chronic musculoskeletal inflammation and 
pain following acute CHIKV infection are common clinical outcomes and that these 
disease signs and symptoms may be due to persistent viral replication. However, our 
knowledge of the host and viral mechanisms that contribute to this chronic phase of 
disease is lacking. It is likely that early events in the viral infection dictate the outcome of 
infection, thus early therapeutic intervention may limit chronic morbidity. Furthermore, 
host immune responses appear to have pathogenic and protective components and may 
even contribute to viral persistence. Thus, an understanding of these responses is 
needed to inform potential therapeutic strategies to modulate the host immune response 
to suppress pathogenic responses while promoting responses that resolve the infection. 
Finally, if indeed CHIKV and related alphaviruses establish long term persistence, the 
viral determinants that contribute to this are unknown. An understanding of how CHIKV 
establishes and maintains persistence for months to years despite robust adaptive 
immune responses will not only provide critical insight into CHIKV biology but also 
contribute to a growing body of evidence that RNA viruses can persist long term after 





 Despite the significant, global and continued public health burden imposed by 
CHIKV infection, our understanding of viral determinants of acute and chronic CHIKV 
pathogenesis is clearly limited and many important questions are unanswered. My work 
presented here contributes new information towards several unanswered questions. 
First, is chronic CHIKV disease due to persistent CHIKV infection? Secondly, if so, how 
does CHIKV evade adaptive immune responses to establish and maintain persistence? 
Lastly, is persistence of CHIKV associated with accumulation of adaptive mutations in 
the viral genome that promote the establishment and/or maintenance of a persistent 
infection? 
In chapter III, I show that CHIKV infection of immunocompetent mice results in 
persistence of viral RNA for up to 4 weeks in lymphoid tissue and at least 16 weeks post 
infection in joint-associated tissue. Furthermore, my studies show that persistence of 
viral RNA in joint-associated tissues is associated with ongoing joint pathology. Studies 
using immune deficient mice demonstrated that T and B cell responses are required to 
clear CHIKV from numerous tissues including the blood and skeletal muscle tissue. In 
joint-associated tissues adaptive immune responses significantly reduced viral burdens 
but were unable to effect clearance. Studies with monoclonal neutralizing antibodies 
showed that prophylactic administration of antibody could prevent development of 
persistence in mice. However, therapeutic administration of antibody showed tissue 
specific efficacy and was able to clear infectious virus from the serum but only modestly 
reduced viral burdens in joint-associated tissue.  
Expanding on these findings, in chapter IV, I found that two highly related strains 
of CHIKV had differential capacity to establish persistence in mice. The CHIKV vaccine 
strain 181/25 was cleared from disseminated sites of infection at later time points, 
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despite replicating to high titers at early time points in these tissues. In contrast, CHIKV 
strain AF15561, the pathogenic parental virus of 181/25, established a persistent 
infection similar to other clinical isolates of CHIKV. However, 181/25-infected mice 
deficient in B cell and antibody responses had persistent viral RNA at equivalent levels 
to that of AF15561-infected mice suggesting that in the absence of antibody responses, 
181/25 is able to establish a persistent infection. These findings raised the intriguing 
question of why antibody responses effectively controlled 181/25 but not AF15561 or 
other persistent strains of CHIKV. Neutralization studies with mouse and human immune 
serum and monoclonal antibodies revealed that a highly conserved residue in the CHIKV 
glycoprotein E2 influenced viral susceptibility to neutralizing antibody responses directed 
against a specific domain within the E2 glycoprotein. Cumulatively these findings 
demonstrate that antibody is a critical component of the host’s ability to control CHIKV 
and importantly demonstrate a mechanism by which CHIKV evades neutralization by 
antibody to establish persistence.  
Finally, it is unclear if persistence of CHIKV requires or is associated with 
accumulation of mutations in the viral genome. Although limited sequencing of viral RNA 
was inconclusive, I isolated and characterized a strain of CHIKV from the serum of 
persistently infected Rag1-/- mice that had significantly enhanced virulence when re-
inoculated into WT mice. Sequencing of this CHIKV strain revealed polymorphisms in 
the E2 glycoprotein and γ′ untranslated region that conferred enhanced musculoskeletal 
disease, expanded tissue tropism and increased viral burdens at early time points post 
infection. Further studies with this virus will provide novel insight into restriction factors 
that limit early CHIKV replication and dissemination within the mouse.  
Together the findings of my thesis provide novel insight into viral determinants of 
acute and chronic CHIKV pathogenesis. I have shown that CHIKV must overcome 
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neutralizing antibody responses to establish long term persistence within joint associated 
tissue. I have further identified two novel virulence determinants that influence early viral 
dissemination and replication. These findings will facilitate further studies examining 
innate and adaptive immune responses to CHIKV and how the virus evades these 






Figure 1-1: Chikungunya virus genome organization and glycoprotein structure.  
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Figure 1-1: Chikungunya virus genome organization and glycoprotein structure. 
(A) Chikungunya virus contains a single-stranded, positive sense RNA genome of 
approximately 11.5-12kb. It encodes 7 major proteins in two open reading frames 
(arrows). The 5′ open reading frame encodes non-structural proteins nsP1-nsP4 that 
form the viral replicase and alter the host cellular environment. The γ′ open reading 
frame encodes the structural proteins, capsid (C) and two glycoproteins E2 and E1. It 
also encodes 3 accessory proteins, E3, 6K and a -1 ribosomal frame shift in 6K 
produces transframe (TF). The RNA genome contains a 5′ cap and γ′ poly-A tail along 
with untranslated regions at both ends and in the junction region between the two ORFs. 
(B) A chikungunya virus E2/E1 dimer is shown. E1 is colored light grey, the E1 fusion 
loop is colored pink, E2 domain A is colored dark blue, E2 domain B is colored orange, 
E2 domain C is colored red, and the E2 arch regions are colored light blue (PDB: 3N42; 
Voss et al. 2010). (B and C ). A single chikungunya virus trimeric spike composed of 
three E2/E1 dimers is shown. The apical surface is facing outward in (B) and facing up 
in (C). E2 and E1 also contain domains that extend through the viral membrane and 
interact with the nucleocapsid (not shown). E2 is responsible for engaging an unknown 
cellular receptor to trigger viral entry. Low pH-induced conformational changes alter this 
structure to expose the E1 fusion loop and trigger fusion between the viral and 





MATERIALS AND METHODS 
Mouse Experiments  
C57BL/6J WT mice (stock # 000664), congenic Rag1-/- mice (stock # 002216) 
and B cell deficient µMT mice (stock # 002288) were obtained from the Jackson 
Laboratory and bred in specific pathogen free facilities at the University of Colorado. 
Tg(IghelMD4)4Ccg/J (MD4tr) C57BL/6J mice, which encode a B cell receptor specific for 
hen egg lysozyme, were provided by John C. Cambier (University of Colorado School of 
Medicine). Animal husbandry and experiments were performed in accordance and with 
approval of the University of Colorado School of Medicine Institutional Animal Care and 
Use Committee guidelines. All mouse infection studies were performed in an animal 
biosafety level 3 laboratory. Three-week old mice were used for all studies. Mice were 
inoculated in the left rear footpad with 103 PFU of virus in diluent (PBS supplemented 
with 1% FBS) in a volume of 10 μl. Mock-infected animals received diluent alone. Mice 
were monitored for disease signs and weighed at 24-hour intervals. Mice that exhibited 
>20% weight loss or were moribund were considered at the humane endpoint and 
euthanized. In some experiments mice were scored for musculoskeletal disease as 
previously described (258). 1 = very mild deficit in hind paw gripping ability of injected 
foot only; 2 = very mild deficit in bilateral hind paw gripping ability; 3 = bilateral loss of 
gripping ability, mild bilateral hind limb paresis; altered gait not readily observable; 4 = 
Bilateral loss of gripping ability, moderate bilateral hind limb paresis, observable altered 
gait; difficulty righting self; 5 = bilateral loss of gripping ability, severe bilateral hind limb 
paresis, altered gait, unable to right self; 6 = moribund. On the termination day of each 
experiment, mice were sedated with isoflurane and euthanized by thoracotomy and 
exsanguination, blood was collected, and mice were perfused by intracardiac injection of 
28 
 
1x PBS or 4% paraformaldehyde, depending on the experiment. PBS-perfused tissues 
were removed by dissection and homogenized in TRIzol Reagent (Life Technologies) for 
RNA isolation or PBS/1% FBS for tissue titers using a MagNA Lyser (Roche). For 
prophylaxis studies, MAbs (β00 μg each of CHIK-152 and CHK-166 (220)or 400 μg of 
WNV E16 (28)) were administered by i.p. inoculation on days -1 and +3 as previously 
described(220). For therapeutic studies, MAbs were administered on days +21 and +25.  
Viruses 
The SL15649 strain of CHIKV (Genbank accession no. GU189061) was isolated 
from a serum sample collected from a febrile patient in Sri Lanka in 2006. This virus was 
passaged twice in Vero cells prior to generation of an infectious cDNA clone (23). CHIKV 
strain 181/25 was generated by serial tissue culture passage of CHIKV strain AF15561 
in MRC-5 cells. An infectious clone of 181/25 was generated by cloning of synthesized 
viral genome fragments into pSinRep5 (259). CHIKV strain AF15561 (Genbank 
accession no. EF452493) was isolated from a human patient during a 1962 outbreak of 
CHIKV in Thailand and passaged twice in Vero cells (141, 142). An infectious clone of 
AF15561 was generated from the 181/25 vaccine infectious clone by reverting 5 non-
synonymous coding changes between 181/25 and AF15561 using site directed 
mutagenesis (260). For mutant CHIKV strains, except for the 44 nt deletion in the γ′ UTR 
of AF15561, infectious clone plasmids were mutated using site directed mutagenesis to 
generate the indicated mutations. Restriction digest was performed to release a 
fragment containing the desired mutation and this fragment was ligated into an 
unmutagenized plasmid. The ligated fragment was sequenced to confirm only the 
desired mutation was present. Virus stocks were generated by electroporation of BHK-
21 cells with in vitro transcribed RNA. Infectious clone plasmids were linearized by 
restriction digest and used as template for an SP6 in vitro transcription reaction 
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(Ambion). RNA was then electroporated into BHK-21 cells and cells incubated for 24-30 
hours. Cell culture supernatants from electroporated cells were collected, clarified by 
centrifugation and aliquoted. Stock virus titers were quantified by plaque assay on BHK-
21 or Vero cells as described below. CHIKV strains 37997 and PO731460 were gifts of 
Ann Powers (Centers for Disease Control, Fort Collins, CO). The PO731460 strain 
(Genbank accession no. HM45788) was isolated from a human patient in India in 1973 
and passaged twice in Vero cells (6). The 37997 strain (Genbank accession no. 
AY726732) was isolated from Aedes furcifer mosquitoes in Senegal in 1983. This virus 
was passaged once in Aedes pseudoscutellaris (AP-61) cells and twice in Vero cells 
(26). Stocks of PO731460 and 37997 viruses were produced after a single passage in 
BHK-21 cells as previously described (27).  
Plaque Purification of CHIKV Strain AF6811P2 
AF6811P2 was isolated by plaque purification from the serum of a viremic Rag1-/-  
mouse infected 28 days previously with WT AF15561. Serum was mixed with PBS + 1% 
FBS and virus allowed to adsorb to Vero cells for 1 h. Following adsorption, the cells 
were overlaid with immunodiffusion agarose (MP Biomedical) + MEM-α + 10% FBS and 
incubated for ~40 hrs to allow plaque formation. From individual plaques, an agarose 
plug was removed and the virus was amplified by a single passage on Vero cells to 
generate viral stocks. Virus stocks were titered by plaque assay on BHK-21 and Vero 
cells. 
Sequencing of M ous e Adapted CHIKV Strain AF6811P2 
RNA was isolated from AF6811P2 stocks. 100μl of viral stock was mixed with 
1ml of TRIzol reagent (Life Technologies) and RNA isolated according to the 
manufacturer’s protocol. To generate cDNA for use in consensus sequencing, a 1:1 mix 
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of oligo-dT and random hexamer primers were used with Super Script IV reverse 
transcriptase (Life Technologies). PCR was then performed with primers spanning the 
viral genome and Q5 high-fidelity polymerase (New England Biolabs). PCR products 
were purified using a PCR cleanup kit (Qiagen) and submitted for Sanger sequencing 
(Eton Bioscience). Resulting sequences were mapped to the AF15561 genome using 
Geneious software (Biomatters). No template controls were included in parallel. In 
parallel to consensus sequencing, the AF6811P2 was sequenced using Illumina based 
sequencing (Illumina). Five hundred nanograms (ng) of isolated viral RNA was reverse-
transcribed using 500 ng of Random Primer 9 (NEB) and SuperScript II Reverse 
Transcriptase (Thermo Fisher Scientific) according to the manufacturer’s directions. 
Briefly, the reaction was equilibrated at 25C for 2 minutes, before the addition of 200 
units of SuperScript II reverse transcriptase. The reverse transcription reaction was 
incubated at 25C for 10 minutes, 42C for 180 minutes, and then inactivated at 70C for 
15 minutes. Double-stranded cDNA was prepared using the NEBNext mRNA Second 
Strand Synthesis Module (NEB) according to the manufacturer’s directions. Sequencing 
libraries were prepared from the double stranded cDNA using the Nextera XT DNA 
Library Preparation Kit (Illumina) following the standard protocol. Residual nucleotides 
were removed using Agencourt AMPure XP beads (BeckmanCoulter) at a DNA to bead 
ratio of 0.6:1. Library size and quality was measured using a 2100 Bioanalyzer (Agilent 
Technologies) and quantified with a Qubit Flourometer using the Qubit dsDNA HS Assay 
Kit (ThermoFisher Scientific). Sequencing reactions were performed on a MiSeq 
Desktop Sequencer (Illumina). Reads were sorted, aligned, and mutations characterized 
by Bowtie2 (261) and Samtools (262) following standard protocols. Results were 




Construction of AF15561 ΔUTR and AF15561 E2 K200R ΔUTR 
To insert the ΔUTR mutation into the AF15561 or AF15561Eβ Kβ00R backbone 
a multi-step cloning approach was used. cDNA from the AF6811P2 stock or WT 
AF15561 was generated by isolation of viral RNA using TRIzol reagent (Lifetech) and 
cDNA generated by SuperScript IV reverse-transcriptase with a 1:1 mix of oligo-dT and 
random hexamer primers. cDNA was utilized as template for PCR using primers 
CHIKV_10699F (5′- GCACCATCTGGCTTCAAGTA -γ′) and CHIKV_12036R (5′ – 
GAAATATTAAAAACAAAATAACATCTCCTA -γ′) and Q5 high-fidelity polymerase (New 
England Biolabs). This PCR reaction amplified a region from the γ′ end of E1 to the γ′ 
UTR immediately preceding the poly-A tail and contains restriction sites for SgrDI 
(10864) and SspI (12032). The PCR product was then cloned into the TOPO-II Zero 
Blunt Vector (Life Technologies) and transformed into DH5α max efficiency cells (Life 
Technologies). Plasmids containing the E1-γ′UTR region from either WT AF15561 or 
AF6811P2 were isolated (Qiagen). To insert the AF6811P2 γ′ UTR containing the 44nt 
deletion into AF15561 or AF15561 E2 K200R cDNA clones, the viral cDNA encoding 
plasmids and the TOPO vector containing the AF6811P2 γ′ UTR were subjected to 
digest by SgrDI (Thermo Fisher), cleaned up using PCR purification kit (Qiagen) and 
then digested with SspI (New England Biolabs). Fragments were isolated by gel 
extraction (Qiagen) and the plasmid backbones were subjected to treatment with 
Antarctic phosphatase (Life Technologies). Fragments were ligated using T4 DNA ligase 
(New England Biolabs) and transformed into DH5α max efficiency cells. Due to a second 
SspI site in the pSinRep5 backbone plasmid 200 bp downstream of the CHIKV poly-A 
tail, this strategy resulted in loss of the poly-A tail and two hundred bp of the plasmid 
backbone. To restore the authentic poly-A tail and plasmid backbone sequence, an 
unmutagenized AF15561 cDNA plasmid was digested with SspI to produce an 
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approximately 200bp fragment containing the authentic γ′ UTR and plasmid backbone. 
The 200bp fragment was isolated by gel extraction (Qiagen). The cDNA plasmids 
lacking the poly-A tail and 200 bp of the plasmid backbone were then linearized with 
SspI and treated with Antarctic phosphatase to prevent self-ligation. The 200bp fragment 
was then ligated into the linearized truncated plasmids and transformed into DH5α max 
efficiency cells. Restoration of the poly-A tail and plasmid backbone was confirmed by 
sequencing. Viral stocks of the mutant viruses were then generated from cDNA clones 
following standard protocols. 
Real-time RT-qPCR  
RNA was isolated using a PureLink RNA Mini Kit (Life Technologies) and the 
amounts of CHIKV positive-strand RNA present in tissues was quantified as previously 
described (25). Briefly, a CHIKV-specific primer (CHIKV1036: 5′-
ggcagtatcgtgaattcgatgcCGTGTCGGTAGTCTTGCACAT-γ′) was used to prime reverse 
transcription. CHIKV sequence-specific forward (CHIKV874: 5′-
AAAGGGCAAACTCAGCTTCAC-γ′) and reverse (CHIKV961: 5′-
GCCTGGGCTCATCGTTATTC-γ′) primers were used with an internal Taqman probe 
(CHIKV899: 5′-[6FAM]-CGCTGTGATACAGTGGTTTCGTGTG-[MGB]-γ′) that amplified a 
region in the nsP1 gene for quantitative PCR on a LightCycler 480 (Roche). Samples 
from mock-infected mice served to ensure assay specificity. For absolute quantification 
of CHIKV RNA, a standard curve was generated: 10-fold dilutions from 108 to 100 copies 
of CHIKV positive-strand genomic RNA, synthesized in vitro, were spiked into RNA from 
BHK-21 cells and reverse transcription and qPCR were performed in an identical 
manner. No template controls were run in parallel. To quantify CHIKV RNA from multiple 
CHIKV genotypes, a modified RT-qPCR assay was designed. In this assay, the first-
strand cDNA reaction was primed with 250 ng of random primers (Life Technologies). A 
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CHIKV sequence-specific forward primer (CHIKVβ411: 5′-
AGAGACCAGTCGACGTGTTGTAC-γ′) and CHIKV sequence-specific reverse primer 
(CHIKV2676: 5′-GTGCGCATTTTGCCTTCGTA-γ′) were used in conjunction with a 
CHIKV sequence-specific Taqman probe (CHIKV2579: 5′-[6FAM]- 
ATCTGCACCCAAGTGTACCA-[MGB]-γ′). A random primed cDNA standard curve was 
generated as described above. To quantify the CHIKV subgenomic 26S mRNA, random 
primed cDNA was used as a template for CHIKV sequence-specific forward 
(CHIKV10239: 5′- CGGCGTCTACCCATTTATGT-γ′) and CHIKV sequence-specific 
reverse (CHIKV10363: 5′- CCCTGTATGCTGATGCAAATTC-γ′) primers and a CHIKV 
sequence-specific Taqman probe (CHIKV10290: 5′-[6FAM]- 
AAACACGCAGTTGAGCGAAGCAC-[MGB]-γ′) that amplified a region in the E1 gene. 
The nsP1 copy number was determined in parallel with random primed cDNA and the 
primers/probe described above. The data was expressed as a ratio of E1 copy number 
divided by the nsP1 copy number.  
Plaque and Focus Forming Assays  
To quantify infectious virus in samples, either a plaque assay or focus forming 
assay was used. For plaque assays, BHK-21 cells were seeded into 6 well dishes. 
Samples containing virus were serially diluted in PBS + 1% FBS + 1x Ca2+ + 1x Mg2+ and 
adsorbed onto the cells for 1 h at 37oC. Cells were overlaid with 1% immunodiffusion 
agarose (MP Biomedicals) and plaques allowed to form for 36 – 40 h at 37oC. Plaques 
were visualized with neutral red stain and titers enumerated as plaques per mL of serum 
or gram of tissue. For focus forming assays, Vero cells were seeded in 96-well plates. 
Samples containing virus were serially diluted in DMEM/F12 + 2% FBS and allowed to 
adsorb onto the cells for 2 h at 37oC. At the end of 2 h, the sample was removed and 
cells overlaid with 0.5% methylcellulose in MEM-α + 10% FBS and incubated at γ7oC for 
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16-18 h. Cells were then fixed with 1% paraformaldehyde and cells probed with CHIKV-
specific monoclonal antibody CHK-11 (220) at 500ng/mL in Perm Wash (1X PBS + 0.1% 
Saponin + 0.1% BSA). Antibody was allowed to bind for 2 h at room temperature. Next 
cells were washed with Perm Wash and a secondary goat anti-mouse IgG conjugated to 
horse-radish peroxidase at 1:2000 in Perm Wash was applied and incubated for 2 h at 
room temperature. Cells were washed with Perm Wash and antigen positive cells 
visualized with TrueBlue substrate (Fisher). Foci were counted with a CTL Biospot 
analyzer and Biospot software (Cellular Technology). Titers were calculated as foci per 
ml of serum or gram of tissue.  
Plaque and Focus Reduction Neutralization T ests  
Neutralizing activity of murine and human serum was quantified using a plaque 
reduction neutralization test (PRNT). Serum was heat-inactivated and serially diluted. 
Diluted serum samples were incubated with 50 PFU of challenge virus at 37°C for 1 h. 
Following incubation, remaining infectious virus was quantified by plaque assay using 
Vero cells as described above. The PRNT50 value was defined as the reciprocal of the 
last dilution to exhibit < 50% infectivity. MAbs were tested for the capacity to neutralize 
CHIKV using a focus reduction neutralization test as described previously (220). MAbs 
were serially diluted in DMEM/F12 + 2% FBS and incubated with an equal volume of 
media containing 100 focus forming units of indicated virus and incubated for 1 h at 37C. 
Afterwards, remaining infectious virus was measured by focus forming assay.  
Histopathological Analysis  
At specific times, mice were sacrificed, perfused by intracardiac injection of 4% 
paraformaldehyde, pH 7.3, and the indicated tissues were dissected and fixed in 4% 
paraformaldehyde, pH 7.3. Tissues were embedded in paraffin and 5-µm sections were 
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prepared. Tissue sections were stained with hematoxylin and eosin (H and E) and 
evaluated by light microscopy. Two anatomic pathologists blindly scored the presence, 
distribution, and severity of histological lesions. For all tissue changes, a scoring system 
was developed as follows: 0, absent; 1, minimal, less than 10% of tissue affected; 2, 
mild, 10-24% of tissue affected; 3, moderate, 25-39% of tissue affected; 4, marked, 40-
59% of tissue affected; 5, severe, greater than 60% of tissue affected.  
Enzyme-Linked Immunosorbent Assay  
CHIKV-binding antibodies in mouse sera were quantified using a virion-based 
enzyme-linked immunosorbent assay (ELISA). Concentrated virus was adsorbed to a 
96-well Immulon 4HBX plate (Thermo Scientific) and then blocked with SuperBlock in 
PBS (Thermo Scientific). Serial dilutions of serum were added to the plate, and bound 
antibody was detected using biotin-conjugated goat anti-mouse IgM or IgG antibodies 
diluted 1:4000 in PBS (Southern Biotech), followed by streptavidin conjugated to 
horseradish peroxidase diluted 1:4000 in PBS (Southern Biotech). Binding was detected 
using γ,γ′,5,5′-tetramethylbenzidine liquid substrate (Sigma). Endpoint titers were 
defined as the reciprocal of the last dilution to have an absorbance two times greater 
than background. Blank wells receiving no serum or serum from naive mice were used 
to quantify background signal.  
Neutralization Index Calculations  
To calculate the neutralization index the following calculation was performed: 
Neutralization Index = (PRNT50 / (IgM ELISA endpoint + IgG ELISA endpoint)).  
Statistical Analysis  
All data were analyzed using GraphPad Prism v.5 or v.6 software. Data were 
evaluated for significant differences using either a two-tailed, unpaired t test with or 
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without Welch's correction, a Mann-Whitney test, a one-way analysis of variance 
(ANOVA) followed by Tukey's multiple comparison test, or by a two-way ANOVA 
followed by Bonferroni post-test analysis. A P value < 0.05 was considered statistically 




CHAPTER III  
CHRONIC JOINT DISEASE CAUSED BY PERSISTENT CHIKUNGUN YA VIRUS 
INFECTION IS CONTROLLED BY THE ADAPTIVE IMMUNE RESPON SE1 
Introduction 
Chikungunya virus (CHIKV) is a mosquito-transmitted, positive-sense, single-
stranded RNA virus in the Alphavirus genus of the Togaviridae family (125, 228, 264). 
CHIKV was first isolated from a patient during an outbreak of febrile disease and acute 
crippling joint pains in the southern province of Tanzania in 1952-1953 (2). Until 2004, 
CHIKV was known to cause debilitating rheumatologic disease in many parts of Sub-
Saharan Africa and Asia (69). However, since 2004, CHIKV has caused a series of 
epidemics, which began in Kenya, spread to islands in the Indian Ocean and India, and 
now occur in Southeast Asia and the Pacific Region (73). These more recent outbreaks 
have resulted in millions of disease cases, and imported CHIKV infections have been 
reported in nearly 40 countries including the United States, Brazil, Japan, and multiple 
European countries (265). In addition, CHIKV has adapted to new mosquito vectors 
(265), which has resulted in autochthonous transmission for the first time in several 
locations, including Italy, France, New Caledonia, Papua New Guinea, and Yemen (79, 
82). This expanded epidemiology prompted the Pan American Health Organization and 
the Centers for Disease Control and Prevention to release a preparedness guide that 
anticipates CHIKV epidemics in the Americas (266). 
The clinical manifestations following CHIKV infection include a sudden onset of 
fever, rash, intense pain in peripheral joints, myalgia, and impaired ambulation (267). 
                                               
1 Portions of this chapter were previously published in the Journal of Virology. 2013. Volume 87. 
Issue 24. and are included with permission of the copyright holder. 
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This acute stage lasts for 1 to 2 weeks and is typically followed by defervescence and 
convalescence. However, in a subset of people infected with CHIKV, some disease 
signs and symptoms, such as joint swelling, joint stiffness, arthralgia, and 
tendonitis/tenosynovitis can last for months to years and often occur in a 
relapsing/fluctuating manner (110, 121, 170, 208, 226, 227). Chronic joint pain is not 
exclusive to CHIKV among alphavirus family members and also is caused by related 
viruses including Sindbis (SINV), Ross River, o'nyong-nyong, and Mayaro (125). Similar 
to CHIKV infections, the cause of persistent joint disease by these other alphaviruses is 
unclear; however, there is little evidence for the development of autoimmunity in 
individuals experiencing chronic disease (125, 267). Thus, an unresolved question in the 
field is whether chronic musculoskeletal disease is associated with or caused by 
persistent CHIKV infection. Several studies have detected persistence of CHIKV-specific 
immunoglobulin M (IgM) in humans, which is suggestive of, although by no means 
conclusive for, the persistence of viral antigens (110, 170, 207, 209, 268); however, the 
persistence of CHIKV-specific IgM has not yet been associated with persistent arthralgia 
or joint pathology (110). Additionally, immunohistochemical analysis of synovial and 
muscle tissues from patients with chronic disease revealed CHIKV antigen in 
perivascular macrophages and muscle satellite cells as well as extensive inflammation 
(170, 257). More recently, CHIKV RNA and antigens were detected up to 90 days post-
inoculation (dpi) in the spleen, lymph nodes, liver, and muscle tissue of infected 
macaques (153). Although CHIKV was detected in macaques inoculated with a range of 
virus doses, only those receiving the highest doses of virus developed musculoskeletal 
disease (153).  
 To investigate the basis of chronic CHIKV disease, we used a recently described 
mouse model in which the major disease signs (arthritis, synovitis, and tenosynovitis) 
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during the acute stage were consistent with acute CHIKV disease in humans (158). 
Utilizing this model, we found that CHIKV RNA was cleared from visceral tissues of wild-
type (WT) mice; however, CHIKV RNA persisted in joint-associated tissues to at least 16 
weeks post-inoculation (wpi). Rag1-/- mice, which lack mature B and T lymphocytes, 
sustained elevated levels of CHIKV RNA in joint-associated tissues, persistence of 
CHIKV RNA in muscle, and persistent viremia, suggesting that adaptive immune 
responses control persistent CHIKV infection. The persistence of CHIKV RNA in joint-
associated tissues was associated with histopathological evidence of arthritis, synovitis, 
and tendonitis. Prophylactic administration of a combination of two highly neutralizing 
monoclonal antibodies (MAbs CHK-166 and CHK-152) (220) prevented Rag1-/- mice 
from developing persistent CHIKV infection. Therapeutic administration of these MAbs at 
late times post-infection had tissue-specific efficacy in clearing CHIKV. Taken together, 
our findings suggest that chronic CHIKV musculoskeletal damage may be due to joint 
tissue-specific persistence of CHIKV infection. Our findings with Rag1-/- mice suggest 
that while the adaptive immune system is necessary for CHIKV clearance from muscle 
tissue and the circulation, it cannot clear the virus from joint-associated tissues. This 
work establishes a small animal model of chronic CHIKV infection that can be utilized to 
investigate molecular mechanisms of chronic disease pathogenesis as well as evaluate 
candidate therapies to mitigate persistent infection and joint pathology. 
Results 
Persistence of CHIKV is tissue-specific . To evaluate the duration of CHIKV 
infection in tissues, we utilized a WT C57BL/6 mouse model in which the major 
pathological findings during the acute stage of infection (arthritis, myositis, and 
tenosynovitis) were consistent with the disease in infected humans (158, 159). WT mice 
were inoculated subcutaneously in the left rear footpad with virus diluent only (mock) or 
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103 plaque-forming units (PFU) of CHIKV strain SL15649. For many of the experiments, 
we monitored CHIKV infection in tissues using a highly sensitive and specific RT-qPCR 
assay. Following extensive intracardiac perfusion with PBS, positive-strand genomic 
CHIKV RNA burdens in the ankles and spleen at 3 dpi (n = 7) and 1 (n = 11), 2 (n = 8), 4 
(n = 11), 6 (n = 7), 12 (n = 8), and 16 (n = 3) weeks post-inoculation (wpi) was quantified 
by RT-qPCR with primers and probes complementary to sequences in the viral nsP1 
coding region (Fig. 3-1A and Table 3-1 ). CHIKV RNA in tissues of mock-inoculated 
mice was below the limit of detection of this assay (data not shown), which confirmed the 
specificity of our measurements. The amount of CHIKV RNA in ankle-associated tissues 
of CHIKV-inoculated mice was highest at 3 dpi and declined during the first 2 to 4 weeks 
post-inoculation. CHIKV RNA was detected in the left ankles of all mice, which is near 
the site of inoculation, for at least 16 wpi. CHIKV RNA also was detected in the right 
ankles of nearly all mice, a tissue distal to the site of inoculation, for at least 16 wpi. In 
addition to ankle-associated tissues, CHIKV RNA was measured at a low level in the 
spleen of WT mice (Fig. 3-1A and Table 3-1 ); however, levels in the spleen waned such 
that after 6 wpi CHIKV RNA was undetectable. CHIKV RNA also persisted in the wrists 
of WT mice (Table 3-1 ), suggesting that CHIKV may establish persistent infections 
preferentially in joint-associated tissues. 
 To evaluate further the tissue specificity of CHIKV RNA persistence, we 
quantified viral RNA levels in the serum (Fig. 3-1B ), quadriceps muscles (Fig. 3-1C and 
D), liver (Fig. 3-1E), brain (Fig. 3-1F), and spinal cord (Fig. 3-1G ) at 3, 14, and 28 dpi by 
RT-qPCR. CHIKV RNA was readily detected in these tissues at 3 dpi, a time point during 
the acute stage of infection. Consistent with the musculoskeletal tissue tropism of CHIKV 
and related arthritogenic alphaviruses (156, 161), the highest CHIKV RNA burdens 
during the acute stage (3 dpi) were present in joint-associated and skeletal muscle 
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tissues (Fig. 3-1 ). In contrast to the ankles and spleen, CHIKV RNA was cleared rapidly 
from the serum, quadriceps muscles, liver, brain, and spinal cord of WT mice (Fig. 3-1 
and Table 3-1 ). These findings indicate that persistence of CHIKV RNA following a 
subcutaneous inoculation is joint tissue-specific.  
CHIKV RNA persists in mice inoculated with East/Central/South African, 
West African, and Asian CHIKV strains . Phylogenetic analyses have identified three 
genotypes of CHIKV strains: East/Central/South African (ECSA), the West African, and 
Asian (70, 73). To determine if persistence of viral RNA in joint-associated tissues was 
specific to CHIKV strain SL15649, a member of the ECSA genotype, we tested two 
distantly related CHIKV strains: Asian strain PO731460 and West African strain 37997 
(73). WT C57BL/6 mice were inoculated subcutaneously in the left rear footpad with 103 
PFU of either CHIKV strain. Following extensive intracardiac perfusion with PBS, viral 
RNA levels in the left and right ankles at 4 wpi (n = 6) were quantified by RT-qPCR. As 
shown in Fig. 3-2 , the amount of CHIKV RNA in ankle-associated tissues at 4 wpi in 
mice inoculated with strain 37997 or strain PO731460 was similar to or higher than that 
detected in ankle tissues of mice inoculated with strain SL15649. These data indicate 
that CHIKV strains from all described genotypes can establish persistent infections in 
murine joint tissue and thus, this is not an unusual property of the recent ECSA epidemic 
strains.  
Adaptive immunity controls persistence of CHIKV . Chronic arthritis could be 
caused by persistent viral infection and/or persistent immunopathology associated with B 
and T cell immunity. To evaluate whether the adaptive immune response controls or 
contributes to CHIKV-induced joint disease and also impacts the tissue-specificity of 
CHIKV persistence, Rag1-/- mice, which lack mature B and T lymphocytes (33), were 
inoculated subcutaneously in the left rear footpad with 103 PFU of CHIKV SL15649. The 
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levels of CHIKV RNA in perfused tissues (ankles, quadriceps muscles, and spleen) at 3 
dpi and 1, 2, 4, 6, and 12 wpi were quantified by RT-qPCR (Fig. 3-3A-E ). The levels of 
CHIKV RNA were elevated in both the left ankle joint (11-fold [P < 0.001], 4-fold [P < 
0.05], 12-fold [P < 0.05], 6-fold [P < 0.01], and 7-fold [P < 0.001] at 1, 2, 4, 6, and 12 wpi, 
respectively) and the right ankle joint (15-fold [P < 0.001], 32-fold [P < 0.001], 23-fold [P 
< 0.001], 26-fold [P < 0.001], and 404-fold [P < 0.001] at 3 dpi, 4, 6, and 12 wpi, 
respectively) of Rag1-/- mice compared to WT mice (Fig. 3-3A and 3-3B ). These data 
indicate that T and/or B cell immunity contributes to the control of CHIKV infection in joint 
tissues but is not sufficient to mediate complete clearance. CHIKV RNA persisted in 
quadriceps muscle tissues of Rag1-/- mice for at least 12 wpi, but was cleared by 2 wpi 
from the same tissues of WT mice (Fig. 3-3C and 3-3D ); thus, in contrast to the joint 
tissues, adaptive T and/or B cell immunity was sufficient to clear CHIKV from muscle 
tissues. Although the amounts of CHIKV RNA detected in the spleens of WT Rag1-/-  
mice were similar at 3 dpi and 1 wpi, remarkably, viral RNA persisted in the spleen of 
WT mice for 6 wpi but fell below the limit of detection in the spleen of Rag1-/- mice at 2, 
4, 6, and 12 wpi (Fig. 3-3E ). These data suggest that the altered organization and/or 
cellularity of the spleen of Rag1-/- mice (34) prevents CHIKV persistence in this tissue; 
alternatively, although it has not been reported CHIKV could have a limited tropism for 
subsets of B and T cells. We also quantified the amounts of infectious virus in the serum 
of CHIKV-inoculated WT and Rag1-/- mice via direct plaque assays. Infectious CHIKV 
was present in sera from both mouse strains at 3 dpi (Fig. 3-3F ) but was not detected in 
sera of WT mice at any of the later time points evaluated. In contrast, Rag1-/- mice 
developed a persistent low level of viremia (Fig. 3-3F ), which showed a pattern of 
fluctuation. A rapid decline in titer occurred between 3 and 7 dpi that was followed by a 
rise in titer between 1 and 2 wpi. Another drop in titer occurred at 4 wpi prior to the 
establishment of a steady-state level by 6 wpi. These data are consistent with recent 
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studies showing that Rag2-/- mice and B cell-deficient mice developed a persistent 
viremia following CHIKV inoculation (201, 204). Taken together, these analyses suggest 
that adaptive immune responses modulate persistent CHIKV infection in a tissue-specific 
manner. 
 During the alphavirus replication cycle, a 26S positive-sense subgenomic RNA, 
co-linear with the γ′ one-third of the full-length genomic RNA, is synthesized from the 
26S subgenomic promoter (5, 269). The 26S subgenomic RNA is synthesized in 3- to 
10-fold molar excess of the full-length positive-strand genomic RNA; thus, quantification 
of this molar excess can be used as an indicator of ongoing alphavirus replication (46, 
50, 270-272). We designed an additional sequence-specific RT-qPCR assay with 
primers and probes complementary to sequences in the E1 coding region which, in 
contrast to the nsP1 coding region, are found in both the full-length and subgenomic 
RNAs produced in infected cells. This assay amplified full-length CHIKV positive-strand 
genomic RNA with similar efficiency as our nsP1-based assay (data not shown). Utilizing 
this assay in combination with our nsP1-based assay, we detected a 2.6 to 4.3-fold 
excess of CHIKV RNA with our E1-based assay in the ankle tissues of WT and Rag1-/-  
mice at 3 dpi (Figs. 3-4A and 3-4B ), suggesting similar levels of replication in these 
tissues at this time point. The E1 RNA/nsP1 RNA ratios declined from 3 dpi to 4 wpi in 
the left ankle tissues of WT mice (P < 0.001) to an average ratio of 1.2 at 4 wpi and then 
increased at 6 wpi (P < 0.001) (Fig. 4A). Similarly, the E1 RNA/nsP1 RNA ratios declined 
or remained constant over time in the right ankle of WT mice (Fig. 3-4B). These data 
suggest that CHIKV replication was restricted in the joint tissues of WT mice during 
persistence. In contrast, the excess of RNA detected with the E1-based assay increased 
over time in both the left ankle (P < 0.05) and right ankle (P < 0.001) of Rag1-/- mice to 
levels that were higher than WT mice, suggesting higher levels of CHIKV replication 
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occurred in joint tissues of Rag1-/- mice compared to WT mice during persistence. 
Consistent with these results, infectious CHIKV was detected in ankle joint tissues of 
Rag1-/- but not WT mice at 42 dpi by direct plaque assay (Fig. 3-4C  and data not 
shown). These data suggest that CHIKV RNA replication occurs at low, fluctuating levels 
in joint-associated tissues of WT mice and further support an important role for adaptive 
immunity in controlling persistent CHIKV infection. 
Persistence of CHIKV is associated with pathology . The data presented thus 
far suggest that CHIKV RNA persists in mice preferentially in joint-associated tissues. To 
determine the extent to which the detection of CHIKV RNA is associated with pathology, 
histological changes in musculoskeletal tissues of uninfected control mice and CHIKV-
infected mice at various times post-inoculation were evaluated in a blinded manner. 
Consistent with prior reports (158, 159), arthritis, synovitis, tendonitis, myositis, and 
myocyte necrosis were most severe during the acute stage (7 dpi) (Fig. 3-5A-F ). 
Histopathology scores for synovitis (Fig. 3-5B ), arthritis (Fig. 3-5C ), and myositis (Fig. 3-
5D) during the acute stage appeared more severe for WT mice compared to Rag1-/- 
mice, consistent with studies reporting a possible pathogenic role of CD4+ T cells in 
acute CHIKV-induced disease (204). At this time point, both WT and Rag1-/-  mice had 
an infiltrating inflammatory cell population predominantly composed of macrophages and 
neutrophils with admixed lymphocytes. At late times post-inoculation (4 to12 wpi) most 
WT (8 of 11) and Rag1-/- (6 of 9) mice had apparent synovitis (Fig. 3-5A and B ). 
However, arthritis (Fig. 3-5C ), metatarsal muscle inflammation (Fig. 3-5D ), metatarsal 
muscle necrosis (Fig. 3-5E ), and tendonitis (Fig. 3-5F ) resolved in WT mice but 
remained evident in the majority of Rag1-/- mice out to 12 wpi. During this chronic stage, 
the infiltrating inflammatory cell population in tissues of WT mice consisted 
predominantly of histiocytes and lymphocytes whereas histiocytes and neutrophils were 
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predominant in the tissues of Rag1-/- mice. Thus, the persistence of CHIKV RNA is 
associated with pathology in joint-associated tissues, muscle tissue, and tendons. 
Moreover, T and/or B cell responses appear to prevent the development of more severe 
chronic disease likely due to their ability to control infection. Nonetheless, synovitis failed 
to resolve in WT mice for at least 12 wpi, which correlated with the joint-tissue specific 
persistence of CHIKV RNA (Fig. 3-1 and Table 3-1 ).    
MAb prophylaxis prevents persistence of CHIKV in tissues of Rag1-/- mice . 
The studies described thus far establish a mouse model that can be used for evaluating 
the efficacy of therapeutic agents against chronic CHIKV infection and joint disease. 
Recently, a combination of two CHIKV MAbs, CHK-152 and CHK-166 (which recognize 
discrete epitopes on CHIKV E2 and E1, respectively) was shown to have therapeutic 
efficacy in murine models of lethal CHIKV infection and acute CHIKV-induced 
musculoskeletal disease (220). To evaluate whether these neutralizing MAbs could 
prevent persistent CHIKV infection, β00 μg each of CHK-152 and CHK-166 or 400 μg of 
a negative control MAb (WNV E16) were administered intraperitoneally to Rag1-/- mice 
one day before and three days after inoculation with CHIKV. Persistence of CHIKV was 
evaluated at 28 days after virus inoculation. Prophylaxis with CHK-152 and CHK-166 
reduced levels of infectious CHIKV in the serum to below the limit of detection (Fig. 3-
6A; P < 0.03). In addition, prophylaxis with CHK-152 and CHK-166 reduced CHIKV RNA 
levels in the left ankle (P < 0.02) and right ankle (P = 0.01) to below the limits of 
detection in 3/5 and 4/5 mice, respectively (Fig. 3-6B and 3-6C ). In the two mice that 
were positive in these tissues, CHIKV RNA levels were reduced by >99% compared to 
mice treated with the negative control MAb.  
MAb therapy has tissue-specific effects on persistent CHIKV infection. To 
evaluate whether the neutralizing anti-CHIKV MAbs could reduce or eliminate an 
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established persistent infection, β00 μg each of CHK-152 and CHK-166 or 400 μg of a 
negative control MAb (WNV E16) was administered intraperitoneally to Rag1-/- mice on 
days 21 and 25 post-CHIKV inoculation and viral burdens were evaluated at 28 dpi. As 
shown in Fig. 3-6D , therapeutic administration of CHK-152 and CHK-166 eliminated 
infectious virus from the sera (P < 0.01). In addition, while we detected infectious CHIKV 
in the quadriceps of 2/3 mice treated with the control MAb, 0/3 mice treated with CHK-
152 and CHK-166 had detectable infectious virus (data not shown), suggesting that the 
CHIKV-specific MAbs could eliminate infectious virus in musculoskeletal tissues. This 
treatment regimen, however, had no effect on viral RNA levels in the left ankle (Fig. 3-
6E) or the quadriceps muscles (data not shown), although a significant, albeit small (3.2-
fold, P < 0.01), reduction of CHIKV RNA was observed in the right ankle (Fig. 3-6F). In 
addition, the E1 RNA/nsP1 RNA ratio in the right ankle was reduced in mice treated with 
CHK-152 and CHK-166 compared to mice treated with the control antibody (P = 0.001) 
(Fig. 3-6G ), suggesting that the CHIKV-specific MAbs reduced virus replication in this 
tissue. Thus, this two-dose, one-week combination MAb therapy was sufficient to reduce 
burdens of infectious virus although a more extended regimen may be required to clear 
CHIKV from some tissues. 
Discussion 
 A defining feature of alphavirus-induced musculoskeletal disease is the 
development of chronic polyarthralgia and/or polyarthritis, which can be debilitating (125, 
273). The underlying processes that result in chronic disease associated with these 
infections are not well understood. Here, we utilized a recently developed mouse model 
of acute CHIKV-induced musculoskeletal disease (158) to investigate the sites and 
duration of CHIKV infection and musculoskeletal tissue pathology, the role of adaptive 
immunity in control of persistent infection, and a possible strategy to prevent or cure 
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persistent infection. Our findings suggest that CHIKV establishes persistent infections in 
joint-associated tissues, that persistence of CHIKV RNA is associated with ongoing 
synovitis, and that the sites of CHIKV persistence and tissue burdens of CHIKV are 
controlled by adaptive immunity. We also found that an antibody-based treatment 
prevents persistent CHIKV infection when administered as prophylaxis and has tissue-
specific effects when administered therapeutically. Together, these studies support the 
hypothesis that chronic CHIKV arthritic disease is associated with persistent infection 
and establish a small animal model that can be utilized to investigate molecular 
mechanisms of chronic disease and test therapies that mitigate persistent CHIKV 
infection and joint pathology.    
Persistence of CHIKV RNA is joint tissue-specific and controlled by 
adaptive immunity. Persistence of alphaviruses in vertebrate hosts was first noted in 
the central nervous system of both WT and scid mice inoculated intracerebrally (i.c.) with 
neuroadapted SINV (274, 275). Subsequent studies established that persistent CNS 
infection with SINV following an i.c. inoculation was controlled by IFN-  production by T 
cells and anti-SINV antibodies produced by antibody-secreting B cells residing in the 
CNS (276-279). In our studies, we found that persistence of CHIKV RNA in WT mice 
was joint tissue-specific, with high levels of viral RNA detected in ankle and wrist tissues, 
but not in several other tissues, for at least 16 wpi. Our studies also indicated that the 
establishment of persistent infection in joint-associated tissues of mice is a common 
property shared by of CHIKV strains from all three genotypes. These data are consistent 
with epidemiological studies which have documented the development of protracted 
disease symptoms during outbreaks of CHIKV in humans involving any of the three 
CHIKV genotypes (69). The detection of CHIKV RNA in joint-associated tissues is also 
consistent with previous studies in humans in which CHIKV antigen was detected in 
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synovial biopsies collected from a patient with chronic disease (280) and in 
experimentally-inoculated rhesus and cynomolgous macaques in which CHIKV RNA 
was detected in joints at later times post-inoculation of (153, 155). Analogously, Ross 
River virus RNA has been detected in knee biopsies collected from patients five weeks 
after the onset of joint symptoms (250).  
 Similar to WT mice, Rag1-/- mice failed to clear CHIKV RNA from ankle joint-
associated tissues. However, the amounts of CHIKV RNA and the E1/nsP1 RNA ratio in 
ankle joint-associated tissues of Rag1-/- mice were elevated compared to WT mice, 
suggesting that adaptive immunity limits viral burden in these tissues. In contrast, WT, 
but not Rag1-/- mice, rapidly cleared CHIKV RNA from quadriceps muscle tissue and 
infectious virus from the serum. Collectively, these data suggest that T and/or B cell-
mediated immunity controls CHIKV burdens in a tissue-specific manner.  
Persistence of CHIKV RNA is associated with chronic synovitis. Similar to 
acute CHIKV rheumatological disease in WT mice, inoculation of Rag1-/- mice with 
CHIKV resulted in synovitis, arthritis, myositis, and tendonitis; thus, CHIKV can induce 
an acute inflammatory response despite the lack of mature T and B cells. These findings 
are similar to studies in Rag1-/- mice infected with Ross River virus in which affected 
joints and muscles were infiltrated with macrophages and NK cells (161). However, our 
detailed assessment of tissue sections at 7 dpi revealed that Rag1-/- mice had less 
severe tissue pathology than WT mice during the acute stage, suggesting an early 
pathogenic role for T and/or B cells. These findings agree with studies reporting less 
severe foot swelling in CHIKV-infected Rag2-/- mice and MHC class II-deficient mice 
(204, 241). More specifically, CD4+ T cells were shown to contribute to CHIKV-induced 
foot swelling and musculoskeletal tissue injury (204).  
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  Assessment of tissue sections from WT and Rag1-/- mice at 4, 6, and 12 wpi 
revealed that CHIKV infection resulted in a low-level, chronic synovitis. Intra-articular 
injection of dsRNA directly into murine joint spaces also is arthritogenic (281), 
suggesting that viral RNA may be sufficient to cause joint inflammation and injury. Thus, 
persistence of CHIKV in joint-associated tissues may promote chronic inflammation of 
synovial membranes. In contrast, arthritis, myositis, and tendonitis resolved in the 
majority of WT mice, but not Rag1-/- mice, between 4 and 12 wpi. Although Rag1-/- mice 
had less severe acute disease, in the chronic phase arthritis, myositis, myocyte necrosis, 
and tendonitis were present in the majority of Rag1-/- mice. These longitudinal analyses 
suggest that functional T and/or B cell responses protect against chronic 
musculoskeletal disease. Our results are consistent with recent findings in rhesus 
macaques in which persistence of CHIKV in the spleen correlated with defects in 
adaptive immune responses (154), and in humans in which the rapid appearance of 
neutralizing IgG3 antibodies correlated with viral clearance and protection from chronic 
CHIKV disease (213).  
Prophylaxis with CHIKV-specific MAbs prevents CHIKV persistence. 
Prophylaxis via passive transfer of human immune plasma or CHIKV IgG to highly 
susceptible Ifnar1-/- mice can protect against CHIKV-induced mortality, suggesting that 
antibody therapy may be a promising disease prevention option for individuals at high 
risk of CHIKV infection (282). More recently, prophylaxis with different CHIKV-specific 
MAbs was shown to protect against lethal CHIKV infection in AGR129 mice (283), which 
lack receptors for type I and type II interferons as well as Rag2, and also in Ifnar1-/- mice 
(220). Importantly, prophylaxis with CHIKV-specific MAbs prevented acute joint swelling 
and inflammatory arthritis in CHIKV-infected WT mice (220). However, none of these 
previous studies addressed whether antibody-based prophylaxis or treatment could 
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impact persistent CHIKV infection. We found that the combination of two neutralizing 
MAbs (CHK-152 and CHK-166), which recognize discrete epitopes on CHIKV E2 and 
E1, respectively, prevented persistent infection in Rag1-/- mice when administered as 
prophylaxis. Together with previous reports, our findings suggest that antibody-based 
prophylaxis in targeted at-risk populations may be a promising strategy to prevent both 
acute and chronic-CHIKV disease. 
MAb therapy after the establishment of persistence enables tissue-specific 
clearance . To test whether the neutralizing anti-CHIKV MAbs could reduce or eliminate 
an established persistent CHIKV infection, we treated persistently-infected Rag1-/- mice 
three weeks after CHIKV inoculation with two doses of MAbs and evaluated viral burden 
one week later. Similar to the prophylaxis results, therapeutic administration of CHK-152 
and CHK-166 eliminated infectious virus in the sera. MAb treatment also prevented 
recovery of infectious virus from quadriceps muscle tissue, suggesting that infectious 
virus in at least some tissues is efficiently eliminated upon treatment. In contrast to 
prophylaxis, therapeutic administration of CHK-152 and CHK-166 had minimal effects on 
CHIKV RNA burdens in joint-associated tissues and quadriceps muscle tissue. These 
findings are similar to a study showing that a single dose of an anti-SINV virus MAb 
administered at 7 days post-infection failed to eliminate virus RNA in the CNS of scid 
mice (45). Although the latter study is complicated by issues of blood-brain barrier 
penetration and accumulation of MAb in a restricted compartment, longer MAb treatment 
regimens may be required to eliminate alphavirus RNA in infected tissues.    
 A high percentage of CHIKV-infected individuals suffer from chronic arthralgia 
(110, 115, 139, 227, 252, 273) and chronic CHIKV disease can be debilitating with 
severe economic consequences (232, 252, 273, 284). Accordingly, an improved 
understanding of the molecular mechanisms of chronic CHIKV disease and the 
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development of effective therapies to prevent or treat viral persistence are critical. Our 
studies report a mouse model with long-term CHIKV infection and pathology localized in 
joint-associated tissues. In this model, adaptive immune responses control rather than 
contribute to the severity of tissue pathology by restricting CHIKV infection in most but 
not all tissues. Prophylaxis with a combination of MAbs effectively prevents persistent 
CHIKV infection whereas therapeutic administration diminished infectious virus burdens 
in tissues. The development of this model will facilitate future studies to increase our 
understanding of the biological basis of chronic CHIKV infection and disease, and allow 




TABLE 3-1 CHIKV infection in tissues of infected animals . a Tissues were analyzed 
for CHIKV positive-strand RNA via RT-qPCR. Limit of detection was 100 CHIKV RNA 
copies/µg of RNA. Serum was analyzed for infectious virus via direct plaque assays. 
Limit of detection was 50 PFU/ml of serum. b Data are expressed as the number of 
tissues that were CHIKV positive divided by the total number of tissues analyzed. Each 






No. of positive tissues/total number of tissues by day post-
inoculationb 
3 7 14 28 42 84 112 
WT 
Left 
ankle 7/7 11/11 12/12 11/11 7/7 8/8 3/3 
Right 
ankle 7/7 11/11 8/8 9/9 7/7 5/8 3/3 
Left wrist ND ND 5/5 ND ND ND 2/3 
Right 
wrist ND ND ND ND ND ND 1/3 
Left 
quad 7/7 1/11 0/8 1/6 0/3 0/5 ND 
Right 
quad 7/7 5/11 0/8 0/9 0/3 0/5 ND 
Spleen 7/7 6/11 4/7 6/11 3/7 0/8 0/3 
Liver 7/7 ND 0/3 0/3 ND ND ND 
Brain 5/7 ND 1/3 0/3 ND ND ND 
Spinal 
cord 6/7 ND 1/3 0/3 ND ND ND 
Serum 6/6 0/6 0/6 0/6 0/6 0/6 ND 
Rag1−/− 
Left 
ankle 6/6 6/6 9/9 6/6 7/7 5/5 ND 
Right 
ankle 6/6 6/6 9/9 6/6 7/7 5/5 ND 
Left 
quad 6/6 6/6 9/9 6/6 7/7 5/5 ND 
Right 
quad 6/6 6/6 9/9 6/6 7/7 5/5 ND 
Spleen 6/6 1/6 0/9 0/6 0/7 0/5 ND 
Liver 6/6 ND 0/3 0/6 0/5 ND ND 
Brain 6/6 ND ND 2/6 0/5 ND ND 










Figure 3-1: CHIKV RNA persists in joint-associated tissue and spleen of WT mice.  
Three-week-old WTC57BL/6 mice were mock inoculated (data not shown) or inoculated 
with 103 PFU of CHIKV by injection in the left rear footpad. Mice were sacrificed and 
perfused by intracardiac injection with PBS, and total RNA was isolated from the 
indicated tissues. (A) At 3 dpi (n = 7 mice) and 1 (n = 11), 2 (n = 8), 4 (n = 11), 6 (n = 7), 
12 (n = 8), and 16 (n = 3) wpi, CHIKV RNA in the ankles and spleen was quantified by 
RT-qPCR. Each data point represents the arithmetic mean ± standard errors of the 
means (SEM), and the dashed line indicates the limit of detection. (B to G) At 3 (n = 7), 
14 (n = 3 to 7), and 28 dpi (n = 3 to 5), CHIKV RNA in the serum (B), left quad (C), right 
quad (D), liver (E), brain (F), and spinal cord (G) was quantified by RT-qPCR. Horizontal 
lines indicate the means, and dashed lines indicate the limits of detection. Data shown 
are derived from 2 to 3 independent experiments, except data for 16 wpi, which were 





Figure 3-2: Persistence of CHIKV RNA in joint-associated tissue is virus genotype 
independent.  Three-week-old WT C57BL/6 mice were inoculated with 103 PFU of 
CHIKV strain 37997 or strain PO731460 by injection in the left rear footpad (n = 6 or 
7/group). At 28 dpi, mice were sacrificed and perfused by intracardiac injection with 
PBS, and totalRNAwas isolated from the indicated tissues.CHIKVRNAin the left ankle 
(A) and right ankle (B) was quantified by RT-qPCR. Levels of CHIKV RNA from mice 
inoculated with 103 PFU of CHIKV strain SL15649 were quantified by the same assay for 
comparison. Horizontal lines indicate the means, and dashed lines indicate the limits of 
detection. *, P = 0.05; **, P = 0.01, as determined by one-way ANOVA followed by 






Figure 3-3: CHIKV persistence in tissues of Rag1-/- mice.  
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Figure 3-3: CHIKV persistence in tissues of Rag1-/- mice. Three-week-old Rag1-/- 
congenic C57BL/6 mice were mock inoculated (data not shown) or inoculated with 103 
PFU of CHIKV by injection in the left rear footpad. At 3 dpi (n = 6) and 1 (n = 6), 2 (n = 
9), 4 (n = 6), 6 (n = 9), and 12 wpi (n = 5), mice were sacrificed and perfused by 
intracardial injection with 1X PBS, and total RNA was isolated from the left ankle (A), 
right ankle (B), left quadriceps muscle (C), right quadriceps muscle (D), and spleen (E). 
Levels of CHIKV RNA were quantified by RT-qPCR. For comparison, values were 
plotted against values in WT mice. (F) Serum was analyzed for infectious virus via direct 
plaque assays. Dashed lines indicate the limit of detection. *, P < 0.05; **, P < 0.01; ***, 
P < 0.001, as determined by two-way ANOVA followed by Bonferroni posttest analysis. 





Figure 3-4: Increased subgenomic mRNA in tissues of Rag1-/- mice . CHIKV RNA in 
the left ankle (A) and right ankle (B) of WT and Rag1-/- C57BL/6 mice at the indicated 
time points was quantified by RT-qPCR assays specific for nucleotide sequences in the 
nsP1 and the E1 genes in parallel as described in Materials and Methods. The E1/nsP1 
ratio was plotted as an indirect measurement of subgenomic mRNA production. *, P < 
0.05; **, P < 0.01; ***, P < 0.001, as determined by one-way ANOVA followed by Tukey’s 
multiple comparison test. (C) Infectious virus in the left and right ankles of Rag1-/- 
C57BL/6 mice at 42 dpi was quantified by direct plaque assay. Dashed line indicates the 





Figure 3-5: Chronic synovitis in WT and Rag1-/- mice. Three week-old WT and Rag1-/-  
C57BL/6 mice were mock inoculated or inoculated with 103 PFU of CHIKV by injection in 
the left rear footpad. (A) At 7 and 42 dpi, 5-µm paraffin-embedded sections were 
generated from the hind limbs and stained with hematoxylin and eosin. Arrows indicate 
areas of synovitis, as identified by an anatomic pathologist. Scale bar, 200µM. Images 
are representative of three mice per group. (B to F) At 1, 4, 6, and 12 wpi, 5-µm paraffin-
embedded sections were generated from the hind limbs, stained with hematoxylin and 
eosin, and scored in a blinded manner by two anatomic pathologists for the degree of 
synovitis (B), arthritis (C), metatarsal muscle inflammation (D), metatarsal muscle 
necrosis (E), and tendonitis (F) based on the following scale for percentage of tissue 
affected: 0, absent (0%); 1, minimal (<10%); 2, mild (11 to 25%); 3, moderate (26 to 





Figure 3-6: Efficacy of MAb prophylaxis and therapy against persistent CHIKV 




Figure 3-6: Efficacy of MAb prophylaxis and therapy against persistent CHIKV 
infection in Rag1-/- mice. (A to C) Three-week-old Rag1-/-  C57BL/6 mice were injected 
i.p. with 400 µg of WNV E16 MAb or 200 µg CHK-152 and 200 µg CHK-166 MAbs on 
days -1 and +3. On day 0, mice were inoculated with 103 PFU of CHIKV in the left rear 
footpad. At 28 dpi, mice were sacrificed and perfused with PBS via intracardiac injection, 
and infectious virus in the serum (A) was quantified by plaque assay. Tissues (left 
ankle/foot [B] and right ankle/foot [C]) were homogenized in TRIzol, and CHIKV RNA 
was quantified by RT-qPCR. Horizontal lines indicate the means, and dashed lines 
indicate the limits of detection. P values were determined by Mann-Whitney tests. Data 
are from two independent experiments. (D to G) Three-week-old Rag1-/-  C57BL/6 mice 
were inoculated with 103 PFU of CHIKV in the left rear footpad. On days 21 and 25, mice 
were injected i.p. with 400 µg of WNV E16 MAb or 200 µg CHK-152 and 200 µg CHK-
166 MAbs. At 28 dpi, mice were sacrificed and perfused with PBS via intracardiac 
injection. (D) Infectious virus in the serum was quantified by plaque assay. The left ankle 
(E) and right ankle (F) were homogenized in TRIzol, and CHIKV RNA was quantified by 
RT-qPCR. (G) CHIKV RNA in the right ankle was quantified by RT-qPCR assays 
specific for nucleotide sequences in the nsP1 and the E1 genes in parallel as described 
in Materials and Methods. The E1/nsP1 ratio was plotted as an indirect measurement of 
subgenomic mRNA production. Horizontal bars indicate the means, and dashed lines 
indicate the limits of detection. P values were determined by the Mann-Whitney test (D) 





CHAPTER IV  
PATHOGENIC CHIKUNGUNYA VIRUS EVADES B CELL RESPONSES TO 
ESTABLISH PERSISTENCE 2 
Introduction  
Chikungunya virus (CHIKV) is a mosquito-transmitted positive-sense, enveloped 
RNA virus in the Alphavirus genus of the Togaviridae. CHIKV has caused epidemics of 
unprecedented scale within the past decade in many regions of the world (285). 
Beginning in 2004, CHIKV re-emerged from Africa and spread to islands in the Indian 
Ocean and South Pacific and countries in southern Asia. In October of 2013, local 
transmission of CHIKV occurred on the Caribbean island of Saint Martin (95). Since that 
time, the virus has spread throughout much of the Americas resulting in at least 1.8 
million confirmed and suspected cases in 45 countries or territories (94).  
 CHIKV infection typically presents with a sudden onset of high fever and severe 
pain in peripheral joints (107, 286). These signs and symptoms can resolve in a few 
weeks. However, in up to 50% of patients, musculoskeletal abnormalities, including joint 
swelling, joint stiffness, and tenosynovitis, endure for months to years after infection 
(110, 227, 231, 232, 273). Infection by related alphaviruses such as Mayaro, 
o’nyong’nyong, Ross River, and Sindbis viruses also can lead to chronic 
musculoskeletal disease in humans (125).  
 Mechanisms by which alphaviruses cause chronic musculoskeletal disease 
remain elusive. Limited studies of human patients suggest that arthritogenic 
alphaviruses establish persistent infections within the host (250, 257, 280). Persistent 
                                               
2 Portions of this chapter were previously published in Cell Reports. 2016. Volume 16. Issue 5 
and are included with permission of the copyright holder. 
63 
 
CHIKV infection also has been detected in experimentally infected mice and non-human 
primates. In cynomolgus macaques, infectious CHIKV or CHIKV RNA is present in 
synovial tissue, muscle, lymphoid organs, and the liver for weeks after infection (153). 
Similarly, CHIKV RNA is present in the spleen of aged rhesus macaques for at least five 
weeks after initial infection (154). Infection of wild-type (WT) C57BL/6 mice with CHIKV 
also results in chronic synovitis and persistence of CHIKV RNA specifically within joint-
associated tissues (157). Consistent with these data, long term persistence of positive- 
and negative-strand CHIKV RNA persists in the feet of CHIKV-inoculated mice (168), 
and mice infected with a recombinant CHIKV strain encoding a luciferase gene display 
gene activity even 60 days post-infection (204). Collectively, these data suggest that 
CHIKV persists for weeks to months in some tissues, and that the chronic 
musculoskeletal disease experienced by CHIKV patients may be due to persistent 
infection or inflammation.  
 Here, we show that the attenuated CHIKV strain 181/25, in contrast to its 
pathogenic parental strain AF15561, is cleared from joint-associated tissues within 4 
weeks of infection. We took advantage of these disparate outcomes to investigate the 
viral and host determinants of CHIKV clearance and persistence. Our findings revealed 
that clearance of the attenuated 181/25 strain is impaired in Rag1-/- mice, B cell-deficient 
μMT mice, and B cell receptor transgenic mice that cannot produce virus-specific 
antibody, and that the persistence of 181/25 in joint tissue of Rag1-/- mice occurred 
without the acquisition of adaptive mutations that confer persistence in WT mice. The 
amino acid at position 82 of the CHIKV E2 glycoprotein, which varies between 181/25 
and AF15561, is a major determinant of CHIKV clearance and the potency of 
neutralization of multiple epidemic CHIKV strains by both murine and human immune 
sera. Notably, neutralization of AF15561 by monoclonal antibodies (MAbs) specifically 
targeting E2 domain B was inefficient relative to 181/25. Overall, our data suggest that 
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virus-specific antibody responses contribute to the clearance of 181/25 infection, and 
that AF15561 evades this response by minimizing the impact of E2 B domain 
neutralizing antibodies to establish persistent infection. 
Results 
CHIKV 181/25 is Cleared from Sites of Dissemination in WT C57BL/6 Mice . 
Pathogenic CHIKV strains establish persistent infections in joint tissues of 
immunocompetent WT C57BL/6 mice (157, 168). To test whether an attenuated CHIKV 
strain also establishes persistent infection in mice, we measured viral loads in joint 
tissues of WT C57BL/6 mice infected with the attenuated CHIKV strain 181/25 and its 
pathogenic parental strain AF15561 (142), which vary at five amino acids (Fig. 4-1A). 
WT mice were inoculated in the left rear footpad with AF15561 or 181/25, and viral loads 
in the contralateral right ankle were quantified by RT-qPCR (Fig. 4-1B). At 3 days post-
inoculation (dpi), 181/25-infected mice had reduced viral RNA levels in the right ankle 
compared with AF15561-infected mice. These data are consistent with previous reports 
demonstrating that CHIKV strain 181/25 has diminished capacity to disseminate in mice 
from the site of inoculation (172, 260). At 7 dpi, levels of viral RNA in the contralateral 
right ankle of mice inoculated with 181/25 were increased compared with levels at 3 dpi 
(P < 0.001), suggesting that 181/25 replicated at that site. Viral loads in the right ankle at 
7 and 14 dpi were comparable in mice infected with 181/25 or AF15561 (Fig. 4-1B). By 
21 dpi, however, levels of viral RNA in the right ankle of 181/25-infected mice were 
reduced 95-fold relative to those in AF15561-infected mice. Similarly, at 28 dpi, high 
levels of viral RNA were maintained in the contralateral right ankle of AF15561-infected 
mice, whereas viral RNA was below the limit of detection in 7 of 8 mice infected with 
181/25. Viral RNA in the right ankle of AF15561-infected mice remained detectable for at 
least 6 weeks post-infection (Fig. 4-1B). Similar to the right ankle, viral RNA levels in the 
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wrist (Fig. 4-1C) and the spleen (Fig. 4-1D) of mice infected with 181/25 were below the 
limit of detection at 28 dpi whereas viral RNA remained detectable at those sites in 
AF15561-infected animals. In contrast, viral RNA was detectable at 28 dpi in the 
ipsilateral left ankle, which is proximal to the site of inoculation (left rear footpad), of mice 
infected with 181/25 (Fig. 4-1E), suggesting that the kinetics, or the influence of the local 
microenvironment on viral RNA clearance are distinct at that site. 
AF15561 has a higher ratio of genome copies to plaque-forming units (PFU) than 
181/25 (25, 260). To determine whether differences in the number of CHIKV particles 
injected into mice contributed to differences in viral RNA persistence or clearance, we 
inoculated WT mice with 6.8 x 104 BHK cell PFU of 181/25, an equivalent number of 
genomes as contained in 1,000 BHK cell PFU of our stock of AF15561 (as determined 
by RT-qPCR, data not shown). Reciprocally, we also inoculated WT mice with 30 PFU of 
AF15561. Higher levels of viral RNA were detectable at 28 dpi in the right ankle of mice 
inoculated with 30 PFU of AF15561 than mice inoculated with 6.8 x 104 BHK cell PFU of 
181/25, as the latter were below the limit of detection in 8 of 11 mice (Fig. 4-1F). Thus, 
differential clearance of CHIKV strains AF15561 and 181/25 at sites of dissemination is 
not attributable to differences in the amount of viral RNA between the two strains at the 
time of inoculation.  
Viral Determinants of CHIKV Persistence in Mice. Two mutations, I12 and 
R82, in the E2 glycoprotein of CHIKV 181/25 are responsible for as attenuation of acute 
disease in mice (144, 260). To determine whether these mutations influenced the 
persistence of viral RNA in joint tissues, we inoculated mice with 181/25 containing E2 
residue 12 reverted to a WT threonine (181/25E2 I12T), E2 residue 82 reverted to a WT 
glycine (181/25E2 R82G) or both revertant mutations together (181/25E2 I12T R82G) and 
quantified viral RNA levels in the right ankle at 28 dpi (Fig. 4-1G). In comparison to mice 
infected with 181/25, infection of mice with 181/25E2 I12T did not alter viral RNA levels in 
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the right ankle at 28 dpi (Fig. 4-1G). However, reversion of E2 residue 82 to a glycine 
(181/25E2 R82G) resulted in 9 of 10 mice having detectable viral RNA in the right ankle at 
28 dpi (Fig. 4-1G), albeit at lower levels than detected in the right ankle of mice 
inoculated with AF15561. Inoculation of mice with the double revertant 181/25E2 I12T R82G 
restored viral RNA levels in the right ankle at 28 dpi to those detected in AF15561-
infected mice (Fig. 4-1G). Although 181/25E2 I12T was cleared from the right ankle at 28 
dpi, the level of viral RNA in the right ankle of mice infected with 181/25E2 I12T R82G was 
higher compared with 181/25E2 R82G -infected mice, suggesting that a threonine at E2 
residue 12 influences viral clearance when paired with the E2 R82G mutation.  
CHIKV 181/25 Persists in Rag1-/- Mice. Based on the kinetics of CHIKV 181/25 
clearance from the right ankle of WT mice (Fig. 4-1B), we hypothesized that adaptive 
immune responses prevented persistence of 181/25 infection. To test this hypothesis, 
WT mice or Rag1-/- mice, which lack mature B and T cells, were inoculated with either 
AF15561 or 181/25 and viral RNA in the right ankle at 3 dpi (Fig. 4-2A) and 28 dpi (Fig. 
4-2B) was quantified by RT-qPCR. Similar to WT mice (Fig. 4-1B), viral RNA levels in 
the contralateral right ankle of Rag1-/- mice at 3 dpi were reduced in 181/25-infected 
mice in comparison to AF15561-infected mice (126-fold, P < 0.05) (Fig. 4-2A), 
suggesting that the lower viral loads of 181/25 in this tissue at this time point are not due 
to the functions of B or T lymphocytes. AF15561-infected Rag1-/- mice had higher viral 
RNA levels in the right ankle at 28 dpi in comparison to AF15561-infected WT mice (26-
fold; P < 0.001) (Fig. 4-2B), indicating that B and/or T cell responses (or both) contribute 
to the control of AF15561 infection but fail to mediate clearance. In comparison, viral 
RNA levels in the right ankle of 181/25-infected Rag1-/- mice at 28 dpi were ~8,000-fold 
higher than those in 181/25-infected WT mice (P < 0.0001) (Fig. 4-2B). In addition, viral 
RNA levels in the right ankle of 181/25- and AF15561-infected Rag1-/- mice at 28 dpi 
were similar (Fig. 4-2B). To confirm these findings, we measured the amounts of 
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infectious virus present in the serum and right ankle at 28 dpi. 181/25- and AF15561-
infected Rag1-/- mice had detectable viremia (Fig. 4-2C) although 181/25-infected Rag1-/- 
mice had reduced levels relative to AF15561-infected mice (9.5-fold; P < 0.001). 
However, 181/25-infected Rag1-/- mice had increased titers of infectious virus in the right 
ankle at 28 dpi compared with the same tissue of AF15561-infected mice (4.4-fold, P < 
0.05) (Fig. 4-2D). These data suggest that CHIKV strains 181/25 and AF15561 exhibit a 
similar capacity to persist in joint-associated tissues in the absence of adaptive immune 
responses. 
 Reversion of attenuating mutations occurs in certain tissues of 181/25-infected 
WT mice (144, 260). Therefore, we next determined whether persistence of 181/25 in 
Rag1-/- mice was associated with reversion of attenuating mutations or the acquisition of 
other adaptive mutations. Consensus sequencing of the E2 gene in viral RNA isolated 
from the right ankle of 181/25-infected Rag1-/- mice did not reveal reversion of the 
mutations at E2 residues 12 or 82 (data not shown). This sequencing strategy does not 
exclude the presence of compensatory mutations outside the region sequenced or low-
frequency variants that could act in a trans-complementing manner to enhance virulence 
(287). To test whether persisting virus in ankle tissue of 181/25-infected Rag1-/- mice 
acquired the capacity to persist in WT mice, WT C57BL/6 mice were inoculated with 6 
PFU of CHIKV from right ankle tissue homogenates (based on the virus titer, 6 PFU was 
the amount present in 20 l of homogenate) from AF15561- or 181/25-infected Rag1-/- 
mice at 28 dpi. As a control, mice were inoculated with a similar dose of AF15561 stock 
virus. At 28 dpi, high levels of viral RNA were detected in the right ankle of mice infected 
with Rag1-/- ankle-derived AF15561 or 6 PFU of stock AF15561 (Fig. 4-2E). In contrast, 
viral RNA levels in the right ankle of all WT mice inoculated with Rag1-/- ankle-derived 
181/25 remained below the limit of detection. Additionally, WT mice inoculated with 
Rag1-/- ankle-derived AF15561 and 181/25 had high levels of CHIKV-specific IgG in the 
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serum (1:8,000 to 1:64,000) at the time of harvest (data not shown), indicating that all 
mice had become infected. These results suggest that in the absence of B and T cell 
immunity, CHIKV strain 181/25 establishes a persistent infection without acquiring 
adaptive mutations that alter the capacity for viral persistence in WT mice.  
B Cells and Virus-Specific Antibody Are Required for Clearance of CHIKV 
181/25. To determine whether B cells are required for clearance of CHIKV 181/25 from 
joint tissues, we inoculated WT mice or μMT mice (deficient in mature B cells) with either 
AF15561 or 181/25 and quantified viral loads in the right ankle at 28 dpi (Fig. 4-3A). 
Although not statistically significant (P > 0.05), we found that similar to Rag1-/- mice, viral 
loads in AF15561-infected μMT mice trended higher compared with WT animals. 
Moreover, μMT mice were unable to control 181/25 infection, with 10 of 10 mice having 
persistent viral RNA in the right ankle in comparison with 181/25-infected WT mice (155-
fold, P < 0.0001). Furthermore, the levels of viral RNA in the right ankle of μMT mice 
infected with AF15561 or 181/25 were similar. These findings suggest that B cells are 
required for clearance of 181/25 infection in joint tissues.  
As μMT mice may have altered T cell responses because of the antibody-
independent functions of mature B cells (288), we repeated these experiments using 
MD4 transgenic mice (MD4tr), which express a B cell receptor (BCR) specific for hen egg 
lysozyme (HEL) on a WT C57BL/6 background. In these mice, greater than 90% of B 
cells express the HEL-specific BCR due to allelic exclusion (289). Similar to μMT mice, 
infection of MD4tr mice with CHIKV strain AF15561 resulted in modestly elevated (6-fold) 
levels of viral RNA in the right ankle at 28 dpi compared with WT mice, although this 
difference was not statistically significant. In contrast, levels of viral RNA in the right 
ankle at 28 dpi in 181/25-infected MD4tr mice were higher in comparison to 181/25-
infected WT mice (350-fold, P < 0.0001) (Fig. 4-3A) and closely matched the levels 
observed in MT mice. Moreover, levels of viral RNA in the right ankle of 181/25- and 
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AF15561-infected MD4tr mice at 28 dpi were similar (P > 0.05) (Fig. 4-3A). Analysis of 
the CHIKV-specific antibody response in these mice by ELISA confirmed markedly 
diminished or absent CHIKV-specific IgG in AF15561- and 181/25-infected MD4tr and 
μMT mice (Fig. 4-3B). These results suggest that CHIKV-specific antibody responses 
are required for clearance of 181/25 from joint tissue, but the persistent AF15661 strain 
evades these clearance mechanisms.  
Antibody Responses to CHIKV AF15561 and 181/25 Infection Are Distinct . 
The magnitude of the CHIKV-specific IgG response was similar at 28 dpi in AF15561- 
and 181/25-infected WT mice (Fig. 4-3B). We next investigated whether differences in 
clearance of CHIKV AF15561 and 181/25 infection from joint tissue of WT mice were 
associated with differences in the kinetics or quality of the anti-CHIKV antibody 
response. Using a virion-based ELISA to quantify CHIKV-specific IgM and IgG present in 
the sera of WT mice, we found that virus-specific IgM responses to both AF15561 and 
181/25 infection developed rapidly, with IgM titers peaking at 5 to 7 dpi and declining 
thereafter (Fig. 4-4A). Levels of anti-CHIKV IgM were higher in AF15561-infected mice 
at both 5 dpi (10-fold, P < 0.0001) and 7 dpi (2.5-fold, P < 0.0001) compared with those 
in 181/25-infected mice (Fig. 4-4A). CHIKV-specific IgG responses also developed 
rapidly, with titers detected at 7 dpi with either strain (Fig. 4-4B). Again, the levels of 
anti-CHIKV IgG in AF15561-infected WT mice at 7 dpi were higher than those detected 
in 181/25-infected mice (12-fold, P < 0.0001). By 14 dpi and after, CHIKV-specific IgG 
titers were equivalent in AF15561 and 181/25-infected mice (Fig. 4-4B) as were the 
individual CHIKV-specific IgG subtypes at 28 dpi (Fig. 4-4C). By these analyses, the 
principal differences in virus-specific antibody responses during AF15561 or 181/25 
infection occurred at early times post-infection; higher antibody levels were detected in 
AF15561-infected animals, which likely reflects the greater levels of viral replication and 
antigen in these mice.  
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 Although early virus-specific IgM and IgG responses were greater after infection 
with AF15561 compared with 181/25, this pattern did not correlate with clearance of 
AF15561 and 181/25 from joint tissue of WT mice. Given this lack of correlation, we 
investigated the qualitative activity of the virus-specific antibody response by measuring 
the neutralization capacity using a plaque reduction neutralization test (PRNT50) with 
181/25 or AF15561 as the challenge viruses. When serum was collected at 7 dpi from 
AF15561- or 181/25-infected mice and tested against the homologous virus, serum from 
181/25-infected mice displayed greater neutralizing activity compared with serum from 
AF15561-infected mice (22-fold, P < 0.0001) (Fig. 4-5A). However, serum from 
AF15561-infected mice displayed neutralizing activity against 181/25 that was 
comparable to serum from 181/25-infected mice (Fig. 4-5A), despite the differences in 
IgM and IgG ELISA binding titers at this time point (Fig. 4-4A and 4- 4B). By combining 
the ELISA and neutralization data, we observed a lower (5.2-fold, P < 0.01) serum 
neutralization index (290) in AF15561-infected mice compared with 181/25-infected mice 
(Fig. 4-5B), suggesting that the early virus-specific antibody response qualitatively 
differed during infection with acutely cleared (181/25) or persistent (AF15561) CHIKV 
strains. Serum collected from 181/25-infected mice at 7 dpi exhibited reduced 
neutralizing activity (Fig. 4-5A) and a reduced neutralization index (Fig. 4-5B) against 
AF15561 compared with 181/25. Although we detected similar neutralization activity 
against 181/25 or AF15561 virus in serum collected at 28 dpi from AF15561- or 181/25-
infected mice, the neutralizing activity of sera from mice infected with either virus was 
consistently reduced against AF15561 compared with 181/25 (Fig. 4-5C and 4- 5D). 
Accordingly, and similar to 7 dpi, we observed a lower serum neutralization index for 
sera from AF15561- or 181/25-infected mice against AF15561 (Fig. 4-5D). 
 To determine whether amino acid differences between 181/25 and AF15561 
explained the differences in serum neutralization capacity, we performed PRNT50 assays 
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using sera from 181/25-infected mice against AF15561, AF15561E2 G82R, 181/25, and 
181/25E2 R82G viruses. In comparison to neutralization of 181/25, the neutralizing activity 
of sera collected from 181/25-infected mice was reduced against AF15561 and 181/25E2 
R82G but not AF15561E2 G82R (Fig. 4-5E). Similar results were observed using sera 
collected from AF15561-infected mice (Fig. 4-5F). Introduction of the E2 G82R mutation 
into the genome of another epidemic CHIKV strain (SL15649) (158) also enhanced 
neutralization of the virus by serum collected from SL15649-infected mice (Fig. 4-5G). 
Furthermore, the neutralizing activity of human sera collected from individuals who 
acquired CHIKV infection in the Caribbean (Fig. 4-6A - 4-6C) (291) or Sri Lanka (Fig. 
4A-6E – 4A-6H) was reduced against AF15561 (an Asian genotype virus with genetic 
similarity to CHIKV strains circulating in the Caribbean) and SL15649 (an East, Central, 
South Africa genotype virus isolated during 2006 outbreak in Sri Lanka) in comparison 
with AF15561E2 G82R and SL15649E2 G82R. Control human sera had no effect on CHIKV 
infection (Fig. 4-6D and 4- 6I). Thus, the amino acid at E2 residue 82 influences the 
neutralization of epidemic Asian and East, Central, South Africa (ECSA) genotype 
CHIKV strains by both murine and human immune sera. 
 To define the structural basis for differences in neutralization, we tested a panel 
of recently characterized CHIKV-specific mouse and human monoclonal antibodies 
(MAbs) with mapped epitopes in E1 and E2 (36, 221, 292, 293) for their capacity to 
neutralize AF15561 and 181/25. MAbs recognizing the CHIKV E1 glycoprotein (CHK-
166, CHK-269, and CHK-155) or E2 domain A or Arch region (h4J21 and h4N12) (see 
Fig. 4-8 for domain organization of E2) had similar neutralizing activity against AF15561 
and 181/25 (Fig. 4-7A – 4-7E). The neutralizing activity of MAbs that bind epitopes 
spanning E2 domains A and B [CHK-152 (220, 293) and 5M16 (292)] was reduced 
modestly against AF15561 compared with 181/25 (2-fold and 3-fold, respectively) (Fig. 
4-7F – 4-7G). In contrast, mouse and human MAbs recognizing epitopes within the E2 B 
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domain (CHK-265, CHK-98, CHK-48, and h8I4) neutralized AF15561 much less 
efficiently than 181/25 (17-fold, 11.5-fold, 19-fold and 600-fold respectively) (Fig. 4-7H – 
4-7K) even though polymorphic E2 residues 12 and 82 are located within the E2 A 
domain and not within the binding footprint of CHK-265, CHK-98, CHK-48, or h8I4 (36, 
221). As expected, West Nile virus-specific mouse and human polyclonal antibodies had 
no effect on virus infection (Fig. 4-7L – 4-7M). These findings, along with the serum 
neutralization data, suggest that E2 residue 82 influences neutralization of CHIKV, with 
pathogenic strains evading the inhibitory activity of antibodies targeting the B domain of 
the E2 glycoprotein. 
Discussion 
Long-term clinical sequelae are a common outcome of infection with CHIKV and 
several related alphaviruses (125). In this study, we found that in contrast to pathogenic 
CHIKV strain AF15561, attenuated CHIKV strain 181/25 was cleared from most tissues 
of infected WT mice within 4 weeks of infection. We reasoned that comparative studies 
of CHIKV AF15561 and 181/25 infection would provide insight into mechanisms that 
influence clearance and persistence of CHIKV infection.  
Viral Determinants Influence CHIKV Clearance and Persistence . Genomes of 
CHIKV strains AF15561 and 181/25 differ at five non-synonymous and five synonymous 
nucleotides positions (144). Mutations resulting in amino acid changes in 181/25 are in 
nsP1 (T301I), E2 (T12I and G82R), 6K (C42P), and E1 (A404V) (Fig 4-1A). We found 
that reversion of the arginine to a glycine at E2 position 82 (181/25E2 R82G) yielded 
increased viral loads in the contralateral ankle at 28 dpi, suggesting that an arginine at 
E2 residue 82 restricts CHIKV persistence. Arginine 82 in E2 enhances the affinity of 
CHIKV particles for glycosaminoglycans (GAGs) in vitro (25), which may limit the 
capacity of CHIKV to disseminate from early sites of primary replication in vivo (172, 
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260, 294). The extent to which altered interactions with GAGs influences CHIKV 
clearance remains to be determined, but our data suggest that an arginine at position 82 
promotes CHIKV clearance by facilitating neutralization of infectious viral particles by 
antibodies. An arginine at position 82 also was found to impair cell-to-cell spread of 
CHIKV in vitro, a mechanism by which CHIKV may evade antibody mediated 
neutralization; however, this mechanism has not been explored in vivo (295). We also 
found that the amino acid at E2 position 12 contributes to persistence of CHIKV in joint 
tissue, as mice infected with 181/25 encoding both revertant mutations together 
(181/25E2 I12T R82G) had increased levels of persistent viral RNA in joint tissue at late times 
post-infection compared with mice infected with either 181/25E2 R82G or 181/25E2 I12T. 
Although the mechanism by which a threonine at E2 position 12 enhances viral burden 
during the persistent phase of infection requires further study, E2 position 12 may 
stabilize the residue at E2 position 82 (144). In addition, for Semliki Forest virus, a 
related alphavirus, a threonine at E2 position 12 increased the pH threshold of viral 
fusion (33), which might enhance replication efficiency. 
CHIKV 181/25 Persists in Mice Lacking the Capacity to Produce Virus-
Specific Antibodies . Pathogenic strains of CHIKV persist in joint tissue of mice, 
suggesting that adaptive immune responses fail to clear primary infection (157, 168). In 
contrast, adaptive immune responses efficiently clear attenuated strain 181/25. Rag1-/- 
mice infected with 181/25 exhibited a nearly 8,000-fold increase in viral load in joint 
tissue distal to the site of inoculation at 28 dpi relative to 181/25-infected WT mice. In 
addition, levels of viral RNA and infectious virus in the contralateral joint tissue of 
181/25-infected Rag1-/- mice were similar or greater than those detected in AF15561-
infected Rag1-/- mice. Increased titers of infectious virus in joint tissues of 181/25-
infected Rag1-/- mice may be due to the enhancement of viral replication within tissues 
by efficient interactions with GAGs, as has been described for a GAG-binding strain of 
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Sindbis virus (296). Infectious virus recovered from joint tissue of 181/25-infected Rag1-/- 
mice at 28 dpi had not gained the capacity to establish persistence in WT mice, and 
reversion of the mutations in the E2 glycoprotein was not detected. Therefore, in mice 
lacking adaptive immune responses, AF15561 and 181/25 establish persistence in joint 
tissues with comparable efficiency.  
Our findings that Rag1-/- mice infected with 181/25 had detectable viremia at 28 
dpi contrast with a previous study in which older 8-10 week old Rag1-/- C57BL/6 mice 
infected with 181/25 did not have detectable viremia (297). Additionally, we consistently 
detected infectious virus at 28 dpi in joint tissues of Rag1-/- mice infected with 181/25. In 
contrast, Seymour et al. did not detect infectious virus at late times post-infection (28-56 
dpi) in various tissues of 181/25-infected Rag1-/- mice although joint tissues were not 
examined. It is possible that the age of mice and specific tissues evaluated in the two 
studies accounts for the disparate findings. Absence of detectable genetic or phenotypic 
reversion of 181/25 virus after 4 weeks of viral persistence in the joint tissue of Rag1-/- 
mice also differs from studies of 181/25-infected WT mice in which rapid reversion of the 
attenuating mutations in virus present in the circulation and the spleen was detected 
(144, 260). Deep sequencing of CHIKV from the serum, brain, or kidney of persistently 
infected Rag1-/- mice revealed small numbers of mutations, suggesting that CHIKV is 
under less selective pressure in Rag1-/- than WT mice (168, 297). Collectively, these 
data suggest that reversion of the attenuating mutations in 181/25 in WT mice likely is 
driven, at least in part, by adaptive immune responses. Similar to our findings with Rag1-
/- mice, 181/25 infection of B cell deficient μMT mice or BCR transgenic mice that have 
normal B cell numbers but are incapable of producing CHIKV-specific antibody, resulted 
in persistence of viral RNA in joint tissue at levels similar to those in AF15561-infected 
WT mice. These findings suggest that CHIKV-specific antibody responses are essential 
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for clearance of 181/25 from joint tissue, and that the pathogenic AF15561 strain evades 
these clearance mechanisms.  
Antibody Responses to Pathogenic and Attenuated CHIKV Strains are 
Distinct . Characterization of the humoral immune response of WT mice to AF15561 and 
181/25 infection revealed differences in the kinetics, magnitude, and quality of the 
antiviral antibody response. Similar to previous studies (201, 218), the anti-CHIKV IgM 
response peaked at day 5 after AF15561 infection. In comparison, the anti-CHIKV IgM 
response in 181/25-infected mice was of lower magnitude and peaked slightly later (7 
dpi). AF15561 infection of WT mice also induced a rapid CHIKV-specific IgG response, 
with high antibody levels detected at 7 dpi. In contrast, 181/25-infected mice did not 
achieve similar CHIKV-specific IgG titers until 14 dpi. Thus, the kinetics and magnitude 
of the early virus-specific IgM and IgG response did not correlate with relative clearance 
of AF15561 and 181/25 in joint tissue of WT mice. In addition, characterization of the 
neutralizing antibody response in AF15561 and 181/25-infected mice revealed three 
important findings: (1) The neutralization capacity of sera from AF15561-infected and 
181/25-infected mice differed when homologous virus was used in the in vitro 
neutralization assay, with lower neutralizing titers detected in sera from AF15561-
infected mice at both 7 and 28 dpi. Given the higher ELISA titers detected in these mice, 
this difference resulted in a diminished neutralization index; (2) When day 7 sera from 
AF15561-infected mice was tested against the heterologous 181/25 virus, we detected a 
lower neutralization index in comparison to day 7 sera from 181/25-infected mice. These 
findings indicate that the higher levels of CHIKV-specific IgM and IgG antibodies in sera 
from AF15561-infected mice do not translate to a higher CHIKV-neutralizing capacity, 
particularly at early times post-infection. Differences in the quality of CHIKV-specific 
antibody responses could contribute to the difference in clearance of the two viruses in 
WT mice. Early neutralizing antibody responses in humans protect against acute 
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disease (298), and the appearance of neutralizing IgG3 antibodies in CHIKV-infected 
patients correlates with reduced chronic CHIKV-induced musculoskeletal disease (213); 
and (3) The neutralization capacity of sera from 181/25-infected mice against AF15561 
was lower in comparison to the neutralization capacity of the same sera against the 
homologous virus. Although sera from AF15561-infected mice did not neutralize 181/25 
as efficiently as sera from 181/25-infected mice, sera from AF15561-infected mice 
neutralized 181/25 to a greater extent than it did AF15561. These findings suggest that 
differences in the display of neutralizing epitopes in AF15561 and 181/25 virions may 
contribute to differential inhibition by serum. Consistent with this hypothesis, the 
neutralization capacity of sera collected from CHIKV-infected mice or humans in Sri 
Lanka and the Caribbean was enhanced against mutated epidemic CHIKV strains 
encoding an arginine at E2 position 82.  
181/25 is Neutralized More Efficiently by Anti-CHIKV Antibodies Targeting 
E2 Domain B . To determine the molecular basis underlying differences in antibody-
mediated neutralization of 181/25 and AF15561, we performed neutralization assays 
using a panel of MAbs targeting epitopes in distinct domains of the CHIKV E1 and E2 
glycoproteins. MAbs recognizing epitopes in the E1 glycoprotein, E2 domain A, or E2 
Arch region had equivalent neutralizing activity against AF15561 and 181/25. 
Importantly, this finding suggests that differences in PFU-to-antigen ratios of the viruses 
do not explain the differential neutralization of the two viruses by sera from virus-infected 
mice. In contrast, several mouse and human MAbs targeting E2 domain B exhibited 
reduced neutralization capacity against AF15561 compared with 181/25. These findings 
are consistent with reports that examined the mechanism of neutralization by the E2 B 
domain specific anti-CHIKV MAb 5F10 (35, 295). Passage of a CHIKV isolate containing 
an arginine at E2 position 82 under selective pressure of MAb 5F10 selected for a 
glycine at position 82 (295), and structural studies suggested that 5F10 neutralizes 
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CHIKV encoding an arginine at E2 position 82 by locking domain B into a rigid 
conformation and preventing exposure of the E1 fusion loop (35). Although 5F10 binds 
to CHIKV strains possessing a glycine at E2 position 82, the binding does not inhibit 
fusion. This mechanism of locking domain B and preventing fusion appears to be 
common to both mouse and human neutralizing antibodies targeting E2 domain B (36, 
292, 293). In our studies, MAb CHK-265, which neutralizes CHIKV by cross-linking E2 
domain B to E2 domain A of an adjacent spike (Fig 4-9) (36), exhibited a substantial 
difference in EC50 values between AF15561 and 181/25. The mutations in 181/25 at 
positions 12 and 82 of E2 are located in domain A away from the CHK-265 footprint, 
suggesting that these mutations do not directly influence the capacity of CHK-265 to 
recognize the virion. Our data support a model proposed by Porta et al. in which 
pathogenic CHIKV strains possessing the highly conserved E2 glycine 82 retain domain 
B flexibility despite bound antibody, thus permitting viral fusion and entry (35). In 
contrast, an arginine at E2 residue 82, located within the core of the E2/E1 trimeric 
spike, introduces repulsive forces that alter the spatial conformation of E2 domain B (Fig 
4-9). This structural perturbation may allow antibodies to lock domain B into a rigid 
conformation that impedes exposure of the E1 fusion loop and entry of the virus. As the 
E2 domain B appears to be a dominant immune target in humans and mice (215), the 
near uniform conservation of E2 glycine 82 in pathogenic strains suggests a general 
mechanism by which CHIKV evades neutralizing antibody responses. Based on our 
findings, we conclude that this immune evasion mechanism contributes to the 
development of viral persistence. In addition, these findings have implications for the 
selection of virus strains used for vaccine development and for the evaluation of vaccine-










Figure 4-1: CHIKV 181/25 is Cleared from Sites of Dissemination in WT mice. (A) 
CHIKV strain 181/25 has 5 non-synonymous mutations from parental CHIKV strain 
AF15561. nsP1 T301I, E2 T12I, E2 G82R, 6k C42F, E1 A404V. (B-E) WT C57BL/6 mice 
were inoculated in the left rear footpad with 103 PFU of the pathogenic CHIKV strain 
AF15561 or the attenuated CHIKV strain 181/25. At the time points shown, CHIKV RNA 
in tissues was quantified by RT-qPCR. (F) WT C57BL/6 mice were inoculated in the left 
rear footpad with 30 PFU of AF15561 or 68,000 PFU of 181/25. At 28 dpi, CHIKV RNA 
in the right ankle was quantified by RT-qPCR. (G) WT C57BL/6 mice were inoculated in 
the left rear footpad with 103 PFU of the virus shown. At 28 dpi, CHIKV RNA in the right 
ankle was quantified by RT-qPCR. Horizontal bars indicate the mean values. The 
dashed lines indicate the limit of detection. Data are pooled from two or more 
independent experiments. P values were determined by two-way ANOVA with 
Bonferroni's multiple comparison test (B), the Mann-Whitney-test (C-E), or one-way 
ANOVA with a Tukey's multiple comparison test (G). *, P < 0.05, **, P < 0.01, ***, P < 









Figure 4-2. CHIKV 181/25 Persists in Rag1-/- Mice  
(A-D) WT or Rag1-/- mice were inoculated with 103 PFU of AF15561 or 181/25. At (A) 3 
dpi of Rag1-/- mice or (B) 28 dpi of WT or Rag1-/- mice, viral RNA in the right ankle was 
quantified by RT-qPCR. Infectious virus in the (C) serum or (D) right ankle was 
quantified by plaque assay. (E) WT mice were inoculated in the left rear footpad with 
clarified ankle tissue homogenate containing 6 PFU of virus from (D) AF15561- or 
181/25-infected animals or 6 PFU of CHIKV strain AF15561. At 28 dpi, CHIKV RNA in 
the right ankle was quantified by RT-qPCR. Horizontal bars indicate mean values. 
Dashed lines indicate the limit of detection. Data are from two or more independent 
experiments. P values were determined by Mann-Whitney test (A and D) or one-way 
ANOVA with a Tukey's multiple comparison test (B, C, and E). *, P < 0.05, ***, P < 





Figure 4-3. Virus-Specific Antibody is Required to Control 181/25 Infection. WT, B 
cell deficient µMT, or BCR transgenic MD4tr C57BL/6 mice were inoculated in the left 
rear footpad with 103 PFU of AF15561 or 181/25. At 28 dpi, (A) CHIKV RNA in the right 
ankle was quantified by RT-qPCR, and (B) CHIKV-specific IgG in the serum was 
quantified by a whole virion-based ELISA. Data are from two or more independent 
experiments. P values were determined by one-way ANOVA with a Tukey's multiple 




Figure 4-4. Virus-Specific Antibody Responses in WT Mice Infected with AF15561  
or 181/25 WT C57BL/6 mice were inoculated in the left rear footpad with 103 PFU of 
AF15561 or 181/25 (n = 5-8 mice per group). At the time points shown, a virion-based 
ELISA was used to quantify the serum endpoint titers of CHIKV-specific (A) IgM or (B) 
IgG. (C) IgG subtype-specific detection antibodies were used to quantify IgG subtypes 
present in serum at 28 dpi (n = 5-6 mice per group). Data are from two or more 
independent experiments. P values were determined by two-way ANOVA with a 
Bonferroni's multiple comparison test (A, B) and Student's t-test (C). *, P <0.05, **, P < 




Figure 4-5. Serum Neutralization of CHIKV Strains.   
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Figure 4-5 . Serum Neutralization of CHIKV Strains. (A-D) WT C57BL/6 mice were 
inoculated in the left rear footpad with 103 PFU of AF15561 or 181/25. At (A) 7 dpi or (C) 
28 dpi, the neutralization capacity of serum was quantified using a plaque reduction 
neutralization test 50 (PRNT50) with AF15561 or 181/25 as the challenge virus. (B and 
D) A neutralization index was calculated using the formula (PRNT50)/(IgG + IgM ELISA 
endpoint). (E-G) The neutralizing activity of pooled serum derived from (E) 181/25-, (F) 
AF15561- or (G) SL15649-infected mice at 28 dpi was determined using the indicated 
viruses. Horizontal bars indicate mean values. Data are from two or more independent 
experiments. Dashed lines indicate the limit of detection. P values were determined by 
one-way ANOVA with a Tukey's multiple comparison test. *, P <0.05, **, P < 0.01 ***, P 










Figure 4- 6. E2 Residue 82 Influences Neutralization of CHIKV with Human Immune 
Sera. (A-C and E-H) The neutralizing activity of human sera from CHIKV-immune 
subjects was quantified using PRNT50 analysis against the indicated viruses. (D and I) 
Non-immune human sera was included as a control. The serum dilutions at which 50% 
of AF15561 (red text), AF15561E2 G82R (black text), SL15649 (pink text), or SL15649E2 
G82R (blue text) were neutralized (PRNT50) were determined by non-linear regression 
(95% CI). Each graph represents the mean and standard error of the mean (SEM) from 





 Figure 4-7. Differential Neutralization of AF15561 and 181/25 by MAbs Targe ting E2 




Figure 4-7. Differential Neutralization of AF15561 and 181/25 by MAbs Targeting  E2 
Domain B.  (A-M) MAbs were incubated with 100 FFU of AF15561 (red) or 181/25 (blue) 
viruses for at 37°C for 1 h. MAb-virus mixtures were added to Vero cells and incu bated 
for 18 h. Virus-infected foci were stained and counted. Wells containing MAbs were 
compared with wells without MAbs to determine relative infection. (L) WNV E60 and (M) 
hE16 MAbs were included as isotype control MAbs. The concentrations at which 50% of 
AF15561 (red text) or 181/25 (blue text) were neutralized (EC50) were determined by 
non-linear regression and are displayed in ng/ml (95% CI). Each graph represents the 





Figure 4-8. Domain Organization of E2-E1 heterodimer. Surface view of the CHIKV 
E2 and E1 heterodimer (PDB: 3N42; Voss et al. 2010). E1 is colored light grey, the E1 
fusion loop is colored pink, E2 domain A is colored dark blue, E2 domain B is colored 
orange, E2 domain C is colored red, the E2 arch regions are colored light blue, and 






Figure 4-9. Possible model of how E2 residue 82 influences virus neutralization by 
antibodies that target the E2 B domain. (A) Cryo-EM reconstruction of CHIKV 181/25 
in complex with CHK-265 Fab fragments (PDB: 5ANY; Fox et al. 2015). The CHK-265 
Fab molecules are colored dark grey, E1 is colored light grey, E2 domain A is colored 
dark blue, E2 domain B is colored orange, E2 domain C is colored red, the E2 arch 
regions are colored light blue, and the arginine (R) residue at E2 position 82 is colored 
yellow. (B) CHK-265 Fab fragments in complex with a CHIKV strain encoding a glycine 
(G) residue at E2 position 82 (yellow) was modeled based on data reported under PDB: 
2XFC (Voss et al. 2010). In this model, the interactions between CHK-265 and the A 
domain of E2 in a neighboring trimeric spike that occur when CHK-265 is complexed 
with viruses encoding an R at E2 position 82 (as shown in A) may occur less efficiently. 
Note the potential change in position of E2 residue 82 within the core of the trimeric 
spike, the change in position of domain A, and the increased space between E2 





CHAPTER V  
CHIKUNGUNYA VIRUS PERSISTENCE IN RAG1-/- MICE IS ASSOCIATED WITH 
MUTATIONS IN THE E2 GLYCOPROTEIN AND 3′ UNTRANSLATED REGION THAT 
ENHANCE VIRAL PATHOGENECITY IN NAÏVE WT MICE 
Introduction 
CHIKV can establish persistent infections in humans (170, 257) and animal 
experimentally-infected animal models (153, 157, 168, 204). However, the viral and host 
determinants of CHIKV persistence are largely unknown. My work has demonstrated 
that adaptive immune responses control CHIKV during persistence but are unable to 
clear CHIKV RNA from joint-associated tissue and that CHIKV evades neutralizing 
antibody responses as a necessary step to establish persistence (Chapter III and IV). 
However, CHIKV likely engages multiple mechanisms to establish and maintain 
persistence as persistent CHIKV infection occurs despite sustained innate and adaptive 
antiviral immune responses of the host. For example, in addition to being essential for 
control of CHIKV infection during the acute phase (156), the type I IFN response is 
sustained weeks post-infection in humans with chronic CHIKV disease and in mice 
persistently-infected with CHIKV (168, 170). Furthermore, CHIKV-specific antibody and 
T cell responses are sustained for weeks to months post infection (201, 205, 233). Thus, 
we hypothesized that persistence of CHIKV requires the acquisition of adaptive 
mutations to host selective pressures (299-301).  
As described in Chapter IV, characterization of infectious CHIKV recovered from 
the joint-associated tissue of infected Rag1-/- mice at day 28 post-infection with CHIKV 
strains AF15561 or 181/25 did not reveal phenotypic changes (See Fig 4-2E), 
suggesting that CHIKV strains AF15561 and 181/25 have an equal capacity to persist in 
mice that lack T and B cells. Furthermore, deep sequencing of viral RNA recovered from 
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the joint-associated tissue of CHIKV-infected WT mice at 42 dpi revealed a limited 
number of coding changes that were not highly conserved across multiple samples 
derived from independently-infected mice (data not shown). Cumulatively, these data 
suggest that CHIKV persistence in joint-associated tissues may occur in the absence of 
adaptive mutations.  
However, tissue-specific selective pressures exist within the host. For example, 
lymphocytic choriomeningitis virus (LCMV) recovered from the brains of chronically-
infected mice showed no phenotypic differences from the parental LCMV Armstrong 
strain. In contrast, LCMV recovered from the lymphoid tissue of the same mice showed 
profound differences and was able to establish a chronic infection along with significant 
immunosuppression when re-inoculated into WT mice (302, 303), demonstrating that 
tissue-specific selection of novel variants can occur during viral persistence. I therefore 
hypothesized that persistence of CHIKV may select for novel variants in a tissue-specific 
manner.  
To explore this hypothesis, I isolated CHIKV from the serum of B and T cell 
deficient Rag1-/- mice at day 28 following infection with CHIKV strain AF15561. 
Surprisingly, I found that CHIKV plaque-purified from this tissue displayed enhanced 
pathogenicity in naive WT mice. Sequencing analysis of a plaque-purified isolate 
identified polymorphisms in the viral E2 glycoprotein and 3′ untranslated region (UTR) 
that, when introduced into a cDNA clone of CHIKV strain AF15561, conferred enhanced 
viral dissemination and pathogenecity in mice. These mutations contrastingly modified a 
highly conserved amino acid in E2 and a highly divergent region of the 3′ UTR. 
Importantly, initial characterization of the virus suggests that this mouse-adapted CHIKV 
(MA-CHIKV) strain retains a primary tropism for musculoskeletal tissues and a 
musculoskeletal disease course. Further studies of the mechanisms by which these 
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mutations confer enhanced CHIKV pathogenesis in mice will provide novel insight into 
the virus – host interactions that influence CHIKV replication, dissemination, and 
virulence. 
Results 
 I hypothesized that during persistent infection, CHIKV acquires adaptive 
mutations that facilitate persistence in specific tissues. I took advantage of the 
observation that Rag1-/- and Rag2-/- mice, in contrast to WT mice, support persistent 
viremia for weeks to months but do not succumb to the infection (Fig. 5-1A and B ) (see 
also Fig 3-3F and 4-2C) (168, 204). To assess whether infectious CHIKV circulating in 
the serum of Rag1-/- mice had acquired adaptive mutations that enhance persistence, I 
inoculated WT C57BL/6 mice in the left rear footpad with β0 μl of serum collected from 
individual viremic Rag1-/- mice at 28 dpi. In parallel, I inoculated WT mice in the left rear 
footpad with 20 µl of clarified right ankle tissue homogenate collected from individual 
CHIKV-infected Rag1-/- mice at 28 dpi. This volume of serum or tissue homogenate 
contained between 10 – 20 PFU of infectious virus as measured by direct plaque 
assays. Mice were monitored daily for virus-induced changes in weight as a sensitive 
measure of disease severity. At day 2 p.i., 4 of 5 mice inoculated with serum from 
persistently-infected Rag1-/- mice had failed to gain weight, and these mice gained 
significantly less weight than mice infected with AF15561 through 10 dpi (P < 0.001, 
Two-Way ANOVA, Bonferroni post-test) (Fig. 5-1C). In contrast, and consistent with 
previous studies, WT mice infected with AF15561 gained weight throughout the course 
of infection (Fig. 5-1C). Mice inoculated with ankle tissue homogenates from CHIKV-
infected Rag1-/- mice showed similar weight gain to AF15561-infected mice (P > 0.05, 
Two-Way ANOVA, Bonferroni post-test). Furthermore, mice inoculated with serum from 
persistently-infected Rag1-/- mice exhibited more severe musculoskeletal disease signs 
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including hind limb grip loss, altered gait, and difficulty righting. In addition, these mice 
exhibited ruffled fur and a hunched posture. At 10 dpi, 4 of 5 mice inoculated with serum 
from persistently-infected Rag1-/- mice had reached humane endpoints and the 
experiment was terminated. These data suggested that AF15561 in the circulation, but 
not ankle tissue, of Rag1-/- mice had acquired adaptive mutations that enhanced acute 
pathogenesis in WT mice.  
 One possible explanation for the enhanced disease observed in WT mice 
inoculated with serum from persistently infected Rag1-/- mice is the co-inoculation of 
factors present in the serum of chronically infected Rag1-/- mice that enhanced virus-
induced disease. To test this possibility, and generate biological clones of CHIKV from 
Rag1-/-  serum for further study, I plaque-purified CHIKV from a serum sample used to 
inoculate a mouse in Fig. 1C. Stocks of the individual plaque-purified isolates, 
AF6811P1-P6, were generated by a single amplification on Vero cells. I inoculated WT 
mice with a low dose of AF15561 or plaque-purified isolates AF6811P1-P3 and 
monitored mice daily for virus-induced effects on weight gain (Fig. 5-1D). In contrast to 
mice inoculated with AF15561, mice inoculated with the plaque-purified viruses exhibited 
reduced weight gain and more severe musculoskeletal disease signs, indicating that the 
plaque-purified viral isolates retained the enhanced virulence of Rag1-/- serum-derived 
AF15561 and that co-inoculation of serum factors is not responsible for the more virulent 
phenotype.  
 I selected plaque-purified isolate AF6811P2 for further evaluation and sequenced 
the complete viral genome at both the consensus level and by Illumina-based deep 
sequencing. Alignment of sequence reads to the reference AF15561 genome identified 
three mutations in the genome of AF6811P2: a lysine (K) to arginine (R) substitution at 
E2 position 200 (E2 K200R), a synonymous A to G mutation in the E1 gene (nt 10506) 
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and a 44 nt deletion in the 3′ UTR (Table 5-1). The deep sequencing results indicated 
the E2 and E1 mutations were present in greater than 99.9% of reads suggesting that 
the AF6811P2 biologic isolate was clonal rather than a quasispecies.  
To confirm that these mutations were responsible for the enhanced 
pathogenecity of AF6811P2, I introduced the E2 K200R mutation and the γ′ UTR 
deletion into the AF15561 cDNA clone to generate AF15561Eβ Kβ00R ΔUTR. WT mice were 
inoculated in the left rear footpad with either WT AF15561, AF6811P2 or AF15561E2 K200R 
ΔUTR and mice were monitored daily for virus-induced effects on weight gain and for the 
development of musculoskeletal disease signs (Fig. 5-2A and 2B ). Similar to AF6811P2 
infected mice, AF15561Eβ Kβ00R ΔUTR mice exhibited diminished gain weight compared with 
mice inoculated with AF15561 (Fig. 5-2A) (P < 0.0001, Two-Way ANOVA, Bonferroni 
post-test) and 1 of 4 mice in both groups succumbed to the infection by 10 dpi. 
Additionally, both AF6811P2 and AF15561Eβ Kβ00R ΔUTR infected mice exhibited more 
severe musculoskeletal disease signs compared with mice inoculated with AF15561 
(Fig. 5-2B) (P < 0.0001, Two-Way ANOVA, Bonferroni post-test). These data indicate 
that these two mutations enhance CHIKV pathogenesis in mice. 
 Based on the failure of mice infected with AF15561Eβ Kβ00R ΔUTR to gain weight at 
early time points post-infection, I hypothesized that these mutations enhanced viral 
dissemination from the site of inoculation and/or increased viral burdens in infected 
tissues at early time points post infection. I therefore inoculated WT mice with either 
AF15561 or AF15561Eβ Kβ00R ΔUTR and evaluated viral burdens in a variety of tissues at 1 
and 3 dpi by focus forming assay. At 1 and 3 dpi, AF15561 and AF15561Eβ Kβ00R ΔUTR 
achieved similar titers in the left ankle tissue which is proximal to the site of inoculation. 
In contrast to the left ankle, AF15561Eβ Kβ00R ΔUTR rapidly disseminated to distal tissues 
and achieved higher viral loads compared to AF15561 infected mice by 1 dpi (Fig 5-3A): 
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Right Ankle, 3,500 fold, P <0.0001; Right Quadriceps, 500 fold, P <0.001; Spleen, 31 
fold, P <0.001; Liver, 22 fold, P <0.05; Brain, 43 fold, P <0.001. Similarly, AF15561E2 
Kβ00R ΔUTR infected mice had higher amounts of virus in the serum compared with 
AF15561 infected mice at 1 (300 fold, P <0.01) and 3 dpi (1,050 fold, P <0.0001) (Fig. 5-
3B). Together, these data suggest that E2 K200R and the 44nt deletion in the γ′ UTR 
enhance the ability of the virus to rapidly disseminate from the site of inoculation.  
 To evaluate the contribution of each mutation individually, I constructed AF15561 
strains encoding just the E2 K200R mutation (AF15561E2 K200R) or just the γ′ UTR 
deletion (AF15561ΔUTR). I inoculated WT mice with either virus and compared weight 
gain and disease scores to mice infected with either WT AF15561 or AF15561E2 K200R 
ΔUTR (Fig. 5-4A and 5-4B ). Mice infected with AF15561E2 K200R exhibited a failure to gain 
weight and significantly enhanced disease compared to AF15561 (P < 0.0001, Two-Way 
ANOVA, Bonferroni post-test) suggesting that the E2 K200R mutation contributes to 
enhanced pathogenesis in mice. In contrast, mice infected with AF15561ΔUTR gained 
weight similar to AF15561-infected mice (P > 0.05, Two-Way ANOVA, Bonferroni post-
test) and exhibited mildly enhanced musculoskeletal disease (P < 0.01, Two-Way 
ANOVA, Bonferroni post-test). Notably however, mice infected with AF15561E2 K200R 
developed less severe musculoskeletal disease compared with AF15561Eβ Kβ00R ΔUTR 
infected mice (P < 0.0001, Two-Way ANOVA, Bonferroni post-test) suggesting that the 
γ′ UTR deletion in conjunction with the E2 K200R mutation enhances CHIKV 





Previous work by our lab and other researchers has demonstrated that mice 
deficient in adaptive immune responses support persistence of infectious CHIKV in a 
variety of tissues for weeks post infection (157, 168, 201, 202, 204, 297). Despite 
sustaining chronic viral replication for as long as 500 dpi, Rag1-/- mice exhibit only mild to 
moderate signs of pathology in joint and lymphoid tissues along with modestly elevated 
serum levels of TNF, IL-6 and IFN-  (157, 168). Thus, the isolation of a mouse-adapted 
strain of CHIKV from the serum of a Rag1-/- mouse was surprising. However, isolation of 
a neurovirulent strain of Sindbis virus from the brains of persistently-infected severe 
combined immune deficiency (scid) mice has been previously reported (304), suggesting 
that persistent replication in immunodeficient mice can select for mouse-adapted 
alphaviruses. Our findings are in contrast to previous work by Poo et al. in which CHIKV 
isolated from the serum of Rag1-/- mice at 100 dpi did not show enhanced fitness when 
inoculated into WT mice (168). Similarly, CHIKV isolated from the kidney or brain of 
Rag1-/- mice 4 – 6 wpi showed a limited number of coding changes, all within the non-
structural proteins (297), although the effects of these mutations on CHIKV replication 
and pathogenesis were not evaluated. It is possible that differences in the mouse model 
(young vs adult mice), founder strain of CHIKV (ECSA vs Asian genotype), and source 
of infectious virus for the inoculum (serum or cell culture passaged) may account for this 
difference. Likewise, one mouse receiving serum derived-AF15561 exhibited less severe 
musculoskeletal disease and improved weight gain suggesting that AF15561 circulating 
in the serum of Rag1-/- mice may be heterogeneous. Although AF6811P2 was isolated 
from the serum, it is unknown which tissues or cell types in Rag1-/- mice are shedding 
CHIKV into the circulation. In contrast to the serum, inoculation of ankle tissue 
homogenates, which contained infectious CHIKV, from persistently-infected Rag1-/- mice 
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did not result in more severe disease signs (see Chapter IV Fig 4-2E), suggesting that 
discrete populations of CHIKV with varying fitness may exist within the same host. 
Further studies of these discrete populations may provide novel insight into tissue-
specific selective pressures exerted on CHIKV during acute and chronic infection.  
The host pressures that selected for the adaptive mutations in AF6811P2 are 
unknown. Initial studies show that AF15561 containing the mouse adaptive mutations 
replicates similarly in cell culture (data not shown) suggesting this virus may overcome a 
host restriction factor. Rag1-/- mice are able to restrict CHIKV replication in the absence 
of adaptive immune responses (157, 168), likely through the type I IFN response. Mice 
deficient in the type I IFN response rapidly succumb to CHIKV infection within days post 
infection (156, 165, 172), demonstrating an essential requirement of this response to 
control early CHIKV replication. Mouse adaptation of the related Semliki Forest virus 
(SFV) resulted in a strain of SFV (L10) resistant to control by the type I IFN response 
(305). This strain of SFV was generated by serial passage of an avirulent SFV strain in 
mouse brains, and despite inducing a robust IFN response in infected cells, displays an 
enhanced ability to overcome the antiviral state conferred by IFN (305). Likewise, 
adaptation of Ebola virus to mice correlated with mutations in virally encoded 
antagonists of the host IFN response (306).  
Accordingly, an attractive hypothesis is that the increased pathogenicity and 
replicative capacity of AF6811P2 in mice is due to increased resistance to control by the 
host type I IFN response. The rapid onset of weight loss, enhanced dissemination and 
higher viral loads observed in a variety of tissues in AF15561Eβ Kβ00R ΔUTR infected mice at 
early time points post infection is similar to what has been observed in type I IFN 
deficient mice infected with clinical isolates of CHIKV (156, 172, 174). Notably, mice with 
defects in type I IFN responses have significantly increased CHIKV burdens in muscle 
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tissue (156) similar to what I observed in mice infected with AF15561Eβ Kβ00R ΔUTR (Fig 5-
3A and C). Antagonism of IFN induced effector functions likely also exacerbates CHIKV 
disease as infants and neonatal mice mount a robust type I IFN response following 
infection yet are unable to control the infection (167). Finally, cellular tropism of the virus 
may significantly influence the IFN response to alphavirus infection as seen in 
comparative studies of EEEV and VEEV infection in mice (18). EEEV is restricted in its 
ability to replicate in monocytes and dendritic cells leading to little induction of type I IFN 
prior to death of the animal (18). In contrast, VEEV replicates robustly in these cell types 
and induces a significant type I IFN response (18). Interestingly, the viral determinants of 
these phenotypes map to the E2 glycoprotein and the 3′ UTR (18, 307). Further studies 
evaluating the sensitivity of AF15561Eβ Kβ00R ΔUTR to type I IFN, the levels of IFN induced 
following infection in vivo and the relative virulence of AF15561 containing one or both of 
the identified mutations in IFN deficient mice may shed light on this hypothesis. 
Importantly, the AF6811P2 and AF15561Eβ Kβ00R ΔUTR CHIKV strains retain a 
musculoskeletal type disease, an important consideration as mouse adaptation can lead 
to important differences between mouse and human disease (308, 309). The higher viral 
loads in the quadriceps muscle of AF15561E2 Kβ00R ΔUTR-infected mice may account for 
the more severe musculoskeletal disease, as musculoskeletal disease in CHIKV- and 
RRV-infected mice correlates with increased viral burdens in muscle tissue (172, 186, 
310). Even though mice are perfused extensively prior to dissection of tissues, further 
studies will be needed to determine if the enhanced viral burdens at sites of 
dissemination are due to enhanced replication within these tissues or if the infectious 
virus detected in these tissues is the result of the higher viremia in AF15561E2 K200R ΔUTR-
infected mice compared to AF15561-infected mice.  
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Our data indicate that the E2 K200R mutation is sufficient to enhance CHIKV 
pathogenicity in mice. However, the mechanisms by which this mutation influences 
CHIKV pathogenesis remain unknown. The CHIKV E2 glycoprotein forms a dimer with 
the E1 glycoprotein and three dimers form one of the 80 spikes on the surface on the 
virion (27). E2 is highly exposed on the virion and is responsible for receptor binding 
while also being the major target of neutralizing antibody responses (201, 215). The E2 
K200 residue is highly conserved among strains of all three CHIKV genotypes. 
Crystallography of the CHIKV E2 – E1 heterodimer revealed that the E2 K200 residue 
makes van der Waals contacts with highly conserved E1 residues (C63 and F95) located 
near or in, respectively, the well conserved E1 fusion loop (27), suggesting that the 
K200R mutation may alter E2 – E1 interactions at this site (Fig. 5-5A) . The E1 C63 and 
F95 residues are conserved even in the distantly related SINV and VEEV, suggesting an 
important function of these E1 residues. E2 – E1 interactions in related alphaviruses 
have been shown to regulate pH mediated entry of the virus (33, 311) as during 
endosomal acidification, the E2 – E1 dimers undergo critical structural rearrangements 
to facilitate viral entry into the cytoplasm (26, 31). Mutations in E2 can also influence 
particle assembly and release in a cell- and host- specific manner (312-314), dictate viral 
tropism and pathogenesis in vivo (260, 294, 296, 315, 316), and play an important role in 
vector competence (103, 104). Further studies are therefore needed to examine whether 
the E2 K200R mutation influences CHIKV tropism, pH of fusion, viral assembly and 
release or another unknown mechanism.  
 Initial characterization of AF15561 containing the γ′ UTR deletion alone, 
AF15561ΔUTR, and the double mutant, AF15561Eβ Kβ00R ΔUTR, suggests that the 44 nt 
deletion in the 3′ UTR also contributes to enhanced pathogenesis in mice. Sequence 
analysis of the CHIKV 3′ UTR indicates that it contains many direct repeat elements 
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formed by duplications of multiple elements within the 3′ UTR (74). Asian genotype 
viruses (e.g., AF15561) encode a highly divergent γ′ UTR compared to the other two 
CHIKV genotypes. This divergent 3′ UTR likely formed by a large deletion in the 3′ UTR 
and subsequent accumulation of adaptive mutations and duplications due to founder 
effects as the Asian genotype diverged from a founder ECSA genotype (Fig. 5-5B) (74). 
Identification of a novel duplication in Asian genotype Caribbean isolates suggests the 
Asian 3′ UTR is still under selective pressures (317). Interestingly, the 44 nt deletion 
identified in AF6811P2 occurs in a region of the γ′ UTR, 3B, that is unique to Asian 
genotype viruses (Fig. 5-5B). Thus, the fitness increase conferred by the 44 nt deletion 
in 3B may be constrained to Asian genotype viruses. However, the 3A element, present 
in all genotypes of CHIKV, contains a homologous region differing by only 1 to 4 nt from 
the 44 nt deletion in 3B of AF6811P2 (Fig. 5-5B black box ). Further studies are 
therefore needed to determine if the 3B deletion uniquely affects CHIKV fitness or 
whether manipulation of the 3A element, present in all CHIKV genotypes, can confer a 
similar fitness increase.  
The mechanism by which the 44 nt deletion enhances pathogenesis of CHIKV in 
mice remains to be determined. The function of the 3′ UTR in alphaviral replication and 
pathogenesis is largely unknown and alphaviruses exhibit significant heterogeneity and 
flexibility in their 3′ UTR (5, 9, 10). Modulation of the 3′ UTR often incurs a fitness cost in 
insect cells or whole insects whereas large deletions are tolerated in mammalian 
systems (18, 20, 196, 318), suggesting critical roles for the 3′ UTR in mosquito cells. 
However, the 3′ UTR is important for stability of the viral genome and likely interacts with 
host and tissue specific factors to facilitate viral replication (21, 319). Specifically, CHIKV 
and other alphavirus γ′ UTRs have been shown to interact with host HuR protein thereby 
protecting the viral RNA from degradation and increasing viral yields (22, 320, 321) and 
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may contribute to the destabilizing of transcripts of important host defense proteins such 
as Rig-I (321). The viral γ′ UTR also can have profound impacts on viral tropism and 
host innate immune responses to RNA virus infection. A miRNA binding site in the γ′ 
UTR of EEEV for a myeloid cell specific miRNA restricts viral replication in myeloid cells 
thereby delaying induction of the type I interferon response (18). West Nile Virus, a 
flavivirus, encodes a miRNA in its γ′ UTR that enhances replication in mosquito cells 
(322) and an RNA secondary structure in the flavivirus UTRs can also influence viral 
replication and innate responses to infection (323). Thus, the functions of viral UTRs are 
diverse and it remains to be determined if the deletion in the γ′ UTR of AF6811P2 
alleviates restriction by a host factor, alters interaction with host proteins that facilitate 
viral replication or modulates some other pathway to enhance viral fitness within the 
mouse.  
The isolation and identification of the mouse-adapted AF6811P2 and 
identification of the E2 K200R and γ′ UTR deletion represent, to our knowledge, the first 
identification of a strain of CHIKV that has enhanced fitness in a mammalian host. 
Although the data is consistent, further studies are needed to confirm these observations 
and to evaluate the role of each mutation individually in the enhanced dissemination and 
viral burdens observed in AF15561Eβ Kβ00R ΔUTR infected mice. This CHIKV isolate and 
identified mutations present a unique opportunity to study many aspects of CHIKV 
biology including viral-host interactions, viral protein function and viral evolution within 
the host. Understanding the mechanisms by which these mutations contribute to 
enhanced pathogenesis in mice will provide critical insight into restriction factors that 
control CHIKV infection and the viral mechanisms that counteract these responses. 
Finally, identification of a mouse-adapted CHIKV strain that faithfully recapitulates in 
mice the severe, disseminated musculoskeletal disease reported in humans will also 
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further improve the mouse model towards use in understanding CHIKV pathogenesis in 
humans and developing novel therapeutics.  
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Table 5-1. Mutations identified in AF6811P2. Mutations identified by both consensus 
level and deep sequencing. Sequencing results aligned against AF15561 reference 





Mutation (WT > 
AF6811P2) 
Amino Acid Change (WT > 
AF6811P2) 
9140 E2 A > G Lys200Arg 
10506 E1 A > T Synonymous 






Figure 5- 1. AF15561 derived from the serum of chronically infected Rag1-/- mice 
has enhanced pathogenesis in WT mice. (A and B) WT or Rag1-/- mice were 
inoculated with 103 PFU of AF15561 in the left rear foot pad. Mice were weighed daily 
(A) and at 28 dpi mice were euthanized and viremia was measured by plaque assay (B). 
Data in (B) adapted from Chapter IV Figure 4 - 2 and shown here for reference. (C) WT 
mice were inoculated with 20 μl of serum from individual Rag1-/- mice in (B) or 20 µl of 
clarified right ankle tissue homogenate containing 10 – 20 PFU into the left rear footpad 
and weighed daily. A representative weight curve of WT mice inoculated with a similar 
dose of AF15561 is shown for comparison. (D) WT mice were inoculated with 10 PFU of 
plaque-purified AF15561 isolates derived from Rag1-/- serum (AF6811P1-3) or AF15561 
in the left rear foot pad and weighed daily. (A and B) Data from two independent 
experiments. P < 0.0001 calculated by Student’s T test with Welch’s correction. (C and 





Figure 5- 2. Mutations in CHIKV glycoprotein E2 and 3 ′ UTR enhance pathogenesis 
in mice . Mutations identified in the E2 gene and the γ′ UTR of AF6811P2 were cloned 
into the AF15561 cDNA clone. (A and B) WT mice were inoculated with 103 PFU of 
AF15561 (black squares), AF6811P2 (blue circles) or AF15561Eβ Kβ00R ΔUTR (purple 
triangles) in the left rear footpad and weighed daily (A) and scored for clinical disease 
(B). Data from one experiment with 4 mice per group. One mouse each from the 






Figure 5-3 . AF15561E2 K200R ΔUTR has enhanced dissemination and increased viral 
burdens in mice. WT mice were inoculated with 103 PFU of either AF15561 (black 
squares) or AF15561Eβ Kβ00R ΔUTR (blue circles) in the left rear footpad. At 1 dpi (A and B) 
or 3 dpi (C and D) mice were euthanized and infectious virus in the indicated tissues was 
measured by focus forming assay. Number of foci per gram of tissue (A and C) or ml of 
serum (B and D) are reported. Data from one experiment with 5 mice per group per time 
point. Dashed line indicates limit of detection. P values were determined by unpaired 





Figure 5- 4. Mutations in CHIKV E2 and 3′ UTR contribute to enhanced 
pathogenesis in mice. WT mice were inoculated with 103 PFU of the indicated viruses 
in the left rear footpad and weighed daily (A) and scored for clinical disease (B). Data 











Figure 5- 5. Mouse adaptive mutations are located in E2 and the 3′ untranslated 
region . (A) The location of the E2 K200 residue on the chikungunya virus E2/E1 dimer is 
shown. E2 domain A (blue), E2 domain B (orange), E2 domain C (red). E2 residue K200 
located in domain B is colored yellow. E1 is colored gray except for the E1 fusion loop 
which is colored magenta. The E1 residues that make van der Waal’s contacts with the 
E2 K200 residue (E1 C63 and E1 F95) are colored cyan. (PDB: 3N42 Voss et al. 2010). 
(B) The γ′ UTRs of CHIKV isolates from the three CHIKV genotypes and the mouse-
adapted AF6811P2 were aligned. Direct repeat (DR) elements were annotated 
according to Chen et al. 2013. (74). DR 1 elements are yellow. DR 2 elements are blue. 
DR 3 elements are red. The 19 nt conserved sequence element preceding the poly-A tail 
is brown. West African (WA) genotype represented by CHIKV strain 37997 (Genbank 
accession no. AY726732). East Central South African (ECSA) genotype represented by 
CHIKV strain SL15649 (Genbank accession no. GU189061). Asian genotype 
represented by AF15561 (Genbank accession no. EF452493). The 44 nt deletion in DR 
element 3B of AF6811P2 is indicated by the cyan annotation. A region with high 
sequence identity to the 44 nt deletion that is present in repeat element 3A is shown in 







 It is clear from clinical reports that CHIKV infection of humans often results in 
long-term inflammation and pain in musculoskeletal tissues, particularly joints and 
tendons, that can impose significant health burdens on the patient. However, our 
understanding of this phase of CHIKV disease is critically absent. Although evidence for 
CHIKV infection inducing an autoimmune inflammatory disease is lacking, a building 
body of evidence indicates that CHIKV and related alphaviruses establish long-term 
persistent infections within immunocompetent hosts. However, CHIKV infection induces 
rapid and robust antiviral immune responses; thus, it is unclear how CHIKV evades 
these responses to establish and maintain persistence. In the absence of a better 
understanding of CHIKV persistence and chronic disease pathogenesis, development of 
therapeutics to prevent or ameliorate chronic CHIKV disease is difficult.  
To address these questions, my thesis work utilized a mouse model of CHIKV 
infection that recapitulates many aspects of acute CHIKV disease reported in humans 
(158). I found that CHIKV infection of mice results in persistent infection in lymphoid and 
joint-associated tissue for weeks post-infection. Persistence of CHIKV in joint-associated 
tissue was associated with chronic pathology, including synovitis. Studies suggest that 
CHIKV and related alphaviral infections induce robust adaptive immune response and 
that these responses have protective and pathogenic roles. To investigate the role of 
adaptive immune responses in chronic CHIKV infection and disease, I evaluated viral 
persistence and acute and chronic joint pathology in WT mice and Rag1-/- mice, which 
lack mature T and B cells. I found that although adaptive immune responses may 
contribute to acute pathology, immune deficient mice had exacerbated chronic pathology 
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and elevated viral burdens in a variety tissues. These data suggest that adaptive 
immune responses are necessary to limit viral persistence and reduce chronic joint 
pathology.  
Much of our knowledge of clinical CHIKV disease comes from the large scale 
Indian Ocean outbreaks of CHIKV that were caused by an ECSA genotype virus. 
Consequently, it is unknown whether the outbreak in the Americas, caused by an Asian 
genotype virus, will have similar clinical outcomes. Limited studies suggest that Asian 
genotype viruses may be less inflammatory than ECSA genotype viruses suggesting 
there may be important differences between the CHIKV genotypes. However, little is 
known about whether there exist differences in the ability to establish persistence 
between the CHIKV genotypes. Therefore, I screened a panel of CHIKV strains 
representing all described CHIKV genotypes and found that all WT strains were able to 
establish a persistent infection in murine joint-associated tissue. In contrast, CHIKV 
vaccine strain 181/25, despite initially replicating to high titers, was cleared from sites of 
dissemination at later time points. CHIKV strain 181/25 was derived by serial passage in 
tissue culture of the parental CHIKV strain AF15561 and the two viruses differ at only 
five amino acid positions across the genome. Comparative studies between these two 
genetically similar strains of CHIKV revealed a critical role of antibody in control and 
clearance of 181/25 infection Furthermore, these studies revealed that a highly 
conserved glycine at position 82 in the E2 glycoprotein of AF15561 (and all other WT 
CHIKV strains) facilitated evasion of a key class of neutralizing antibodies directed 
against the B domain of the E2 glycoprotein.  
Lastly, to address the hypothesis that persistence of CHIKV is associated with 
accumulation of adaptive mutations in the viral genome, I isolated and characterized a 
strain of CHIKV from the serum of a persistently-infected Rag1-/- mouse. Sequencing of 
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this isolate revealed polymorphisms in the E2 gene and the γ′ UTR. Cumulatively, these 
findings improve our knowledge of CHIKV pathogenesis while also providing a 
foundation for exploration of critical host restriction factors and viral virulence 
determinants. 
Chikungunya Virus Can Establish a Persistent Infection in Mice 
 The recent large scale epidemics of CHIKV have confirmed that a common 
clinical outcome of CHIKV infection is protracted, often debilitating, musculoskeletal 
disease signs and symptoms lasting for months to years after infection (228). Infection 
with related arthritogenic alphaviruses causes similar chronic disease signs and 
symptoms, suggesting that protracted musculoskeletal disease is a common clinical 
feature of infection with this group of alphaviruses (125). Patients exhibiting chronic 
symptoms often have swelling, redness, radiographical evidence of inflammatory joint 
lesions (117, 138) and elevated levels of pro-inflammatory cytokines in the circulation 
and the joint (170), suggesting an ongoing inflammatory immunopathology. However, 
despite the large scale epidemics of CHIKV and vast numbers of patients experiencing 
chronic disease complications, the cause of these disease signs and symptoms remains 
unknown. Limited data from patients suggests that chronic CHIKV disease may be 
associated with viral persistence (170, 250, 257). Compounding this issue are data 
demonstrating protective and pathogenic host immune responses to the infection (172, 
191, 200, 201, 204), suggesting there may also be important host factors that contribute 
to the development of chronic disease. Thus, further studies are needed to understand if 
indeed CHIKV establishes persistent infections, the role of persistent infection in chronic 
disease, the role of adaptive immune responses in controlling persistent infection and 
the development of chronic disease, and how CHIKV evades host immune responses to 
establish and maintain persistence. 
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 CHIKV infection of WT mice recapitulates many aspects of acute disease in 
humans including viremia, arthritis, myositis and tenosynovitis (158). In the first aim of 
this thesis, described in Chapter III, I sought to expand on these findings by evaluating 
the clearance kinetics of CHIKV infection in specific tissues, the resolution (or not) of 
histopathological lesions in musculoskeletal tissues, and the host immune responses 
that contribute to control of the infection. At 3 dpi with a clinical isolate of CHIKV, WT 
mice had high viral burdens in musculoskeletal tissues with the highest viral burdens 
detected in ankle-associated tissue and skeletal muscle tissue. These data are 
consistent with other reports indicating a strong tropism of the virus for musculoskeletal 
tissue in vivo, including humans (153, 159), and suggest that the excruciating joint pain 
reported by CHIKV-infected patients may be due to direct viral infection of these tissues 
(107). CHIKV was also detected in the liver and lymphoid tissue of WT mice, consistent 
with other reports in mice and NHPs (153, 159). At later time points (e.g., 14 and 21 dpi) 
CHIKV RNA was effectively cleared from most tissues evaluated. However, the amount 
of CHIKV RNA in joint-associated tissue declined until about 4 wpi at which point it 
established a set point and remained detectable at consistent levels for 16 wpi. The 
spleen also had detectable viral RNA in a subset of animals at 4 wpi (6 of 11 mice 
positive) and 6 wpi (3 of 7 mice positive). These data demonstrated that although CHIKV 
infected a variety of tissues at early time points, the virus uniquely persisted in joint-
associated tissue and lymphoid tissue of mice. Furthermore, histopathological analysis 
of joint tissue from CHIKV-infected mice revealed that the persistence of viral RNA in 
this tissue was associated with synovitis, tendonitis and necrosis, supporting the 
hypothesis that persistent viral infection contributes to chronic CHIKV disease.  
These data are consistent with other experimental infections of animals. For 
example, in a follow-up study to my work, CHIKV-infected WT mice were shown to have 
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viral burdens in a variety of tissues at early time points but CHIKV persisted within joint 
tissue of mice for at least 100 dpi (159, 168). In NHPs, CHIKV RNA, antigen and 
infectious virus were found to persist in joint, liver and lymphoid tissue (153-155). 
Cumulatively, these data suggest that CHIKV can establish long-term persistence in joint 
tissue. Viral persistence in joint-associated tissue may account for the protracted joint 
disease signs and symptoms reported by CHIKV-infected patients. Furthermore, CHIKV 
may be able to establish persistence at other sites such as the liver and spleen (153) 
although the consequences of viral persistence in these tissues remains to be 
determined.  
 Among alphaviruses, long-term viral persistence is not unique to CHIKV. 
Infection with the related RRV, MAYV and SINV results in similar protracted disease 
signs and symptoms for months to years following infection (124, 126, 136, 189, 223-
225) and RRV RNA was found in synovial biopsies of symptomatic patients weeks post-
infection (250). Similar to my findings in mice, infection of WT C57BL/6 mice with MAYV 
results in long-term persistence of MAYV RNA specifically in joint-associated tissues of 
the ankles and wrists (Michael Diamond, personnel communication). RRV-infected WT 
mice had high levels of viral RNA in quadriceps muscle and ankle tissue for at least 21 
dpi (203), and I have consistently detected RRV RNA in joint tissue of WT mice at 28 dpi 
(data not shown), suggesting that RRV establishes persistence within joint tissue similar 
to CHIKV and MAYV. The finding that RRV may persist long term in muscle tissue is in 
contrast with my findings in CHIKV-infected WT C57BL/6 mice, but is consistent with the 
finding of persistent CHIKV antigen in a muscle biopsy from a CHIKV-infected patient 
three months post-infection (257). Furthermore, the prototypic alphavirus SINV has been 
studied for its ability to persist in the CNS of infected mice. WT BALB/c mice infected 
with SINV showed detectable viral RNA in the CNS of mice until 3 months post-infection 
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and viral RNA was still detectable 17 months post infection (275). Similarly, another 
study reported that SINV-infected BALB/c mice remained positive for viral RNA for at 
least 6 months post infection (279). These data suggest that persistence of alphaviruses 
may be a common outcome of infection and that alphaviruses may be uniquely poised to 
adopt persistent replication in vivo.  
 Persistence of CHIKV adds to a growing appreciation that infections with viruses 
typically considered to cause an acute disease may indeed establish persistent 
infections. Rubella virus, a virus in the Togaviridae family, has been shown to establish 
persistence in the periphery and synovium of children and periphery of adults with 
rubella-associated arthritis (324, 325). In addition, rubella virus was found to persist for 
three years in the eye of a patient who acquired rubella prior to birth (326). The recent 
large outbreak of Ebola virus, a negative-sense RNA filovirus, in West Africa revealed 
that Ebola virus may persist for months in the eyes and semen of survivors (327-329). In 
fact, 26% of male survivors remained RT-PCR positive for Ebola in their semen 9 
months post infection (330). Coxsackie B viruses, a group of positive-sense RNA 
enteroviruses, can establish persistence in heart muscle tissue with serious clinical 
consequences (331-333). West Nile Virus (WNV), a positive-sense RNA flavivirus has 
been found in urine samples of human patients years after infection (334) and was found 
to persist in several tissues of a subset of mice for months post infection (335). Zika 
virus (ZIKV), another flavivirus, has been found to persist in semen for up to 80 days 
post infection (336) and sexual transmission of ZIKV is possible one month after 
infection (337). Parvovirus B19, a small ssDNA virus, can establish persistent infections 
in a variety of tissue and is associated with chronic arthritis (338). Cumulatively, viral 
persistence following acute infection may be an underappreciated outcome with clinical 
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consequences and the diverse pathogens able to persist within the host suggest they 
may utilize a variety of strategies to establish and maintain persistence.  
 Host Immune Responses Control Persistent Chikungunya Infection 
 A consistent risk factor for the development of chronic CHIKV disease is old age 
(170, 208, 227, 232-234, 239) suggesting that age-related declines in adaptive immunity 
may contribute to CHIKV persistence and chronic disease (154, 339). Furthermore, 
chronic CHIKV disease is routinely reported in patients in the absence of rheumatoid 
factor or anti-citrullinated peptide antibodies (112, 170, 209, 252-255), arguing against 
development of a classical rheumatoid arthritis pathology (256). Lastly, patients who 
develop an early neutralizing antibody response following CHIKV infection were 
protected from chronic disease (213). My findings expand on these reports and further 
suggest that adaptive immune responses protect from chronic CHIKV infection and 
disease signs.  
I found that CHIKV-infected Rag1-/-  mice, lacking mature B and T cell responses, 
had significantly higher viral RNA burdens in the ankles at early and late time points 
compared with WT mice. At 4 and 6 wpi in the right ankle, Rag1-/- mice had >10-fold 
higher viral RNA burdens than CHIKV-infected WT mice, indicating that adaptive 
immune responses contribute to control of infection in this tissue. Furthermore, Rag1-/- 
mice had detectable viral RNA in the quadriceps muscle at 4 wpi whereas in WT mice 
CHIKV RNA was cleared from these tissues by 2 wpi. In addition, I have been able to 
consistently isolate infectious CHIKV from the serum and joint-associated tissue of 
Rag1-/- mice for at least 12 wpi and 6 wpi, respectively. These data suggest that 
although CHIKV RNA is able to persist within joint-associated tissue for weeks post 
infection, adaptive immune responses effectively clear CHIKV from a variety of tissues 
and restrict CHIKV in joint-associated tissue during persistence. Interestingly, CHIKV-
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infected Rag1-/- mice had undetectable levels of viral RNA in the spleen after 7 dpi, in 
contrast to CHIKV-infected WT mice which had detectable viral RNA out to at least 6 
wpi, potentially suggesting a cellular reservoir of persistence is absent in the altered 
lymphoid tissue of mice deficient in mature B and T lymphocytes (340).  
Histopathological analysis of joint tissue showed that at early time points, in 
comparison to WT mice, Rag1-/- mice had reduced signs of synovitis, arthritis and 
muscle inflammation, suggesting that adaptive immune responses may contribute to 
pathology at early time points. In addition, I have observed reduced footpad swelling in 
CHIKV-infected Rag1-/- mice compared to WT mice (data not shown) that is consistent 
with other reports in Rag2-/- mice (204). CHIKV-infected mice deficient in CD4+ T cells 
had reduced footpad swelling and joint pathology (204) suggesting CD4 T cells may 
contribute to tissue damage. However, at later time points, the elevated viral burden in 
joint-associated tissue of CHIKV-infected Rag1-/- mice was associated with more severe 
tissue pathology compared to WT mice. Rag1-/- mice had higher incidences of arthritis, 
muscle inflammation, muscle necrosis and tendonitis suggesting that adaptive immune 
responses were necessary to limit chronic joint pathology.  
My data are consistent with other reports that adaptive immunity is critical for 
limiting acute CHIKV infection and expand these findings to demonstrate that adaptive 
immune responses are critical for limiting CHIKV persistence and chronic pathology. 
Similar to my findings, CHIKV-infected Rag1-/- or Rag2-/- mice have been found to 
support persistent viremia for weeks post infection (168, 201). Humoral immune 
responses are likely critical for control of viremia. I have found that the decline in viremia 
in WT mice is coincident with early CHIKV-specific IgM and IgG responses and in 
addition to Rag1-/- or Rag2-/- deficient mice, μMT mice, which lack mature B cells, support 
persistent viremia for weeks post infection (168, 201). In addition to persistent viremia, 
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CHIKV-infected μMT mice have significantly increased acute footpad swelling compared 
to WT mice (168, 201). RRV-infected Tlr7-/- mice or CHIKV-infected Tlr3-/- mice have 
diminished neutralizing antibody responses and exacerbated acute disease (217, 218) 
suggesting that antibody may be required to limit acute pathology although further 
studies are needed as these mice are deficient in critical innate immune signaling 
pathways. T cell responses also appear to contribute to control of viremia, as CHIKV-
infected µMT mice had significantly lower viremia compare with CHIKV-infected Rag1-/- 
mice (168). These data are supported by my findings in which CHIKV-infected μMT mice 
had lower viremia at 28 dpi than CHIKV-infected Rag1-/- mice (data not shown). 
Furthermore, in a preliminary experiment, adoptive transfer of T cells was sufficient to 
clear infectious virus from the serum of CHIKV-infected Rag1-/- mice (data not shown). 
Antibody and T cell responses to CHIKV are sustained long term in mice and 
humans after CHIKV infection (201, 205, 233) raising the question of why these 
sustained responses are ineffective at clearing CHIKV from sites of persistence. 
Although not described for CHIKV, chronic infection with several other human pathogens 
involves progressive immune dysfunction. Sustained type I IFN signaling, as observed in 
tissues persistently infected with CHIKV (168), may suppress T cell responses (341, 
342). LCMV sustains chronic viral infection due to T cell exhaustion (303, 343) and 
suppression of antibody affinity maturation (344). Similarly, persistence of Hepatitis B 
and C viruses is associated with T cell exhaustion (345, 346). Furthermore, antibody 
effector functions can become impaired during chronic infection (347, 348) preventing 
antibody-mediated viral clearance from tissues. Investigation into whether these 
pathways contribute to CHIKV persistence and chronic disease is warranted as 
therapies that restore proper immunological function may be effective in resolving 
chronic viral infections (349). 
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Lastly, my data showing that pathogenic strains of CHIKV evade humoral 
immune responses to establish persistence, discussed later in this chapter, demonstrate 
that there exist important viral determinants that facilitate evasion of adaptive immune 
responses. Cumulatively, my data support a role for adaptive immune responses in 
controlling persistent CHIKV infection and suggest that therapies that engage adaptive 
immune response during acute infection or stimulate adaptive immune responses during 
chronic infection may be beneficial in resolving the disease signs and symptoms 
observed during chronic CHIKV disease.  
Joint and Lymphoid Tissue as Sites of Chikungunya Virus Persistence 
My findings that adaptive immune responses are necessary and effective in 
clearing CHIKV from a variety of tissues suggest that there exist tissue specific factors 
that facilitate persistence of CHIKV in lymphoid and joint-associated tissue of WT mice. 
Long term persistence of viruses in immunoprivileged sites such as Zika in semen (336), 
Ebola virus in the eyes and semen of survivors (327-329) and SINV in the CNS of mice 
(275) suggest that CHIKV persistence could involve an immunoprivileged niche.  
However, it seems unlikely that the joint tissue as a whole is a site of 
immunoprivilege. During acute infection with CHIKV or RRV, muscle and joint tissue is 
heavily infiltrated with innate and adaptive immune cells (159, 161, 169). CHIKV antigen 
was detected in synovial macrophages surrounded by NK and CD4 T cells in a human 
synovial biopsy sample collected from a patient with chronic CHIKV disease (170). 
Likewise, CHIKV antigen was detected in muscle tissue of a patient that was also 
heavily infiltrated with T cells (257). Whether B cells and/or antibody infiltrate joint 
tissues during CHIKV infection is unclear, however in rheumatoid arthritis antibody 
secreting plasma cells and pathogenic antibodies are readily found in synovial tissue, 
suggesting that the joint is not privileged from the antibody response (350). Furthermore, 
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my work and work in NHPs has shown that CHIKV can persist long term in lymphoid 
tissue (153, 157), a tissue with pervasive immune surveillance. Cumulatively these data 
would suggest that CHIKV can persist in tissues that are well surveilled by host adaptive 
immune responses. 
Nevertheless, CHIKV and RRV in joint-associated tissues is likely sheltered from 
immune mediated clearance. Although type I IFN responses are induced and sustained 
within joint-associated tissue of CHIKV-infected mice (168, 241), a variant of RRV that 
replicates to lower levels in muscle tissue due to enhanced susceptibility to type I IFN 
responses replicates similarly to WT RRV in joint-associated tissue (186), suggesting 
that type I IFN responses are active within joint-associated tissue but may exert limited 
control on CHIKV. Furthermore, CHIKV in the joint-associated tissue is resistant to 
adaptive immunity. My findings demonstrate that adaptive immune responses effectively 
clear CHIKV from muscle tissue and the circulation but are unable to clear CHIKV from 
joint-associated tissue. Specifically, CHIKV and RRV in these tissues may be resistant to 
both humoral and cell-mediated responses. I found that therapeutic administration of 
neutralizing MAbs at day +21 and +25 effectively cleared CHIKV from the serum but only 
had a modest effect on CHIKV persisting in joint associated tissue of CHIKV-infected 
Rag1-/- mice. Likewise, RRV-infected mice deficient in CD8 T cells had significantly 
elevated viral loads in muscle tissue but not joint-associated tissue (203) suggesting 
CD8 T cells have limited efficacy in this tissue.  
The cellular tropism of CHIKV infection in joint-associated and lymphoid tissue 
during the persistent phase is not known, and studies of CHIKV and other human 
pathogens suggest that cellular niches within joint and lymphoid tissue may have altered 
immune signaling or immunosuppressive microenvironments. Harvesting of joint-
associated tissue for quantification of viral RNA by my methods includes the joint, 
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tendons, muscle, ligaments and bone marrow proximal to the joint. Therefore, the 
precise location of the CHIKV RNA within these tissues is unknown. Within the bone 
marrow there exist immunoprivileged niches such as the hematopoietic stem cell niche 
(351). Mesenchymal stem cells (MSCs) form an important component of this niche (352) 
and can actively suppress local immune responses including suppressing CD4 and CD8 
T cell proliferation, suppressing natural killer T cells, suppressing NK cells and interfering 
with dendritic cell maturation (353, 354). In addition to the bone marrow, cells with MSC 
characteristics are found in a multitude of tissues including the spleen (355) and MSCs 
have been found to infiltrate joint tissue following injury (356) although it has yet to be 
shown if these cell types infiltrate joint tissue following CHIKV infection. 
Similarly, macrophages may be a site of CHIKV persistence (153, 170), are a 
major component of the inflammatory infiltrate of joints following CHIKV or RRV infection 
(161, 191), can exhibit altered innate immune signaling either intrinsically (357) or upon 
viral infection (358, 359) and actively suppress antiviral T cell responses (200). Follicular 
dendritic cells are present in the spleen and lymphoid tissue (360), have been identified 
in the synovium of RA patients (361, 362) and can shelter viral pathogens such as HIV in 
a non-replicative state for months (363). Follicular dendritic cells can even convert 
antibody neutralized HIV into infectious forms (364) suggesting viral pathogens can 
escape neutralizing antibody responses in this cell type. Furthermore, persistence of 
parvovirus B19, a small DNA virus, in the synovium and bone marrow of patients with 
rheumatoid arthritis (338), rubella virus in the synovium of patients with rubella-
associated arthritis (325) and persistence of the bacteria Borrelia burgdorferi, the 
causative agent of Lyme’s disease, in joint tissue of mice (365) suggests that joints and 
associated tissue may contain cell types with altered immune signaling or 
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immunosuppressive microenvironments that support long term persistence of a variety 
of pathogens.  
Collectively, these data demonstrate that cellular niches within the sites of CHIKV 
persistence can have important immunological features and accordingly, a more refined 
understanding of the cellular tropism of CHIKV during persistence in joint-associated and 
lymphoid tissues is needed. These findings would be of importance not just for CHIKV 
pathogenesis but would also further our understanding of viral persistence in general, 
inflammatory joint disorders and novel immunological niches within otherwise 
immunologically surveilled tissues. These findings would also inform directed therapeutic 
techniques to ameliorate the symptoms of chronic CHIKV disease and/or resolve the 
chronic infection. 
Chikungunya Virus Strain 181/25 has Enhanced Susceptibility to  
Adaptive Immune Responses 
 Prior to the work described in this thesis, viral determinants that facilitate 
persistence of CHIKV were unknown. Viruses that establish persistent infections utilize 
several strategies to avoid clearance including latency (366), immunosuppression (303), 
infection of immune privileged niches (275, 328) and escape of neutralizing immune 
responses (344, 367, 368) and therefore persistence of CHIKV in vivo may require one 
or more of these strategies to avoid clearance by adaptive immune responses. To 
facilitate investigation of these hypotheses in the context of CHIKV infection and 
persistence, I sought to identify a strain of CHIKV unable to establish persistence. 
Comparative studies between a persistent and non-persistent strain of CHIKV would 
allow for identification of successful immune responses and the viral mechanisms 
necessary to counteract these responses and establish persistence. 
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CHIKV live-attenuated vaccine strain 181/25 is attenuated for acute disease 
(142, 144) and I hypothesized 181/25 may be attenuated for persistence. Indeed, when I 
evaluated the live-attenuated vaccine strain 181/25, I found that WT mice infected with 
CHIKV strain 181/25 had significantly reduced viral burdens in joint-associated tissue 
distal to the site of inoculation with 7 of 8 mice having viral RNA in the right ankle below 
the limit of detection of our qRT-PCR assay at 28 dpi. This was in contrast to WT mice 
infected with the parental, pathogenic strain AF15561 which had significant viral burdens 
at 28 dpi in this tissue. Further analysis revealed that although mice infected with CHIKV 
strain 181/25 had significantly diminished viral burdens compared to AF15561-infected 
mice in the right ankle at 3 dpi, by 7 and 14 dpi 181/25-infected mice had similar levels 
of viral RNA as AF15561-infected mice. However, beginning by 21 dpi 181/25 was 
cleared from this tissue. In contrast, AF15561-infected mice established a persistent 
infection similar to what I observed in mice infected with CHIKV strain SL15649. 
Cumulatively, these data indicated that although CHIKV strain 181/25 replicated 
efficiently at sites of dissemination at early time points, it was cleared from these sites by 
3 to 4 weeks post infection. 
CHIKV strain 181/25 was developed as a live-attenuated vaccine candidate by 
serial passage of the parental AF15561 strain in MRC-5 cells (142). Initial 
characterization of 181/25 demonstrated it had reduced virulence in neonatal mice, 
reduced or absent viremia when inoculated into NHPs and could induce protective 
responses against lethal CHIKV challenge (142). 181/25 reached phase II clinical trials 
where although immunogenic, it was found to cause transient arthralgia in some 
volunteers and further development was abandoned (143). Although development of 
181/25 for use as a vaccine was abandoned, further studies continued to evaluate the 
mechanisms of attenuation. Comparative sequence analysis of AF15561 and 181/25 
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revealed 5 non-synonymous changes in the viral genome. One in the nsP1 protein 
(nsP1 T301I), two in the E2 glycoprotein (E2 T12I and E2 G82R), one in the 6k 
accessory protein (6k C42F) and one in the E1 glycoprotein (E1 A404V) (144) (Fig 4-1). 
In studies performed in mice, attenuation of CHIKV strain 181/25 for acute disease was 
found to be due to just the two mutations in E2, E2 T12I and E2 G82R, likely explaining 
the insufficient attenuation observed in human clinical trials (144). 
Tissue culture adaptation of alphaviruses typically results in accumulation of 
mutations that enhance interactions with glycosaminoglycans (GAGs) such as heparan 
sulfate (294, 369). Interactions with GAGs likely attenuate alphaviruses in vivo by limiting 
dissemination and viremia (370), although these interactions can conversely enhance 
neurovirulence when virus is inoculated directly into the brain (296, 371). In CHIKV strain 
181/25, GAG binding is conferred by the E2 G82R mutation (25) and limits viremia and 
the kinetics of viral dissemination (260, 294).  
However, whether GAG binding is sufficient to attenuate CHIKV in vivo is 
unclear. CHIKV with an E2 R82 residue, conferring GAG binding, was found to replicate 
to similar titers in joint and muscle tissue at 1 dpi in WT mice and replicated to 
significantly higher titers in skeletal muscle tissue at 5 dpi (260). Likewise, WT CHIKV or 
CHIKV containing an E2 R82 residue or novel mutations that conferred GAG-binding 
replicated to similar titers in joint-associated and skeletal muscle tissue at 2 dpi (294). 
Although I found that at 3 dpi 181/25-infected WT mice had significantly reduced viral 
RNA in the right ankle tissue, by 7 dpi these mice had similar levels of viral RNA to 
AF15561-infected WT mice suggesting viruses with an E2 R82 residue replicate 
efficiently in joint-associated tissue. Similarly, I found that 181/25-infected Rag1-/- mice 
had significantly higher levels of infectious virus in ankle tissue than AF15561-infected 
Rag1-/- mice. Persistence of 181/25 in joint-associated tissue of Rag1-/- was also not 
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associated with accumulation of compensatory mutations that altered its phenotype from 
that of stock 181/25 when inoculated into WT mice suggesting an E2 R82 residue is not 
selected against in joint-associated tissue. These data support the hypothesis that an E2 
R82 residue and as a corollary, GAG binding, does not attenuate CHIKV replication in 
musculoskeletal tissue.  
In contrast, dissemination of CHIKV containing an E2 R82 residue to lymphoid 
tissue is severely restricted (260, 294) suggesting that this residue may influence 
pathogenesis by altering host – viral interactions in lymphoid tissue and subsequently 
altering early immune responses. Indeed, I found that mice infected with AF15561 had 
significantly more IgM and IgG at early time points demonstrating that early adaptive 
immune responses to CHIKV strains containing an E2 G82 or E2 R82 residue are 
distinct. Furthermore, my data indicate that CHIKV strains with an R at E2 82 are more 
sensitive to neutralization by antibody suggesting that these strains may be more 
sensitive to early control by natural antibody (201). Lastly, full attenuation of pathogenic 
CHIKV isolates required both the E2 T12I and E2 G82R mutations (144). My data 
similarly demonstrated that restoration of persistence of CHIKV strain 181/25 to that of 
parental strain AF15561 required reversion of both E2 position 12 and E2 position 82 to 
WT codons. Together this suggests that full attenuation of 181/25 likely requires 
mechanisms in addition to those influenced by the residue at E2 position 82. Therefore, 
further studies are needed to determine if early immune responses to CHIKV containing 
E2 G82 or R82 residues are distinct and if these distinct early responses contribute to 
the attenuation of CHIKV in vivo. 
These data, in addition to my findings that CHIKV strain 181/25 was cleared from 
joint-associated tissue beginning at 21 dpi led me to hypothesize that 181/25 infection 
was more susceptible to B and T cell-mediated clearance mechanisms. To test this 
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hypothesis, I infected Rag1-/- mice with AF15561 or 181/25 and found that in contrast to 
infection of WT mice, infection of Rag1-/- mice with 181/25 resulted in viral persistence in 
the right ankle tissue. Notably, the levels of viral RNA in the right ankle tissue of 181/25-
infected Rag1-/- mice was similar to that of AF15561-infected Rag1-/- mice, suggesting 
that in the absence of adaptive immunity 181/25 can establish a persistent infection. 
Furthermore, quantification of infectious virus in the right ankle at late times post-
inoculation demonstrated that 181/25-infected Rag1-/- mice had significantly higher viral 
loads than AF15561-infected Rag1-/- mice. AF15561- or 181/25-infected Rag1-/- mice 
also had persistent viremia, supporting the role of T and B cell responses in the 
clearance of CHIKV from the blood. Supporting the role of GAG binding in limiting 
CHIKV viremia, quantification of viral loads in 181/25-infected Rag1-/- mice showed that 
although viral loads at 3 dpi were elevated compared to 181/25-infected WT mice, they 
were still significantly reduced compared to AF15561-infected Rag1-/- mice at 3 dpi. 
Nevertheless, these data suggest that in the absence of adaptive immune responses 
CHIKV strains AF15561 and 181/25 have a similar capacity to establish persistence in 
joint-associated tissue.  
More specifically, I hypothesized that B cells and CHIKV-specific antibody 
attenuate 181/25 for persistence, as CHIKV-infection induces a rapid and robust 
antibody response (201), early induction of neutralizing antibodies correlate with 
protection from persistent disease in humans (213), and the attenuating mutations are 
located in E2, a dominant target of neutralizing antibody responses (212). To investigate 
this hypothesis, I inoculated WT or B-cell deficient μMT mice with AF15561 or 181/β5 
and evaluated viral persistence at 28 dpi. Similar to what was observed with 181/25-
infected Rag1-/- mice, I found that 181/25-infected μMT had high viral burdens in the right 
ankle at 28 dpi. Furthermore, the viral burdens in 181/25-infected µMT mice were similar 
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to the viral burdens in AF15561-infected µMT mice suggesting that in the absence of B 
cell responses, 181/25 is able to establish a persistent infection similar to that of 
AF15561. These findings were recapitulated in 181/25-infected MD4tr mice, which while 
possessing mature B cells, express a B cell receptor against the irrelevant antigen hen-
egg lysozyme. Together these data suggested that in the absence of adaptive immune 
responses, specifically B cells and CHIKV-specific antibody 181/25 could establish 
persistence in joint-associated tissue.  
Chikungunya Virus Evades B Cell Responses to Establish Persistence 
 My findings raised the question that if antibody was required to control and clear 
181/25, why did they not similarly control AF15561 infection? A potential explanation is 
that AF15561 or 181/25 infection induce distinct antibody responses. Indeed, the 
magnitude of early neutralizing antibody responses correlate with asymptomatic CHIKV 
infections (298) and early appearance of neutralizing antibody to CHIKV infection 
correlate with protection from chronic CHIKV disease (213). Furthermore, diminished 
neutralizing antibody responses in mice can exacerbate acute RRV or CHIKV infection 
(217, 218). These data suggest that early antibody responses, particularly the 
neutralization capacity of the antibody response, can be a determinant of the clinical 
outcome of CHIKV infection.  
Additionally, my data suggests that the kinetics of the antibody response may be 
important. Prophylactic administration of neutralizing MAbs on day -1 and +3 was able to 
block persistence of CHIKV in the serum and joint tissue of CHIKV-infected Rag1-/- mice. 
In contrast, administration of neutralizing MAbs on day +21 and +25 was able to clear 
CHIKV from the serum but had a modest effect on viral burdens in joint tissue of CHIKV-
infected Rag1-/-  mice. Furthermore, in hepatitis C virus (HCV)-infected patients, rapid 
appearance of neutralizing antibodies was associated with viral clearance and protection 
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from chronic infection (372). Likewise, early IgM responses are necessary to prevent 
LCMV persistence (373) and poorly neutralizing antibody responses promote persistent 
infection with LCMV (344). Lastly, the antibody response against CHIKV likely needs to 
be sustained to control CHIKV infection, as adoptive transfer of mouse immune serum 
only transiently suppressed viremia in CHIKV-infected Rag1-/ -mice (168). These data 
suggest that antibody responses, particularly during the early stages of infection, may be 
important determinants of the outcome of CHIKV infection. 
 I therefore analyzed the antibody response in AF15561- or 181/25-infected mice 
by ELISA to measure induction of CHIKV-specific antibody. Interestingly, I found that 
AF15561-infected WT mice had significantly more IgM at 5 and 7 dpi compared to 
181/25-infected mice. Similarly, AF15561-infected WT mice had significantly more IgG at 
7 dpi than 181/25-infected mice. At 28 dpi, AF15561- or 181/25-infected mice had similar 
levels of IgG. IgG antibodies exist as different isotypes (IgG1, 2b, 2c and 3 in C57BL/6 
mice) with important differences in the Fc portion of the antibody that can give the IgG 
antibody isotypes distinct Fc effector activities (374). These Fc effector functions may be 
important for control of infections with CHIKV and other alphaviruses as Fab fragments, 
antibodies lacking the Fc portion of the antibody, are less protective than administration 
of whole-antibody in VEEV infection (375) and a monoclonal antibody with a point 
mutation abolishing Fc interactions was less protective in CHIKV-infected mice (220). 
Therefore, I measured the IgG response induced in either AF15561- or 181/25-infected 
WT mice at 28 dpi using isotype specific detection antibodies and found that AF15561 
and 181/25 induced similar antibody isotypes with IgG2c and 2b being the dominant 
isotypes induced during both infections. In summary, AF15561-infected mice induced 
more IgM and IgG at early time points and at later time points the IgG response in 
AF15561- and 181/25-infected mice was similar in magnitudes and in isotype profiles. 
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These data were discordant with my data showing that 181/25 was cleared from mice in 
a B cell and antibody dependent manner.  
 Although AF15561-infected mice had more virus-specific antibody at early time 
points, clinical data and data from CHIKV-infected mice suggests that the neutralization 
capacity of the serum may be important in controlling the infection (213, 218, 298). I 
therefore used a plaque reduction neutralization test (PRNT) with infectious AF15561 or 
181/25 as the challenge virus to measure the neutralization capacity of serum from 
AF15561- or 181/25-infected mice. From these analysis, I came to three major 
conclusions. First, the neutralization capacity against homologous virus of the serum 
from AF15561-infected mice at 7 dpi was significantly less than the neutralization 
capacity of serum from 181/25-infected mice. Second, when serum from AF15561-
infected mice at 7 dpi was challenged with the heterologous virus, infectious 181/25, 
serum from AF15561-infected mice showed a significantly reduced neutralization index 
compared to serum from 181/25-infected mice challenged with 181/25. This 
demonstrated that although AF15561-infected mice had significantly more IgM and IgG 
at this time point, it did not translate into a concomitant increase in neutralization 
capacity and suggests that the early antibody response to AF15561 infection is poorly 
neutralizing. Furthermore, chemical depletion of IgM in the day 7 serum from AF15561-
infected mice abolished neutralization activity (data not shown), suggesting that the early 
IgG response induced by AF15561-infection is non-neutralizing. Third, sera from 181/25-
infected mice neutralized infectious 181/25 significantly better than it was able to 
neutralize infectious AF15561. Similarly, sera from AF15561-infected mice neutralized 
infectious 181/25 significantly better than it was able to neutralize homologous infectious 
AF15561. This suggested that AF15561 was resistant to neutralization by antibody 
potentially through an altered display of neutralizing epitopes on the virion.  
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 It was interesting that AF15561 infection induced a robust CHIKV-binding but 
poorly neutralizing antibody response. In preliminary experiments using flow cytometry, I 
found that the B cells in the draining popliteal lymph node of AF15561- or 181/25-
infected mice are similarly activated (as measured by CD69 expression) at 3 dpi (data 
not shown). However, activated B cells in AF15561- but not 181/25-infected mice had 
significantly reduced levels of CD21/35 (complement receptor 2/1) and CD23 on their 
surface (data not shown). These data suggest that early activated B cells are 
phenotypically distinct following AF15561 or 181/25 infection (376, 377). Although these 
phenotypes require further study, differential engagement of innate immune pathways by 
AF15561 or 181/25 infection could influence early antibody responses. CHIKV-infected 
TLR3 deficient or RRV-infected TLR7 deficient mice have poor quality antibody 
responses (217, 218), suggesting that innate immune responses can drive the B cell 
response to CHIKV infection. Furthermore, type I IFN can induce B cells into a semi-
activated state, priming them to respond quickly upon B cell receptor signaling (378). 
Type I IFN is also required for rapid B cell activation and induction of virus-specific 
antibody secretion in influenza and vesicular stomatitis virus infection (379, 380). 
However, whether AF15561 and 181/25 infection results in differing levels of TLR or type 
I IFN signaling remains to be shown. Additionally, lymphoid tissue of AF15561-infected 
WT mice had significantly higher viral burdens at early time points compared to 181/25-
infected mice (260) potentially influencing B cell responses through direct engagement 
of TLRs on B cells (381, 382) or induction of a local IFN response.  
 I only measured CHIKV-specific antibody responses and it is possible that 
increases in CHIKV-binding antibody in AF15561-infected mice are coincident with 
polyclonal, antigen non-specific activation of B cells. In my preliminary flow cytometric 
analysis of B cells in the draining popliteal lymph node, >70% of B cells at 3 dpi were 
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CD69+, suggesting that activation of these B cells was independent of specificity for 
CHIKV. Furthermore, studies of infection with other viral pathogens suggest that viruses, 
through the induction of type I IFN, can induce polyclonal B cell activation. Mice infected 
with SFV upregulated CD69 on the majority of B and T cells within 24 hpi and this 
activation was dependent on type I IFN (383). Similar patterns are observed in WNV and 
influenza infection where >50-70% of B cells in the draining lymph nodes upregulated 
CD69 at early time points post-infection in a type I IFN dependent manner (379, 384). 
HIV and dengue virus can also activate B cells in a polyclonal manner (385, 386). 
Alternatively, LCMV infection of mice can induce polyclonal hypergammaglobulinemia 
early after infection independent of type I IFN and was instead dependent on CD4 T cell 
help (387). Therefore, it would be interesting to further evaluate CHIKV-specific and 
CHIKV-non-specific antibody responses following CHIKV-infection and to investigate 
whether the B cells activated early following CHIKV infection differentiate into antibody 
secreting plasma cells.  
 My finding that infectious AF15561 was more resistant to neutralization by 
antibody than 181/25 suggested that AF15561 and 181/25 have an altered display of 
neutralizing epitopes on the virion, that mutations in E2 between AF15561 and 181/25 
directly altered a key neutralizing epitope or that differences in the particle-to-PFU ratio 
were influencing the ability of these viruses to be neutralized in vitro. To evaluate these 
hypotheses, I utilized the PRNT assay to map the resistance to neutralizing antibody to 
the residue at E2 position 82. Viruses containing an E2 G82 residue (AF15561, SL15649 
or 181/25E2 R82G) were consistently resistant to neutralization by mouse serum regardless 
as to whether the serum was from mice infected with an E2 G82 or E2 R82 containing 
virus. Conversely, viruses containing an E2 R82 (AF15561E2 G82R, SL15649E2 G82R or 
181/25) were consistently neutralized more efficiently by mouse serum regardless as to 
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whether the serum was from mice infected with an E2 G82 or E2 R82 containing virus. I 
also tested the contribution of the E2 T12I mutation and found no significant influence on 
neutralization (data not shown), suggesting that the residue at E2 position 82 mediated 
sensitivity to antibody-mediated neutralization. Furthermore, these findings were 
supported by additional experiments in which I evaluated serum collected from patients 
infected during the Caribbean CHIKV epidemic or in Sri Lanka for the ability to neutralize 
CHIKV containing an E2 G82 (AF15561 or SL15649) or CHIKV containing E2 R82 
(AF15561E2 G82R or SL15649E2 G82R). Consistent with my findings using sera from 
experimentally-infected mice, human sera from geographically diverse CHIKV outbreaks 
more efficiently neutralized CHIKV containing an E2 R82 residue. Taken together, these 
data suggest that in humans and mice, neutralization of CHIKV containing an E2 G82 
residue is impaired compared to neutralization of CHIKV containing an E2 R82 residue. I 
therefore hypothesized that the residue at E2 position 82 altered the display of key 
neutralizing epitopes on viral particles.    
To investigate this hypothesis, I utilized a panel of CHIKV-neutralizing mAbs with 
known binding epitopes to probe the surface of AF15561 and 181/25 in an attempt to 
identify regions where neutralizing antibody exhibited significant differences in 
neutralization capacity. Neutralizing antibodies directed against several domains of the 
virus, E2 domain A, E2 arch region and E1, equivalently neutralized AF15561 and 
181/25, suggesting these epitopes were displayed similarly. Furthermore, these findings 
suggested that AF15561 and 181/25 could be neutralized similarly and that my findings 
that AF15561 was consistently harder to neutralize by mouse serum was unlikely to be 
due to confounding differences between AF15561 and 181/25 such as their different 
particle-to-PFU ratios. However, antibodies directed against E2 domain B were 
consistently able to neutralize 181/25 more efficiently than AF15561, suggesting that the 
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display of E2 domain B was altered between AF15561 and 181/25. This was an 
interesting finding as E2 position 82 residue is located in the A domain, well removed 
from domain B (Fig 4-8 ). Although the mechanism by which E2 residue 82 influences 
neutralization by antibodies against E2 domain B remains to be determined, studies 
investigating how antibodies against E2 domain B neutralize infection provide valuable 
insight.  
E2 domain B is located at the distal end of the E2 glycoprotein (Fig 4-8) and 
consequently is highly exposed on the virion. Structural studies of the alphavirus E1 and 
E2 glycoproteins, including those of CHIKV, revealed that at low pH, E2 domain B 
becomes disordered and folds away to expose the E1 fusion loop as an initial event in 
the fusion of the CHIKV membrane with host endosomal membrane (26, 27, 31). 
Therefore, E2 domain B is intrinsically flexible and antibody binding to E2 domain B is 
unlikely to neutralize the virus unless it can interfere with this structural rearrangement. 
Multiple studies have identified that interfering with the rearrangement of CHIKV E2 
domain B is a common mechanism by which antibodies neutralize infection. CHIKV 
neutralizing antibody 5F10 binds to E2 domain B and likely due to steric hindrance 
between multiple bound antibody molecules, locks E2 domain B into a rigid conformation 
and prevents the necessary rearrangement of E2 domain B during low pH-mediated 
fusion (35). Monoclonal antibody CHK-152, binds to E2 domain A, B and arch region, 
and prevents rearrangement of E2 domain B (293). Likewise, human monoclonal 
antibodies 4J21, which binds E2 domain A and arch region, and 5M16, which binds E2 
domain A, B and arch region, also neutralize by stabilizing E2 domain B. Similarly, 
studies of CHK-265, which showed a 17-fold difference in neutralization between 
AF15561 and 181/25, neutralizes infection by binding to E2 domain B and cross-linking it 
to an adjacent trimeric spike (Fig 4-9) (36). Cumulatively, these findings suggest that 
136 
 
multiple epitopes on the virion targeted by antibodies functionally converge to inhibit E2 
domain B flexibility and the rearrangements necessary for viral fusion. Furthermore, this 
common mechanism of neutralization is not limited to CHIKV. E2 domain B is a critical 
neutralization epitope on the Ross River viral particles and VEE viral particles (388, 389) 
and neutralizing antibodies against VEEV E2 domain B inhibit infection by interfering 
with the structural rearrangement of E2 domain B (390). This suggests that host 
antibody responses to diverse alphavirus infections target similar structural epitopes on 
the virion and neutralize infection by similar mechanisms.  
I observed a 17-fold difference in mAb CHK-265 EC50 values between AF15561 
and 181/25 despite E2 G82 (and E2 T12) being well outside the footprint of CHK-265 
(36). Similarly, passage of CHIKV containing an E2 R82 residue under selective 
pressure of an E2 domain B targeting antibody selected for an E2 G82 residue despite 
E2 G82 being well removed from the binding footprint of the antibody (35, 295). These 
data suggest that the introduction of an arginine residue at E2 position 82 introduces 
large conformational changes of the E2 protein that enhance susceptibility of CHIKV to 
neutralization by E2 domain B antibodies.  
Although the mechanism by which the residue at E2 position 82 influences 
neutralization of AF15561 and 181/25 by antibody remains to be determined, our data 
support a model proposed by Porta et al. in which the conformation of the trimeric spike 
is altered by the residue at E2 position 82 (35). In this model, the introduction of a large, 
positively-charged arginine at E2 position 82 (E2 R82) introduces repulsive electrostatic 
forces that “open” the conformation of the spike and place Eβ domain B in close 
proximity to domains of adjacent trimers. In contrast, CHIKV containing a small, 
uncharged glycine at E2 position 82 (E2 G8β) adopt a “closed” conformation of the spike 
that increases the spatial separation between E2 domain B and adjacent spikes (Fig 4-
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9). This in turn limits the ability of antibody to cross-link E2 domain B and thus, although 
antibody is able to bind to CHIKV containing an E2 G82, it is unable to impair 
rearrangement of E2 domain B during fusion (Fig 4-9). Furthermore, the “closed” 
conformation of the spike in E2 G82 containing viruses likely limits the accessibility of 
epitopes to antibody and steric hindrance imposed by bound antibody may prevent 
further binding of antibody necessary for efficient neutralization (35). Comparative cryo-
EM studies of CHIKV and RRV containing mutations affecting the electrostatic potential 
of the trimeric core, with or without bound antibody, will be needed to empirically 
determine the effect of introducing charged residues into the core of the trimer. 
Although my work has focused on CHIKV, this mechanism may extend to other 
alphaviruses. Attenuated SINV strain SB-RL is attenuated due to a serine to arginine 
mutation at E2 position 114 (E2 S114R) (391). This mutation introduces a positively 
charged amino acid into the core of the trimeric spike and likely confers HS binding to 
SINV (391). And although WT SINV and attenuated SB-RL bound similar amounts of 
neutralizing MAbs R6 and R13, SB-RL was more potently neutralized by these MAbs 
(392-394). Interestingly, escape mutations of MAb R13 mapped to the E2 arch domain 
(394) suggesting that introduction of positively charged amino acids into the core of the 
trimer can influence neutralization by antibodies targeting epitopes other than those in 
E2 domain B. Furthermore, passage of VEEV vaccine strain TC-83, which contains an 
E2 T120K mutation that introduces a large positively charged lysine into the core of the 
trimeric spike, under selective pressure of a neutralizing antibody selected for escape 
mutations that abolished positive charged amino acids in the core (E2 delK116) or 
introduced a negatively charged residue (E2 K115E), potentially compensating for the 
T120K mutation (395). This suggests that similar to CHIKV, introduction of positive 
charges into the core of the VEEV trimeric spike enhances neutralization by antibody. 
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However, this interpretation is confounded as the binding footprint of the antibody 
selecting for these mutations is located within this region (390). Nevertheless, it remains 
likely that altering the electrostatic potential of residues within the core of the trimer of 
other alphaviruses enhances susceptibility to neutralization. In fact, in preliminary 
experiments, I found that introduction of positively-charged residues into the core of RRV 
(E2 S82R and/or E2 Y86R) significantly enhanced neutralization of RRV by mouse 
immune serum (data not shown). Further studies are needed to evaluate the impact of 
these mutations on viral persistence in joint tissues of WT and B cell deficient mice.  
   My work identified several epitopes on the CHIKV virion that are similarly 
neutralizing between AF15561 and 181/25 (E2 domain A, E2 arch region, E1) 
suggesting that antibody responses against these epitopes could protect against chronic 
disease. However, my studies demonstrated that the neutralizing capacity of human and 
mouse immune serum was significantly reduced by a glycine residue at E2 position 82, 
suggesting that the neutralizing response in some CHIKV-infected humans and C57BL/6 
mice is largely directed against E2 domain B. Indeed, studies with CHIKV in which E2 
domain B was replaced by domain B of SFV demonstrated that human and mouse 
neutralizing antibody responses to CHIKV-infection predominantly target E2 domain B 
(215). Thus, it is tempting to speculate that the polyclonal antibody response to CHIKV-
infection may consist of few neutralizing clones and/or be limited in breadth. In a study of 
MAbs isolated from CHIKV-infected mice, of 230 hybridomas producing CHIKV-binding 
antibody, 194 (84%) were non-neutralizing. Similarly, in a panel of 30 human 
hybridomas producing CHIKV-binding antibody 13 (43%) were non-neutralizing (221) 
with another study reporting 5 of 7 (71%) being non-neutralizing (396). Although these 
studies are not quantitative nor representative they suggest that neutralizing responses 
that arise during the endogenous response to CHIKV infection may target a limited set of 
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neutralizing epitopes. Analysis of the antibody epitopes targeted in CHIKV-infected 
humans, NHPs and mice showed that in addition to antibody against surface exposed 
epitopes on E2, antibody was directed against epitopes located within the core of the 
trimeric spike, regions that are likely inaccessible on the intact virion (27), or non-
structural proteins (201, 211, 214) suggesting they may be non-neutralizing. 
Furthermore, I observed that at early (7 dpi) or late time points (28 dpi) serum from 
AF15561-infected mice retained similarly poor neutralization capacity for AF15561. I 
obtained similar results with serum from AF15561-infected mice 42 dpi (data not shown), 
demonstrating that the neutralization capacity of serum from AF15561-infected mice did 
not increase over time. These data are supported by studies in NHPs which 
demonstrated that the neutralization capacity and epitopes targeted by early (9 dpi) and 
late (180 dpi) antibody responses to CHIKV infection were similar (211). Likewise, in 
humans, the epitopes targeted at 2-3 months post infection were similar to the epitopes 
targeted at 21 months post infection (214). These data suggest that the early 
neutralizing CHIKV response may be limited in breadth and this response does not 
appreciably increase in quality or breadth over time. Further studies are therefore 
needed to understand whether the epitopes targeted in mice infected with either 
AF15561 or 181/25 are similar and if the antibody response to either infection undergoes 
significant maturation in the weeks to months following infection. 
My findings demonstrate that one mechanism that contributes to the successful 
clearance of 181/25 infection is the enhanced susceptibility of the virus to neutralization 
by antibodies directed against E2 domain B. However, whether other functions of 
antibodies are necessary to clear 181/25 infection is unknown. Neutralizing and non-
neutralizing antibodies can be protective through their engagement of Fc receptors or 
complement activation (220, 397-400). However, clearance of SINV from the neurons of 
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persistently infected mice was independent of complement or NK cell activity (274) and 
instead may rely on cross-linking of E2 glycoproteins on the surface of the infected cell 
(401).  
In contrast, pathogenic strains of CHIKV resist neutralization by this response 
due to a highly conserved glycine in the E2 glycoprotein and establish a persistent 
infection within the host. In addition, pathogenic strains of CHIKV induce a rapid CHIKV-
binding but poorly neutralizing antibody response suggesting that the quality of the host 
antibody response is an important determinant of CHIKV infection outcome. Non-
neutralizing antibody or sub-neutralizing concentrations can be pathogenic, exemplified 
by the well-established antibody-dependent-enhancement (ADE) of dengue virus 
disease (402, 403). Interestingly, I have observed ADE of CHIKV infectivity during my in 
vitro neutralization assays and ADE has been described for RRV infection of 
macrophages leading to persistent infection (358) and disrupted antiviral gene 
expression (359). However, the in vivo relevance of these findings is currently unknown. 
Furthermore, non-neutralizing antibodies can interfere with neutralizing antibody 
responses. Antibodies directed against a non-neutralizing epitope on HCV can interfere 
with antibodies directed against neutralizing epitopes allowing viral persistence despite 
circulation of neutralizing antibody (404, 405). Likewise, non-neutralizing antibodies 
prevent complete neutralization of human cytomegalovirus (406). Thus, it is possible that 
the early CHIKV-binding but non-neutralizing antibody response induced in AF15561-
infected mice may interfere with otherwise effective antibody-mediated control of the 
virus. Therefore, further studies are needed to understand if the early non-neutralizing 
antibody response to AF15561 infection contributes to development of persistence.  
These findings suggest that screening of the neutralization capacity of human 
sera during acute infection may provide a valuable prognostic indicator to identify those 
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at risk of developing chronic CHIKV disease. Indeed, patients with a rapid neutralizing 
antibody response to CHIKV infection are protected from development of chronic 
disease (213). My findings expand on this observation and suggest that screening of 
human serum for neutralization against CHIKV possessing an E2 G82 or R82 residue 
may identify patients whose neutralizing antibody response is directed against protective 
epitopes and therefore at reduced risk of developing chronic disease. Furthermore, 
understanding the mechanisms by which CHIKV infection induces a rapid antibody 
response within days of infection may inform therapeutic strategies seeking to induce 
rapid antibody responses such as post-exposure prophylaxis or vaccination efforts to 
contain spread of an outbreak.  
Is Persistence of Chikungunya Virus Associated with Adaptive 
Mutations in the Virus? 
 CHIKV, like most RNA viruses, encodes a low-fidelity RNA-dependent RNA-
polymerase allowing CHIKV to potentially adapt to selective pressures by acquiring 
adaptive mutations in its genome. CHIKV encoding a higher-fidelity polymerase is 
attenuated in vivo for acute disease suggesting that the virus quasispecies and 
exploration of sequence space is important for acute CHIKV pathogenesis (39). CHIKV 
strain 181/25 rapidly reverts attenuating mutations in some tissues during acute infection 
of WT mice, demonstrating that selective pressures can quickly select for CHIKV 
variants with increased fitness (260). I found that the E1:nsP1 ratio, a marker of active 
viral replication, declines in response to adaptive immunity, suggesting that CHIKV may 
subdue its replication to avoid immune surveillance. Although the mechanism by which 
this occurs is unknown, mutations in the non-structural proteins can alter RNA replication 
(43, 50). Additionally, persistence of several viral pathogens is associated with 
accumulation of adaptive mutations due to host selective pressures. Long-term infection 
142 
 
with HIV or HCV is associated with accumulation of escape mutations in antibody and T 
cell epitopes (299, 300, 407). Viruses can also mutate to exploit novel cellular niches as 
evidenced by HIV adaptation during chronic infection to use the CxCR4 co-receptor 
(301, 408, 409). Similarly, LCMV Clone 13 was isolated from the spleen of a chronically 
infected mouse (303) and in comparison to parental strain LCMV Armstrong had 
accumulated mutations that allowed it to infect distinct cell types in lymphoid tissue (410-
412). Persistence of SINV in the CNS of scid mice was associated with mutations in E2 
that confer enhanced neurovirulence (304). Contrastingly, persistence of coxsackie B 
virus in muscle tissue can occur in the absence of mutations (413). Furthermore, 
although alphavirus replication in mammalian cells is typically cytopathic in vitro, multiple 
alphaviruses can establish persistent infections of mammalian cells (272, 414-416) 
typically through acquisition of mutations that alter viral protein nsP2 interactions with the 
host. These data suggest that alphaviruses accumulate adaptive mutations to facilitate 
persistent replication in vitro. To date, however, limited studies have evaluated whether 
persistence of CHIKV in vivo is associated with accumulation of adaptive mutations. 
Infectious virus recovered from the sera of CHIKV-infected Rag1-/- mice at 100 dpi and 
then amplified on C6/36 insect cells revealed few mutations and no overt phenotypic 
differences compared to WT CHIKV when inoculated into WT mice (168). Likewise, 
sequencing of CHIKV from the brain and kidneys of CHIKV-infected Rag1-/- mice at 4 to 
6 wpi revealed few coding changes, all within the non-structural proteins (297). Thus, 
whether persistence of CHIKV requires accumulation of adaptive mutations in response 
to host selective pressures in vivo is unclear.  
I performed limited deep sequencing of viral RNA from the ankle tissue of WT 
mice infected with CHIKV at 42 dpi and found few changes in the viral genome. In two 
individual mice, I identified two distinct mutations in the nsP4 gene that were present in 
143 
 
20-25% of reads, suggesting they had been selected for during persistence. The first 
mutation was a C>G substitution at nt position 5952 that resulted in a substitution of a 
proline with an arginine at nsP4 residue 96 (nsP4 P96R). The second mutation was an 
A>G substitution at nt position 6132 resulting in a substitution of a glutamate with a 
glycine in nsP4 at residue 156 (nsP4 E156G). Intriguingly, both of these mutations were 
located proximally (within 1-2 aa) to residues identified in SINV that regulate RNA 
synthesis by influencing replicase RNA elongation activity or modulating nsP4 
interactions with nsP2 (417). Although my preliminary characterization of these mutants 
for acute replication in vivo did not reveal any overt phenotypes compared to WT CHIKV 
(data not shown), further characterization of these mutants for persistence is necessary. 
In a different approach, phenotypic characterization of infectious CHIKV AF15561 
recovered from joint-associated tissue of chronically infected Rag1-/- mice showed no 
overt changes in acute disease or persistence compared to WT AF15561, suggesting 
the virus had not accumulated mutations that altered viral fitness in WT mice.  
However, my isolation of a mouse-adapted strain of CHIKV from the serum but 
not ankle tissue of Rag1-/- mice chronically-infected with CHIKV suggests that the host 
pressures acting upon CHIKV can select for adaptive mutations during persistence but 
these host pressures may be tissue specific. Furthermore, the joint tissue may be a site 
of limited selective pressure. This hypothesis is supported by my findings that CHIKV 
strain 181/25 recovered from the joint-tissue of Rag1-/- mice at 28 dpi had not 
accumulated mutations that allowed it to persist in WT mice. In contrast, 181/25 in 
lymphoid tissue of WT mice rapidly reverted attenuating mutations (260). Likewise, a 
strain of RRV which replicates to significantly reduced titers in skeletal muscle tissue due 
to mutations in nsP1 that enhance sensitivity to type I IFN replicates to similar titers as 
WT RRV in joint-associated tissue (186) suggest type I IFN responses may have limited 
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efficacy against the virus in this tissue. Furthermore, my findings that CHIKV persisting 
in the ankle tissue of Rag1-/- mice was resistant to clearance by therapeutically 
administered neutralizing antibody and findings that CD8 T cells appear limited in 
controlling RRV viral loads in joint tissue (203), suggest that CHIKV replication in joint-
associated tissue may also be under limited adaptive immune pressure.  
 Although the tissue or cell type shedding CHIKV into the circulation of chronically 
infected Rag1-/- mice is unknown, isolation of MA-CHIKV from the serum suggests that 
there are reservoirs within the mouse that exert significant selective pressure on CHIKV 
during persistence. Excitingly, initial characterization of MA-CHIKV suggests that this 
variant has significantly enhanced virulence in the mouse facilitating studies of several 
aspects of CHIKV biology including viral restriction factors and genotypic constraints on 
adaptation of CHIKV to its host in addition to investigating the selective pressures acting 
upon CHIKV during persistence.  
 In contrast to type I IFN deficient mice which succumb to CHIKV infection within 
days, Rag1-/- mice support chronic viral infection for weeks post infection. Although, 
Rag1-/- mice chronically-infected with CHIKV only showed a transient systemic induction 
of type I IFN (168), human patients with chronic symptoms following CHIKV infection 
had sustained type I IFN responses (170) and CHIKV-infected WT mice had sustained 
upregulation of IFN stimulated genes at day 30 p.i. in joint-associated tissue (168). Thus 
it is likely that Rag1-/- mice control CHIKV replication through induction of a type I IFN 
response and accordingly MA-CHIKV may have evolved to overcome this restriction. 
However, if indeed the E2 K200R mutation and/or the deletion in the γ′ UTR were 
selected to overcome type I IFN restriction, the mechanism is unknown. There exists 
three, non-exclusive general mechanisms by which MA-CHIKV could overcome 
restriction by the type I IFN response. First, MA-CHIKV may evade detection by host 
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antiviral sensors such as RIG-I, MDA-5 or the TLRs leading to a delay or diminishment 
of the type I IFN response. Alternatively, MA-CHIKV may more potently antagonize IFN 
signaling by interfering with necessary signaling cascades needed to translate IFN 
receptor signals into ISG expression. Finally, MA-CHIKV may be resistant to IFN-
induced effector functions. These distinct strategies are all employed by alphaviruses 
(18, 179, 305, 307, 371, 415, 418, 419), therefore it is reasonable to hypothesize that the 
mutations in MA-CHIKV may engage one or more of these pathways to overcome IFN 
restriction. Furthermore, the window for type I IFN to restrict alphavirus replication may 
be brief (159, 420), so mutations that alter type I IFN induction or allow viral escape from 
IFN-induced restriction factors, even if only briefly, may have substantial consequences 
on viral pathogenesis. However, the role of the E2 K200 residue or the γ′ UTR of CHIKV 
in the type I IFN response is not well defined. The γ′ UTR of SINV can bind the RNA 
stabilizing protein HuR allowing for efficient viral replication while destabilizing host 
transcripts for innate antiviral proteins such as RIG-I (22, 321). However, the sequence 
of the CHIKV γ′ UTR that binds HuR is not affected by the 44 nt deletion identified in 
MA-CHIKV (320). Interestingly, preliminary in vitro IFN sensitivity assays in Vero cells 
suggest that the deletion in the γ′ UTR of MA-CHIKV may indeed confer resistance to 
type I IFN (data not shown).  
In addition, the mutations identified in MA-CHIKV may also influence tissue 
tropism of CHIKV within the host. Although impairment of the type I IFN response greatly 
expands tissue tropism of CHIKV and other alphaviruses (156, 165, 421, 422), there 
remain intrinsic determinants on viral tropism, encoded by the viral genome, with many 
determinants in the E2 glycoprotein (18, 260, 307, 421, 423-425) reflecting the role of E2 
in attachment, binding and entry. These intrinsic determinants of viral tropism can have 
significant influence on viral pathogenesis (260, 370, 371, 421) and induction of innate 
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immune responses (18, 307, 371). The role of the CHIKV γ′ UTR in influencing tissue 
tropism is unknown but the host factors that interact with the 3′ UTR to facilitate viral 
replication may be tissue specific (319). Therefore, it is possible that the mouse adaptive 
mutations evolved to expand tissue tropism by alleviating virally intrinsic restrictions on 
CHIKV in the mouse.  
Complicating formulation of hypotheses on how the 44 nt deletion in the γ′ UTR 
of MA-CHIKV influences CHIKV pathogenesis is a lack of data on the sequence and 
RNA secondary structure requirements of the CHIKV γ′ UTR for efficient viral replication 
in vivo. The γ′ UTR of viruses within the alphavirus genus are highly divergent containing 
numerous repeat elements (10, 74) and with the exception of a 19 nt conserved element 
preceding the poly-A tail (10) and binding sites for the HuR host protein (22, 320), the 
pressures that select for a particular γ′ UTR during CHIKV replication are unclear. 
Alphaviruses containing large deletions of their 3′ UTR replicate efficiently in mammalian 
tissue culture cells suggesting that relatively little of the γ′ UTR is needed for the virus to 
replicate its genome in mammalian cells (18, 20, 196, 318). Nevertheless, it is likely that 
the γ′ UTR is required for efficient replication and pathogenesis in vivo. The flavivirus γ′ 
UTR contains direct repeat elements that form secondary structures important for viral 
replication (426) and inhibition of innate immune responses (323) suggesting the 
numerous repeat elements in the alphavirus γ′ UTR may form important secondary 
structures. Mfold predictions of the CHIKV γ′ UTR of all three CHIKV genotypes 
predicted formation of numerous stem loop secondary structures in the γ′ UTR (74). 
Furthermore, these stem loop structures may be distinct at mammalian and insect body 
temperatures, suggesting these structures vary as CHIKV replicates in dissimilar hosts 
(74). Consequently, it is tempting to speculate that the 44 nt deletion in the γ′ UTR of 
MA-CHIKV alters a critical secondary structure. Mfold predictions performed by Chen et 
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al. demonstrated that the unique duplication present in the γ′ UTR of Asian genotype 
viruses introduces additional secondary structures to the γ′ UTR without globally altering 
the overall secondary structure of the γ′ UTR (74). Therefore, the 44 nt deletion may 
alter RNA secondary structure specifically within the unique duplicated region of the 
Asian genotype γ′ UTR without altering secondary structure elsewhere in the γ′ UTR. 
Indeed, preliminary RNA SHAPE analysis performed by collaborators on the WT 
AF15561 γ′ UTR or γ′ UTR containing the 44 nt deletion suggest that the deletion 
removes a double stem-loop structure without globally altering the secondary structure 
of the UTR. The viral or host interactions that occur at this stem loop structure remain to 
be determined.  
Thus, it is clear there are many potential mechanisms by which the identified 
mutations in E2 or γ′ UTR could influence CHIKV pathogenesis. Therefore, further 
characterization of MA-CHIKV and the mechanisms by which they influence CHIKV 
pathogenesis has the potential to reveal novel insight into critical host and viral 
determinants of acute and chronic CHIKV pathogenesis. Follow up experiments 
comparing the replication and viral burdens of WT vs MA-CHIKV in WT or type I IFN 
receptor deficient mice (Ifnar1-/-) or mice unable to induce an IFN response (Irf3/7-/-) mice 
would be informative and dictate studies needed to gain mechanistic insight into how 
these mutations confer adaptation to mice. 
Finally, MA-CHIKV may serve as a useful tool to study broader scale 
evolutionary selective pressures on CHIKV. My isolation of MA-CHIKV from the serum of 
Rag1-/- mice infected with Asian genotype AF15561 contrasts sharply with findings that 
CHIKV isolated from the serum of Rag1-/- mice infected with an ECSA genotype CHIKV 
had limited coding changes and no increased virulence when re-inoculated into mice 
(168). Likewise, I have isolated CHIKV from the serum of Rag1-/- mice at 42 dpi with an 
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ECSA genotype virus and preliminary in vivo characterization showed no increase in 
virulence (data not shown). This suggests that ECSA strains of CHIKV may be unable to 
similarly adapt to mice as Asian genotype viruses. Additionally, although the E2 K200 
residue is conserved among Asian and all other CHIKV genotypes, the deletion in the γ′ 
UTR of MA-CHIKV occurs in a region of the γ′ UTR unique to Asian genotype viruses. 
Together, this data suggests that MA-CHIKV might serve as a useful tool in studying 
whether there exist genotypic constraints on adaptation to the mammalian host, similar 
as to what has been observed for CHIKV adaptation to mosquito vectors (102, 103).  
Additionally, the E2 K200 residue, while conserved in CHIKV and ONNV, is not 
conserved among related alphaviruses: MAYV (possessing E2 S200), SFV (E2 N200) 
and RRV (E2 N200) or more distantly related alphaviruses SINV (E2 E200) and VEEV 
(E2 E200) (Fig. 6-1A ). The poor conservation of E2 K200 between CHIKV and closely or 
distantly related alphaviruses contrasts with the absolute conservation of the residues in 
the glycoprotein E1 that interact with the residue at E2 position 200, E1 C63 and F95 
(Fig. 6-1B and C ). This suggests that residues other than a lysine at E2 position 200 are 
well tolerated in alphaviruses and the residue at this position may have been selected for 
in divergent alphaviruses due to unique selective pressures in their respective hosts. 
Thus, studies investigating whether the K200R mutation uniquely influences CHIKV 
pathogenesis or whether other amino acids at E2 position 200 enhance CHIKV 
pathogenesis are warranted. 
 Due to the obligate cycling between mammals and insects during the life cycle of 
CHIKV and related alphaviruses, mutations that arise in the wild that confer an 
advantage in either host are constrained by the requirement to retain fitness in the 
dissimilar host. Consequently, adaptation to a particular host frequently results in 
attenuation in the dissimilar host (312, 313, 427, 428). However, adaptation to particular 
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host selective pressures can occur without fitness costs in the dissimilar host (429). 
Therefore, determining if the E2 K200R mutation or γ′ UTR deletion confer a fitness cost 
in the mosquito host will be of importance in predicting whether similar adaptive 
mutations are likely to arise in nature. These findings would provide valuable insight into 
the potential evolution of the Asian genotype CHIKV currently circulating in the 
Americas. If gains in CHIKV fitness and pathogenesis in mammals can occur without 
compensatory defects in mosquito vector fitness, it could portend rapid increases in the 
severity of CHIKV infection. 
Concluding Remarks 
My work demonstrates that CHIKV establishes long term persistence in the joint-
associated and lymphoid tissue of mice. Persistence of CHIKV in joint tissue of mice is 
associated with ongoing joint pathology strengthening the hypothesis that chronic CHIKV 
disease reported in many patients following acute CHIKV infection may be due to 
chronic viral infection. Furthermore, my work demonstrates that adaptive immune 
responses are necessary to limit viral burdens and joint pathology during persistence. 
Additionally, I have shown that evasion of antibody responses is a necessary step in 
CHIKV persistence. These data suggest that therapies that modulate the host adaptive 
immune response either during acute infection or during chronic disease could be 
effective in ameliorating symptoms. Furthermore, continued comparative studies 
between CHIKV strain AF15561 and 181/25 will give valuable insight into the host 
immune responses that dictate clinical outcome of viral infections.  
Lastly, the isolation and preliminary characterization of a mouse-adapted strain of 
CHIKV lays the foundation for exciting studies into the host restriction factors that limit 
CHIKV replication within the host. The identification of novel mutations with the viral 
genome, E2 K200R and a 44 nt deletion in the γ′ UTR, that are contrastingly in highly 
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conserved and highly divergent regions of the genome will allow for investigations of 
evolution of CHIKV within the host and more broadly within the context of the evolution 
of distinct CHIKV genotypes.  
Cumulatively, these findings expand our knowledge of the host and viral 
determinants of CHIKV persistence while facilitating future studies that will contribute to 





Figure 6-1. Alignments of E2 K200 and contact residues E1 C63 and F95. (A-C) 
Amino acid alignment of CHIKV strain AF15561 (Genbank Accession No. EF452493), 
ONNV (AF079456.1), MAYV (DQ001069.1), SFV (X04129.1), RRV (GQ433359.1), SINV 
(NC_001547.1) and VEEV (L01442.2) in the regions of E2 K200 (A) or the contact 
residues in E1, C63 (B) and F95 (C). Amino acids numbered according to CHIKV E2 
and E1 protein sequence. 100% homology is indicated by dots. Alignment performed in 
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